sampleid,Sample_ID,patientId,labId,dbgap_subject_id,dbgap_dnaseq_sample,dbgap_rnaseq_sample,gender,ageAtDiagnosis,priorMalignancyNonMyeloid,priorMalignancyType,cumulativeChemo,priorMalignancyRadiationTx,priorMDS,priorMDSMoreThanTwoMths,priorMDSMPN,priorMDSMPNMoreThanTwoMths,priorMPN,priorMPNMoreThanTwoMths,dxAtSpecimenAcquisition,specificDxAtAcquisition,secondarySpecificDxAtAcquisition,dxAtInclusion,specificDxAtInclusion,fabBlastMorphology_old,AML_subtype,ELN2022,AMLFusion,karyotype,otherCytogenetics,mutationsSummary,FLT3_ITDCall,NPM1Call,CEBPA_Biallelic,ageAtSpecimenAcquisition,timeOfSampleCollectionRelativeToInclusion,replicate,diseaseStageAtSpecimenCollection,Status,specimenGroups,specimenType,priorTreatmentTypeCount,priorTreatmentTypes,priorTreatmentRegimenCount,priorTreatmentStageCount,priorTreatmentStages,responseToInductionTx,typeInductionTx,responseDurationToInductionTx,cumulativeTreatmentRegimens,mostRecentTreatmentRegimen,currentTreatmentType,currentStage,currentTreatmentDuration,vitalStatus,overallSurvival,causeOfDeath,percentBlastsBM,percentBlastsPB,percentAbnormalPlasmaBM,percentBandsPB,percentBasophilsPB,percentEosinophilsPB,percentImmatureGranulocytesPB,percentLymphocytesPB,percentMetamyelocytesPB,percentMonocytesPB,percentMyelocytesPB,percentNeutrophilsPB,percentNucleatedRBCsPB,percentPromonocytes,percentPromyelocytes,percentPromyelocytesPB,percentReactiveLymphocytesPB,percentWBC,wbcCount,plateletCount,albumin,bCellGeneRearrangement,bilirubin,creatinine,hemoglobin,tCellReceptorGene,ALT,AST,LDH,MCV,surfaceAntigensImmunohistochemicalStains
C541,C541,1094,17-00332,,,,Female,41.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M1,M1,NonInitial,RUNX1-RUNX1T1,"46,XX,t(8;21)(q22;q22),t(16;17)(q24;q11.2)[17]//46,XY[3]","RUNX1T1/RUNX1:  56/100 cells (56%) had  a double fusion signal pattern, consistent with RUNX1T1/RUNX1 fusion and  the 8;21 translocation observed in the metaphase karyotype, and as seen previously. ",ASXL1 (p.W1065*; MAF 4%)|ETV6 (p.Q347P; MAF 35%)|IKZF1 (p.R184W; MAF 3%)|TET2 (p.N752fs*60; MAF 28%),Negative,Negative,,45.0,1397.0,,Relapse,Relapse,Post-Transplant|Relapse|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,4.0,Dead,1497.0,Dead-Disease,65.0,55.0,,,0.0,0.0,0.0,3.5,,6.0,,35.3,0.1,,,,,,17.28,32.0,2.5,,,1.17,10.6,,78.0,28.0,453.0,110.1,"partial CD11b, CD13, dim CD33, CD34, bright CD38, CD58,  partial CD64, dim CD71, dim CD117, dim CD123, HLA-DR and MPO"
C20,C20,1098,14-00765,,,,Female,31.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XX[20]",Not available,BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%),Negative,,,38.0,1489.0,,Relapse,Relapse,Post-Chemotherapy|Post-Transplant|Relapse,Bone Marrow Aspirate,4.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),9.0,7.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,24.0,Dead,2661.0,Dead-Unknown,8.0,1.0,,,0.2,1.9,,7.6,,7.5,,82.7,,,,,,,1.6,72.0,,,,,12.3,,,,,,"CD2(-), CD4(dim +), CD7(-), CD10(partial +), CD11b(-), CD13(-), CD14(-), CD15 (-), CD16(-), CD22(partial +), CD33(+), CD34(+), CD36(-), CD38(partial dim +), CD45(dim +), CD56(+), CD64(-), CD117(variably +), HLA-DR(-)"
C2,S80,1246,14-00495,2079.0,BA2735D,BA2735R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,Other,"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]","nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]",CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted),Positive (MAF 71%; AR 5.666666667),Positive (W288fs*10+; MAF unlisted),,64.0,254.0,,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6.0,5.0,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",Crenolanib,Targeted Therapy - Kinase Inhibitor(s),Experimental,141.0,Dead,568.0,Dead-Unknown,,,,,,,,,,,,,,,,,,,27.4,30.0,2.9,,,,9.6,,23.0,26.0,,,
C54,S117,1532,15-00482,2029.0,BA2065D,BA2065R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%),Negative,Positive (p.W288fs*>9 ; MAF 39%),,47.0,424.0,,Relapse,Relapse,Relapse,Bone Marrow Aspirate,1.0,Standard Chemotherapy,5.0,3.0,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Re-induction,4.0,Dead,1373.0,Dead-Disease,70.0,59.0,,,0.0,3.5,0.9,17.7,,0.0,,13.3,0.0,,,,,,16.95,138.0,2.8,,,0.72,12.6,,184.0,77.0,,94.4,"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive"
C4,S119,1533,14-00528,2241.0,,BA2463R,Female,57.0,1.0,Ovarian cancer|Ovarian cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,NUP98_re,"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1] (Abnormal female karyotype with three related clones containing multiple structural and numerical abnormalities in nineteen of twenty cells examined. A normal female chromosome complement was observed in one cell. .ish der(8)(D8Z2+,RUNX1T1+),der(21) (RUNX1+,RUNX1T1+)[19])","nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,58.0,111.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,4.0,4.0,Consolidation|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea","Decitabine, Hydroxyurea",Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,138.0,Dead-Unknown,,58.0,,5.0,0.0,0.0,,14.0,,3.0,1.0,19.0,,,,,,,11.2,31.5,3.7,,,,7.7,,24.0,116.0,,,"CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+)."
C6,S134,1664,14-00464,2160.0,BA2651D,BA2651R,Female,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,M1,M1,Intermediate,KMT2A_re,"46,XX,t(9;11)(p22;q23)[22]",,FLT3-D835,Negative,Negative,,22.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4.0,4.0,Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7.0,"ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)","Cyclophosphamide, TBI",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,826.0,Alive,65.0,90.0,,,,,,,,0.1,,,,,,,,,40.2,,,,,,,,,,,,"CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO"
C7,S135,1670,14-00477,2457.0,BA2278D,,Male,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XY,t(11;19)(q23;p13.1)[20]",,,Positive (MAF 80%; AR 4),Negative,,47.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Supportive/Palliative Care|Intrathecal,5.0,5.0,Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,7.0,"HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,9.0,Dead,228.0,Dead-Disease,70.0,79.0,,,,,,,,2.0,,,,,,,,,261.2,,,,,,,,,,,,"CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19"
C1,C1,1682,14-00494,,,,Female,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M0,M0,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.A368V; MAF 44%)|FLT3-ITD (MAF ~75%)|NPM1 (p.W288fs*12; MAF 48%)|TET2 (p.S835*; MAF 49%)|WT1 (p.F460-_S461insV; MAF 44%)|WT1 (p.R369fs*16; MAF 24%),Positive (MAF 66%),Positive (p.W288fs*12; MAF 48%),,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,5.0,5.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,6.0,Dead,223.0,Dead-Other,86.0,84.0,,,0.0,0.0,0.0,20.0,,3.5,,1.7,0.1,,,,,,59.03,16.0,3.1,,,0.8,7.6,,166.0,117.0,934.0,86.3,"dimCD11b, CD13, CD33, CD34, dimCD38, dimCD117, and CD123 Positive"
C8,S136,1693,14-00504,2385.0,BA2377D,BA2377R,Male,35.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,AML with mutated NPM1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,,,Intermediate,KMT2A_re,"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1] (Abnormal male karyotype containing a complex three-way (9;11) translocation involving a third chromosome in nineteen of 20 cells examined. A normal male chromosome complement was observed in one cell.)","nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion),Positive (MAF 71%; AR 2.448275862),Positive,,35.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin","Busulfan, Cyclophosphamide, Thymoglobulin",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1156.0,Alive,86.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)"
C9,S137,1696,14-00514,2003.0,BA2499D,BA2499R,Male,71.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,,,Not available,,Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Hypomethylating/Low Dose Cytarabine,,,,Azacitidine,Azacitidine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,107.0,Dead,53.0,Dead-Disease,,50.0,,12.0,0.0,1.0,,17.0,,1.0,,13.0,,,,,,,45.6,11.0,3.2,,,1.83,7.7,,19.0,42.0,766.0,92.2,Not Run
C3,S138,1702,14-00527,2167.0,BA2016D,,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,63.0,0.0,,Relapse,Relapse,Post-Chemotherapy|Relapse,Peripheral Blood,1.0,Standard Chemotherapy,4.0,4.0,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",HiDAC,Standard Chemotherapy,Maintenance,5.0,Dead,544.0,Dead-Disease,82.0,47.0,,,0.0,2.0,,34.0,,9.0,,9.0,,,,,,,11.7,127.0,3.8,,,0.95,12.1,,11.0,28.0,932.0,87.4,"CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +)."
C5,S139,1708,14-00537,2112.0,BA2350D,BA2350R,Male,17.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,KMT2A_re,"46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]",Not available,,Negative,Negative,,17.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Unknown,Standard Chemotherapy,-1.0,"Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine",Bu/Cy/ATG,Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,74.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,not done
C29,S143,1727,14-00803,2104.0,BA2517D,,Male,45.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,NonInitial,Other,"47,XY,der(7)t(1;7)(q10;p10)+8[20]",,"CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 94%)|EZH2 (p.S538L; MAF 89%)|GATA2 (p.K389delins; MAF 47%)|RUNX1 (p.S308fs*174; MAF 46%)",Negative,Negative,,46.0,112.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,5.0,4.0,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine","GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Standard Chemotherapy,Salvage,4.0,Dead,259.0,Dead-Disease,15.0,,,,0.0,0.0,0.0,7.9,,76.3,,11.4,0.0,,,,,,12.25,27.0,3.4,,,0.57,8.5,,25.0,12.0,295.0,93.0,"CD34, CD13, HLA-DR, CD123, and CD58.  In addition there is a predominant (about      60%) and atypical monocytic population expressing: CD11b, CD13, CD14,      patial CD16, CD33dim, partial CD56, CD64bright, HLA-DR."
C102,S146,1745,15-00974,2510.0,BA2727D,BA2727R,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,,,NonInitial,MECOM_re,"46,XX,inv(3)(q21q26)[5]",FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor,,Negative,Negative,,38.0,494.0,1745_1,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant,Peripheral Blood,3.0,DLI|Standard Chemotherapy|Bone Marrow Transplant,7.0,6.0,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide",Decitabine,Standard Chemotherapy,Salvage,4.0,Dead,533.0,Dead-Disease,,,,,0.0,0.9,0.0,13.9,,0.0,,0.9,0.4,,,,,,7.08,38.0,2.8,,,,10.3,,59.0,28.0,,99.4,
C512,C512,1745,16-00049,,,,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,,,NonInitial,MECOM_re,"46,XX,inv(3)(q21q26)[5]",FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor,,,,,38.0,513.0,1745_2,Residual,Residual,Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant,Peripheral Blood,3.0,DLI|Standard Chemotherapy|Bone Marrow Transplant,7.0,6.0,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide",Decitabine,Standard Chemotherapy,Salvage,4.0,Dead,533.0,Dead-Disease,,,,,0.0,0.0,0.0,12.5,,0.0,,4.2,0.0,,,,20.8,,15.22,23.0,2.0,,,0.62,6.7,,12.0,26.0,495.0,93.1,
C10,S583,1749,14-00608,2026.0,BA2122D,BA2122R,Female,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,NonInitial,NotDetected,"46,XX[8]",,,Negative,Negative,,77.0,716.0,,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,1131.0,Azacitidine,Azacitidine,Standard Chemotherapy,Induction,1131.0,Dead,1134.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C11,S147,1752,14-00613,2370.0,BA2053D,BA2053R,Male,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]","nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5’CBFB sep 3’CBFBx1)[164/200]",,Negative,Negative,,31.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,5.0,Unknown,595.0,,80.0,56.0,,,,2.0,,17.0,,21.0,1.0,3.0,,,,,,,41.35,34.0,3.9,,,0.91,10.2,,63.0,39.0,434.0,,"CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +)."
C12,C12,1755,14-00620,,,,Male,32.0,1.0,Bladder Cancer,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Unknown,,,,,,,,32.0,0.0,1755_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Alive,621.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C16,C16,1755,14-00711,,,,Male,32.0,1.0,Bladder Cancer,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,NonInitial,,,,,Negative,,,32.0,47.0,1755_2,Unknown,Unknown,Unknown,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Alive,621.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C13,C13,1760,14-00630,,,,Male,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,,,,,,,,67.0,0.0,,Unknown,Unknown,,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",MiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,98.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C15,S149,1763,14-00643,2050.0,BA2354D,BA2354R,Male,37.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M2,M2,Favorable,RUNX1-RUNX1T1,"45,X,-Y,t(8;21)(q22;q22)[20]","RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.",EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% ),Negative,Negative,,37.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,0.0,Unknown,1348.0,,,,,,0.8,0.0,7.5,17.5,,0.0,,37.5,0.4,,,,,,8.15,42.0,3.0,,,0.89,5.5,,22.0,13.0,411.0,100.6,"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive"
C14,S150,1765,14-00644,2729.0,BA3273D,BA3273R,,,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Intermediate,Other,"47,XY,der(7)t(1;7)(q21;q36),+14[4]/46,XY[16]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2, D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2 [198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",IKZF1 (Foundation; S63fs*2),Negative,Negative,,,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Cyclophoshamide, TBI, ATG|CALGB 10403","Cyclophoshamide, TBI, ATG",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,560.0,Alive,96.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD2(-), CD4(+), CD7(-), CD11b(few dim +), CD13(-), CD14(-), CD15(partial +), CD16(-), CD19(partial +), CD20(-), CD22(partial +), CD25(partial +), CD33(partial +), CD34(+), CD36(-), CD38(+), CD45(partial +) | CD64(-), CD79a(partial +), CD117 (-), HLA-DR(partial +), CD123(variably +), MPO(+), TdT(+)"
C19,S151,1775,14-00658,2455.0,BA2893D,BA2893R,Female,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XX[20]",Normal,NPM1,Positive (MAF 50%; AR 1),Positive,,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC","Azacitidine, Sorafenib",Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,254.0,Dead-Disease,51.5,72.0,,,,,,,,,,,,,,,,,89.17,,,,,,,,,,,,"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia."
C17,S153,1810,14-00712,2415.0,BA2872D,BA2872R,Male,65.0,1.0,Pancreatic adenocarcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Adverse,Other,"46,XY,i(17)(q10)[20]","TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.",ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% ),Negative,Negative,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)",Decitabine,Standard Chemotherapy,Salvage,9.0,Dead,158.0,Dead-Disease,18.0,12.0,,,0.0,0.9,32.0,7.4,,35.2,,18.5,4.8,,,,,,161.89,40.0,2.9,,,1.65,6.7,,44.0,165.0,3923.0,81.0,"CD13, CD33, CD34, CD117, and HLA-DR positive"
C289,S154,1813,17-00641,2523.0,BA3145D,BA3145R,Male,74.0,1.0,Prostate Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(6;9)(p23;q34); DEK::NUP214 fusion,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,DEK-NUP214,"47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]","DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",DNMT3A (F827fs*4)|FLT3-ITD,Positive,Negative,,77.0,979.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,3.0,2.0,Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat",Crenolanib,Targeted Therapy - Other,Maintenance,433.0,Dead,1003.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C21,S155,1820,14-00739,2484.0,BA2541D,BA2541R,Male,39.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XY,t(6;11)(q27;q23)[20]",MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).,MLL (PTD),Negative,Negative,,39.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Intrathecal,4.0,3.0,Induction|CNS|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate","MEC (Cytarabine, Etoposide, Mitoxantrone)",Standard Chemotherapy,Re-induction,4.0,Dead,216.0,Dead-Disease,91.0,,,,0.0,0.0,0.0,28.3,,17.7,,3.5,0.0,,,,,,21.12,31.0,3.0,,,0.97,10.7,,19.0,14.0,,98.4,"dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive."
C22,C22,1822,14-00747,,,,Male,1.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute megakaryoblastic leukaemia,Myeloid proliferations associated with Down syndrome,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,M7,M7,Unknown,Other,"47,XY,+21c[20]",c/w karyotype,,,,,1.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"COG-AAML0431 (IT/IV Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Thioguanine)","COG-AAML0431 (IT/IV Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Thioguanine)",Standard Chemotherapy,Induction,-1.0,Alive,567.0,Alive,,,,,0.0,0.0,0.0,28.3,,1.8,,18.6,0.0,,,,,,33.81,12.0,2.2,,,0.33,7.9,,31.0,37.0,,76.6,
C23,C23,1826,14-00752,,,,Male,70.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Unknown,NotDetected,"46,XY[20] (Normal male karyotype)","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",,Negative,,,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1.0,"Jakifi (JAK2 inhibitor)|7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,208.0,Dead-Unknown,12.0,25.0,,,0.0,4.2,,5.1,2.5,5.1,5.1,44.1,,,1.4,,,,113.0,397.0,4.6,,,,9.4,,13.0,42.0,,,"CD34(+), CD4(partial +), CD5(partial +), CD13(dim +), CD15(-), CD25(-), CD33(+), CD38(variably +), CD45 (moderately +), CD117(+), CD123(partial dim +), HLA-DR(dim +). MPO(-), TdT(-)"
C26,C26,1831,14-00792,,,,Male,59.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Unknown,Other,"48,XY,+8,+9[20]","nuc ish(D8Z2x3,D20S108x2)[170/200]",HIST1H2BK (T20I; MAF 47%)|PTPN11 (S502P;MAF 41.0%)|STK11 (F354L;MAF 46.0%),Negative,,,59.0,18.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,6.0,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Sirolimus|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,106.0,Dead,247.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,1.09,,,,,,,
C18,C18,1833,14-00760,,,,Female,72.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XX[20]",,,,,,72.0,0.0,,Residual,Residual,Residual Disease,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Induction|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,186.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Re-induction,62.0,Unknown,417.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C24,S158,1847,14-00781,2517.0,BA2497D,BA2497R,Male,71.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"47,XY,t(1;11)(p32;q23),+8[cp20]","c/w karyotype (CEP 8: 56/100 cells (56%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  RUNX1T1: 70/100 cells (70%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  MLL: 72/100 cells (72%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting MLL rearrangement and its involvement in the 1;11 translocation.)",CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%),Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|MiDAC",MiDAC,Standard Chemotherapy,Consolidation,5.0,Dead,162.0,Dead-Disease,80.0,80.0,,,0.0,0.0,2.0,21.0,,4.0,,1.0,0.8,,,,,,71.19,59.0,3.2,,,1.61,10.0,,29.0,282.0,7759.0,102.3,"CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive"
C25,S159,1848,14-00787,2119.0,BA2718D,BA2718R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XY[20]",Normal,CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%),Negative,Negative,bi,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,2423.0,Alive,90.0,90.5,,,0.0,0.0,0.0,8.2,,2.2,,0.9,0.8,,,,,,427.46,34.0,3.1,,,1.21,5.2,,22.0,43.0,1873.0,96.1,"CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)"
C27,S160,1852,14-00798,2043.0,BA2575D,BA2575R,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XX,inv(16)(p13.1q22)[20]","CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ",KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%),Negative,Negative,,36.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,15.0,Dead-Treatment,74.0,82.0,,,0.0,1.7,1.7,6.7,,82.3,,3.4,0.0,,,,,,117.53,12.0,2.7,,,0.68,7.1,,45.0,36.0,,87.6,"Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a promonocyte/monoblast population expressing:"
C28,S161,1854,14-00800,2404.0,BA3008D,BA3008R,Male,68.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,NonInitial,NotDetected,"46,XY[20]",,CBL (p.C404Y; MAF 28%)|SF3B1 (p.K666N; MAF 36% )|TET2 (p.L1047fs*11; MAF 34% ),Negative,Negative,,69.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,2.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,4.0,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,4.0,Dead,114.0,Dead-Disease,,,,,,,,,,,,,3.6,,,,,,53.76,17.0,3.1,,,1.07,7.2,,26.0,65.0,1004.0,90.1,
C30,S163,1865,14-00817,2461.0,,BA2593R,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,NotDetected,"46,XY[20]",Normal,FLT3-ITD,Positive (MAF 48%; AR 1.083333333),Negative,,53.0,0.0,1865_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Unknown,21.0,,66.0,56.0,,,,,,,,,,,,,,,,,180.0,123.0,,,,,,,,,,,"large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes"
C31,C31,1865,14-00818,,,,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,NotDetected,"46,XY[20]",Normal,FLT3-ITD,Positive,Negative,,53.0,0.0,1865_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Unknown,21.0,,66.0,56.0,,,,,,,,,,,,,,,,,180.0,123.0,,,,,,,,,,,"large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes"
C32,S165,1868,14-00832,2150.0,BA2620D,BA2620R,Female,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,,,,FLT3-ITD (MAF 45%),Positive,Negative,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,0.0,Alive,2426.0,Alive,,30.0,,,0.8,0.0,12.5,24.2,,28.3,,18.4,0.0,,,,,,31.66,60.0,3.0,,,0.78,7.4,,23.0,29.0,561.0,107.2,"CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive"
C33,S166,1870,14-00901,2486.0,BA2629D,BA2629R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,Other,"46,XY,t(1;4)(q21;p14)[20]",Normal,BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%),Negative,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",MiDAC,Standard Chemotherapy,Consolidation,44.0,Dead,104.0,Dead-Treatment,80.0,,,,0.0,0.0,0.0,45.5,,0.8,,0.0,0.3,,,,,,13.68,57.0,2.4,,,0.73,6.9,,14.0,18.0,178.0,103.4,"partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive"
C34,S585,1924,15-00043,2032.0,BA2348D,BA2348R,Female,43.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]","Positive for an EVI1 rearrangement (Percent:      42.5 Total Cells:  200 Cutoffs:       <  0.9%) | ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy (2.5 Total Cells:  200 Cutoffs:       <  0.3%)",,Negative,Negative,,44.0,0.0,,Remission,Remission,Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,12.0,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1105.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C84,S173,1973,15-00874,2301.0,BA2674D,BA2674R,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,NonInitial,Other,"47,XY,+4[2]/46,XY[18]","Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",ASXL1 (p.Q588*; MAF 49%),Negative,Negative,,71.0,281.0,1973_1,Relapse,Relapse,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Supportive/Palliative Care,4.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine","Azacitidine, Itacitinib",Standard Chemotherapy,Salvage,449.0,Dead,1389.0,Dead-Disease,90.0,,,,0.0,0.0,0.0,27.8,,2.9,,8.6,0.4,,,,,,73.42,91.0,3.3,,,,10.2,,81.0,43.0,235.0,94.7,"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117"
C140,S174,1973,16-00315,2301.0,BA2809D,BA2809R,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,NonInitial,Other,"47,XY,+4[2]/46,XY[18]","Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",,Negative,Negative,,72.0,423.0,1973_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,4.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine","Azacitidine, Itacitinib",Standard Chemotherapy,Salvage,449.0,Dead,1389.0,Dead-Disease,,,,,0.0,0.0,0.0,15.5,,6.9,,5.2,0.0,,,,,,50.58,44.0,3.1,,,0.8,9.1,,79.0,38.0,,87.7,
C35,C35,1981,15-00137,,,,Female,28.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,,,NonInitial,Other,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",Not available,,,,,30.0,0.0,1981_1,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,6.0,6.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,6.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ","Fludarabine, Cyclophosphamide, TBI ",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,843.0,Dead-Disease,,95.0,,,0.0,0.0,0.0,2.0,,0.0,,1.0,13.6,,,,,,19.16,19.0,3.5,,,0.3,9.3,,63.0,34.0,,86.8,"CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive."
C36,S175,1981,15-00147,2262.0,BA3025D,BA3025R,Female,28.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,,,NonInitial,Other,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",Not available,,Negative,Negative,bi,30.0,2.0,1981_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,6.0,6.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,6.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ","Fludarabine, Cyclophosphamide, TBI ",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,843.0,Dead-Disease,,,,,0.0,0.0,0.0,4.1,,0.0,,2.1,32.3,,,,,,20.18,8.0,3.7,,,0.3,9.2,,54.0,37.0,,91.3,"CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive."
C37,S180,1993,15-00159,2214.0,BA2835D,,Male,75.0,1.0,Prostate Cancer|Renal cell carcinoma,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,75.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,5.0,,58.0,31.0,,,0.0,0.0,,24.0,5.0,9.0,,31.0,,,4.0,,,,12.8,36.0,3.9,,,1.72,12.1,,11.0,23.0,379.0,94.0,"CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(small subset +) (56% population of variably-sized cells)"
C38,S181,1998,15-00167,2189.0,BA2049D,,Male,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XY[20]",Normal,IDH2 (p.R140Q; MAF 46% )|NOTCH1 (p.H2488R; MAF 47%)|NPM1 (p.W288fs*12; MAF 45%)|PTPN11 (p.D61A; MAF 44%),Negative,Positive (p.W288fs*12; MAF 45%),,42.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,3.0,SWOG S1203 (7+3 +/- Vorinostat),SWOG S1203 (7+3 +/- Vorinostat),Standard Chemotherapy,Induction,3.0,Dead,35.0,Dead-Treatment,50.0,55.0,,,1.7,0.9,4.4,13.2,,23.7,,14.0,0.0,,,,,,93.94,176.0,2.1,,,0.91,7.3,,22.0,30.0,,90.6,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+"
C40,S182,1999,15-00175,2250.0,BA2441D,BA2441R,Male,50.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,Adverse,Other,"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]",deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement,"NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D,  MAF  60%)|TP53 (p.R273H; MAF 44%)",Negative,Negative,,50.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)","MEC (Cytarabine, Etoposide, Mitoxantrone)",Standard Chemotherapy,Salvage,4.0,Dead,99.0,Dead-Disease,76.0,93.0,,,0.0,0.0,0.0,6.1,,1.7,,1.8,0.0,,,,,,50.74,14.0,2.2,,,0.44,6.3,,7.0,10.0,,85.8,"CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58,   CD117 and HLA-DR+"
C81,S184,2001,15-00829,2409.0,BA2695D,BA2695R,Female,67.0,1.0,Not specified,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"47,XX,+11[5]/48,idem,+19[15]","nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2}[199]",FLT3-ITD|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%),Positive (MAF 57%; AR 1.325581395),Negative,,68.0,254.0,2001_1,Residual,Residual,Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease,Peripheral Blood,4.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4.0,3.0,Salvage|Experimental|Supportive/Palliative Care,,,,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,449.0,Dead-Disease,,,,,,,,,,,,,,,,,,,27.5,24.0,4.1,,,,6.8,,18.0,25.0,,,
C88,C88,2001,15-00880,,,,Female,67.0,1.0,Not specified,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"47,XX,+11[5]/48,idem,+19[15] (Abnormal female (host) karyotype with two related clones containing trisomy of chromosome 11 in every cell examined. The second abnormal clone contains trisomy of chromosome 19, as an additional aberration.) | 47,XX,+11[5]/48,idem,+19[15]","nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] | nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2}[199]","FLT3-ITD (Foundation; FLT3-ITD (D593_F594insFREYHPP):MAF 30%)|IDH1 (Foundation; R132G; MAF 51%)|IDH1 (p.R132G; MAF 51%)|KMT2A (Foundation; MLL-PTD, exons 2-10)|KMT2A (MLL-PTD (exons 2-10))|TP53 (Foundation; R283C; MAF 49%)|TP53 (p.R283C; MAF 49%)",Positive (MAF 75%),Negative,,68.0,273.0,2001_2,Relapse,Relapse,Post-Chemotherapy|Post-DLI|Post-Transplant|Relapse,Leukapheresis,4.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4.0,3.0,Salvage|Experimental|Supportive/Palliative Care,,,,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,449.0,Dead-Disease,,16.9,,,0.0,1.8,,10.7,2.7,65.2,,0.9,,,,,,,68.85,30.0,3.3,,,,7.2,,14.0,57.0,,,
C39,S185,2002,15-00171,2400.0,BA2520D,BA2520R,Male,80.0,1.0,Mature B-Cell Neoplasm,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,Other,"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]",Positive for deletion of 20q12 in 11.5% of 200 cells,ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%),Negative,Negative,,80.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Consolidation|Salvage|Experimental,,,,"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC",Decitabine,Targeted Therapy - Kinase Inhibitor(s),Salvage,-1.0,Dead,309.0,Dead-Disease,80.0,86.0,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,,"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5"
C41,C41,2005,15-00176,,,,Male,73.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,NotDetected,"46,XY[20]",Normal,ASXL1 (p.G643fs; MAF 32.9%)|GATA2 (p.A318T; MAF 48.8%)|IDH1 (p.G105G; MAF 50%)|SRSF2 (p.P95H; MAF 46.9%)|TET2 (p.E798X; 49.6%)|TET2 (p.Q414X; MAF 49.6%),Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3.0,2.0,Salvage|Experimental,,,,"FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)","Azacitidine, Lenalidomide",Standard Chemotherapy,Salvage,76.0,Dead,441.0,Dead-Disease,55.0,39.0,,,,,,,,,,,,,,,,,46.8,25.0,,,,,,,,,,,"positive for CD34, CD117, CD13, CD33, and HLA-DR"
C47,S186,2028,15-00237,2069.0,BA2932D,BA2932R,Female,29.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML without maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (MAF 50%)|MLL (PTD),Positive,Negative,,29.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Standard Chemotherapy,Allogeneic - Matched Unrelated Donor,-1.0,Alive,2383.0,Alive,95.0,78.0,,,0.0,0.9,0.0,11.7,,0.0,,13.5,1.8,,,,,,68.79,12.0,3.0,,,0.54,7.9,,20.0,25.0,1119.0,95.8,"dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive."
C48,S187,2033,15-00248,2275.0,BA2844D,BA2844R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NotDetected,"46,XY[20]","nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%),Negative,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",Azacitidine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,-1.0,Unknown,195.0,,64.0,47.4,,,0.0,1.7,,23.3,,27.6,,0.0,,,1.0,,,,20.8,20.0,3.7,,,1.01,10.3,,29.0,26.0,578.0,99.7,"CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-). (73% population of medium to large sized cells)"
C42,S188,2052,15-00261,2170.0,BA2660D,BA2660R,Female,43.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46,XX[20]",Normal,FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%),Positive,Negative,,43.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Supportive/Palliative Care,3.0,3.0,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)",Cytarabine,Supportive/Palliative Care,Supportive/Palliative Care,125.0,Dead,245.0,Dead-Disease,,,,,0.0,0.0,0.0,31.9,,12.4,,2.6,0.1,,,,,,22.95,59.0,3.0,,,0.77,7.5,,26.0,16.0,297.0,95.7,"Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b, CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and HLA-DR positive"
C43,S190,2059,15-00276,2366.0,BA2714D,BA2714R,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,NotDetected,"46,XY[20]",Normal,FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%),Negative,Positive (p.W288fs*12; MAF 50%),,60.0,0.0,2059_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,167.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",Azacitidine,Standard Chemotherapy,Salvage,6.0,Dead,870.0,Dead-Disease,90.0,61.0,,,0.0,1.0,4.0,47.0,,10.0,,1.0,0.1,,,,,,70.84,80.0,2.4,,,1.17,4.6,,30.0,26.0,612.0,104.5,"dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT"
C260,S191,2059,17-00350,2366.0,BA3317D,BA3317R,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,Other,"46,XY,t(3;4)(p21;q21)[20]",Normal,FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%),Negative,Positive (p.W288fs*12; MAF 41%),,62.0,769.0,2059_2,Relapse,Relapse,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,167.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",Azacitidine,Standard Chemotherapy,Salvage,6.0,Dead,870.0,Dead-Disease,80.0,45.0,,,0.0,1.8,0.0,49.6,,0.0,,3.5,0.9,,,,,,3.42,44.0,3.0,,,0.85,9.3,,31.0,20.0,261.0,99.6,"CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123,  partial TdT, and partial MPO+ "
C46,S193,2068,15-00302,2445.0,BA2036D,BA2036R,Female,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,,,,KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%),Negative,Positive (p.Trp288fs (NM_002520.6); MAF 27.4%),,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Dead,21.0,Dead-Treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia"
C49,S195,2075,15-00309,2584.0,BA3053D,BA3053R,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XY[6]",,,Positive (MAF 44%; AR 0.785714286),Positive,,64.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,395.0,Dead-Disease,,,,,,,,,,,,,,,,,,,25.7,,,,,,,,,,,,
C45,S196,2079,15-00296,2114.0,BA2952D,BA2952R,Female,16.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,M5,M5,Intermediate,KMT2A_re,"46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]","MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS:   62% of cells had three signals for both ABL and ASS (9q34), consistent with the clone with +9. | RUNX1T1 (8q22):   69% of cells had three signals for RUNX1T1, consistent with the clone with +8. | EGR1:   7% of cells had three signals for EGR1 (5q31), consistent with the clone with +5.",KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF19%),Negative,Negative,,16.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Induction|Intensification,Complete Response,Standard Chemotherapy,10.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine, Mitoxantrone|Etoposide, Cytarabine","Cytarabine, Mitoxantrone",Standard Chemotherapy,Intensification,-1.0,Alive,2272.0,Alive,93.0,,,,0.0,0.0,0.0,33.0,,67.0,,0.0,0.0,,,,,,24.72,39.0,,,,0.72,6.1,,,,934.0,100.0,"CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56, CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive"
C44,S197,2087,15-00279,2342.0,BA2139D,BA2139R,Female,48.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5b,M5,Intermediate,NotDetected,"46,XX",,DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%),Positive (MAF 44%; AR 0.785714286),Positive,,48.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4.0,4.0,Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16","TBI, VP-16",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,939.0,Alive,86.0,77.0,,,,,,,,,,,,,,,,,81.0,,,,,,,,,,,,"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population of atypical monocytic cells (weaker than normal CD33, partial loss of CD13) including promonocytes/monoblasts representing approximately 50% of the leukocytes"
C50,S198,2094,15-00338,2323.0,BA2532D,BA2532R,Female,42.0,1.0,Cervical Cancer|Pituitary Tumor,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XX,t(15;17)(q24;q21.1)[1]","nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,42.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Targeted Therapy - Other|Intrathecal,3.0,3.0,Induction|Experimental|Maintenance,Complete Response,Targeted Therapy - Other,34.0,"ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate","ATRA, 6-MP, Methotrexate",Standard Chemotherapy,Maintenance,-1.0,Alive,952.0,Alive,92.0,83.0,,,0.0,0.0,,11.0,1.0,4.0,,0.0,,,,1.0,,,,35.0,3.9,,,0.66,7.6,,35.0,35.0,475.0,88.4,"CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-)."
C51,S199,2113,15-00371,2533.0,BA2515D,BA2515R,Male,74.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,"46,XY[18]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,mono,75.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,91.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",HiDAC,Standard Chemotherapy,Consolidation,48.0,Dead,324.0,Dead-Unknown,32.0,5.0,,,0.0,0.0,,69.0,,8.0,,18.0,,,3.0,,,,2.3,178.0,4.3,,,1.21,11.1,,23.0,22.0,199.0,,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +) (34% population of variably-sized cells)"
C52,S200,2116,15-00377,2566.0,BA2748D,BA2748R,Female,10.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Favorable,NotDetected,"46,XX[20]",Normal,"CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF 5%)|NRAS (p.Q61H; MAF 10%)",Negative,Negative,bi,10.0,0.0,2116_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,33.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,2143.0,Alive,80.0,75.0,,,0.0,1.7,6.1,17.4,,7.8,,11.3,0.7,,,,,,39.69,74.0,3.7,,,0.51,9.1,,24.0,22.0,688.0,83.7,"variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive"
C190,S201,2116,16-01097,2566.0,BA2577D,BA2577R,Female,10.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,NonInitial,Other,"47,XX,+10[19]/46,XX[1]",Normal,,Negative,Negative,bi,12.0,568.0,2116_2,Relapse,Relapse,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,33.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,2143.0,Alive,46.0,,,,0.0,0.0,0.0,81.3,,8.3,,10.4,18.1,,,,,,1.93,11.0,3.8,,,0.53,10.2,,31.0,27.0,,96.8,"variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive"
C157,S202,2119,16-00548,2453.0,BA2758D,BA2758R,Male,76.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,NonInitial,Other,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]","Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male. | Two cells had non-clonal abnormalities. 50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.",,Negative,Negative,,77.0,417.0,2119_1,Relapse,Relapse,Post-Chemotherapy|Relapse,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),Incyte trial (azacitidine and JAK 1 inhibitor),Standard Chemotherapy,Induction,77.0,Dead,520.0,Dead-Unknown,50.0,10.0,,,0.0,0.9,,60.3,,38.5,,0.3,,,,,,,3.4,7.0,3.2,,,1.0,8.6,,19.0,19.0,261.0,102.5,"dim CD4, CD13, bright CD34, dim CD45, CD117, HLA-DR, and dim TdT positive"
C160,C160,2119,16-00603,,,,Male,76.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,NonInitial,Other,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]","Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male. | Two cells had non-clonal abnormalities. 50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.",,,,,77.0,433.0,2119_2,Residual,Residual,Residual Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),Incyte trial (azacitidine and JAK 1 inhibitor),Standard Chemotherapy,Induction,77.0,Dead,520.0,Dead-Unknown,,,,,0.0,0.0,0.9,48.3,,48.2,,0.0,0.0,,,,,,8.59,36.0,3.3,,,1.1,8.7,,19.0,22.0,,97.0,
C164,C164,2119,16-00615,,,,Male,76.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,NonInitial,Other,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]","Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male. | Two cells had non-clonal abnormalities. 50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.",,,,,77.0,444.0,2119_3,Residual,Residual,Residual Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,35.0,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),Incyte trial (azacitidine and JAK 1 inhibitor),Standard Chemotherapy,Induction,77.0,Dead,520.0,Dead-Unknown,,,,,0.0,0.0,0.0,49.6,,39.1,,4.3,0.0,,,,,,10.85,9.0,3.2,,,1.3,9.0,,19.0,23.0,,94.9,
C53,S210,2147,15-00464,2412.0,BA2052D,BA2052R,Male,71.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]","nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]","BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)",Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Supportive/Palliative Care,1.0,1.0,Hypomethylating/Low Dose Cytarabine,,,,Azacitidine,Azacitidine,Supportive/Palliative Care,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,288.0,Dead-Unknown,34.0,,,,0.9,2.8,,,,,,,,,1.0,,,,,73.0,4.2,,1.7,1.18,9.8,,28.0,27.0,194.0,,"CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of medium to large cells)"
C55,S211,2195,15-00534,2101.0,BA2804D,BA2804R,Male,87.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Intermediate,Other,"47,XY,+21[3]/46,XY[9]",9.5% gain 21q22,ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%),Negative,Negative,mono,87.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,2.0,Hypomethylating/Low Dose Cytarabine|Experimental,,,,AG-120|Decitabine,AG-120,Targeted Therapy - Other,Experimental,-1.0,Dead,249.0,Dead-Disease,60.0,39.0,,,,,,,,2.0,,,,,,,,,139.9,43.0,,,,,,,,,,,"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO"
C56,S212,2196,15-00539,2456.0,BA2670D,BA2670R,Female,72.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]","nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",RUNX1 (PB)|SF3B1 (PB),Negative,Negative,,73.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Other,4.0,2.0,Hypomethylating/Low Dose Cytarabine|Maintenance,,,,"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine","Clofarabine, Cytarabine",Other,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,465.0,Dead-Disease,,25.0,,,0.0,0.0,,2.0,1.0,54.0,,18.0,,,,,,,58.2,,3.6,,0.4,0.58,8.8,,41.0,34.0,,,
C57,S213,2202,15-00556,2133.0,BA2675D,BA2675R,Male,10.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M2,M2,Intermediate,NotDetected,"46,XY[20]",,CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%),Positive,Negative,mono,10.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Other,4.0,4.0,Unknown|Induction|CNS|Re-induction,Refractory,Other,33.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC",Unknown,Bone Marrow Transplant,Unknown,-1.0,Alive,2095.0,Alive,75.0,86.0,,,0.0,0.0,0.0,7.5,,1.8,,4.7,0.1,,,,,,133.63,42.0,3.6,,,0.47,6.9,,13.0,23.0,970.0,96.0,"variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive"
C58,S214,2204,15-00563,2387.0,BA2031D,BA2031R,Female,2.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XX,t(6;11)(q27;q23)[19]/46,XX[1]",,,Negative,Negative,,2.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4.0,3.0,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,136.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1937.0,Alive,80.0,70.0,,,0.0,0.0,1.8,46.0,,0.0,,0.0,0.2,,,,,,57.08,40.0,,,,0.24,6.9,,22.0,53.0,,92.8,"CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive"
C59,S217,2213,15-00571,2338.0,BA2933D,,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,NotDetected,"46,XY[20]",Normal,ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%),Positive,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Dead,42.0,Dead-Disease,84.0,78.0,,,,,,,,,,,,,,,,,25.0,,,,,,,,,,,,"partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)"
C60,S218,2214,15-00578,2066.0,BA2066D,BA2066R,Female,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,KMT2A_re,"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]","MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia",ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%),Negative,Negative,,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Other,4.0,4.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,7.0,"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG","Fludarabine, Melphalan, TBI, ATG",Bone Marrow Transplant,Allogeneic - Child,-1.0,Dead,317.0,Dead-Other,95.0,71.0,,,0.0,0.0,0.0,9.5,,23.3,,0.0,0.1,,,,,,87.72,26.0,3.3,,,0.78,9.1,,54.0,57.0,861.0,93.2,"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR"
C133,C133,2225,16-00265,,,,Female,71.0,1.0,Follicular lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]","- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.",,Positive (MAF 50%),,,72.0,249.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,5.0,4.0,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,280.0,Dead-Disease,96.0,99.0,,,,,,,,,,,,,,,,,20.39,,,,,,,,,,,,
C252,S229,2254,17-00304,2292.0,BA3400D,BA3400R,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XX[20]","nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Positive,,54.0,616.0,,Relapse,Relapse,Relapse,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)","MEC (Cytarabine, Etoposide, Mitoxantrone)",Standard Chemotherapy,Salvage,-1.0,Dead,633.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C62,S230,2265,15-00670,2424.0,BA2035D,BA2035R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,NotDetected,,Normal,DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% ),Positive,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea",Midostaurin,Targeted Therapy - Kinase Inhibitor(s),Maintenance,284.0,Alive,2182.0,Alive,92.0,98.0,,,0.0,0.0,0.8,2.6,,0.0,,0.0,0.1,,,,,,84.96,49.0,3.2,,,0.86,6.8,,35.0,23.0,330.0,106.4,"dim CD33, CD34, CD38, dim CD45, CD117, and MPO"
C61,C61,2269,15-00673,,,,Female,54.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,M4,Adverse,Other,"50,XX,+8,+10,+12,+21[20]",- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells,EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%),Negative,Negative,,54.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,19.0,"7+3 (Cytarabine, Idarubicin) plus Sorafenib","7+3 (Cytarabine, Idarubicin) plus Sorafenib",Standard Chemotherapy,Induction,19.0,Dead,36.0,Dead-Treatment,75.0,,,,,,,,,39.0,,,,,,,,,37.2,9.0,,,,,,,,,,,"CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO"
C63,S231,2272,15-00680,2291.0,BA2201D,BA2201R,Male,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Adverse,NotDetected,"46,XY[20]",Normal,FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%),Positive,Positive (p.W288fs*; MAF 49%),,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,23.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)","Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,861.0,Dead-Other,86.0,,,,0.9,0.0,0.0,2.6,,20.8,,0.9,0.2,,,,,,134.36,83.0,2.9,,,1.49,10.8,,20.0,28.0,1211.0,95.9,"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive"
C504,S232,2276,15-00688,2088.0,BA2113D,BA2113R,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]","EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo",TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%),Negative,Negative,,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,9.0,Decitabine,Decitabine,Standard Chemotherapy,Induction,9.0,Dead,25.0,Dead-Disease,41.0,,,,1.8,0.9,0.0,79.6,,0.9,,14.2,0.0,,,,,,1.61,6.0,2.7,,,0.98,9.4,,21.0,19.0,404.0,88.5,"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive."
C64,S233,2277,15-00692,2402.0,BA2155D,BA2155R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M0,M0,NonInitial,RARA_re,"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]","nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%),Negative,Negative,bi,73.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Supportive/Palliative Care,3.0,4.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",Azacitidine,Supportive/Palliative Care,Hypomethylating/Low Dose Cytarabine,112.0,Dead,565.0,Dead-Disease,81.0,94.0,,,0.0,0.0,,5.0,,3.0,,1.0,,,,,,,35.0,10.0,4.5,,,0.99,9.6,,11.0,16.0,,,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +) (87% pop of med to large size cells) | HLA-DR(partial +)"
C65,S235,2280,15-00701,2328.0,BA2502D,BA2502R,Female,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with minimal differentiation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,NonInitial,Other,"48,XX,+11,+13[19]",Not available,,Negative,Negative,,50.0,0.0,,Residual,Residual,Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Other,6.0,5.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",Hydroxyurea,Other,Hypomethylating/Low Dose Cytarabine,365.0,Dead,302.0,Dead-Disease,,,,,0.0,0.0,2.6,8.8,,17.6,,2.6,0.0,,,,,,206.64,31.0,,,,,6.4,,,,,93.4,
C66,S236,2281,15-00702,2060.0,BA2322D,BA2322R,Female,35.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M2,M2,Favorable,CBFB-MYH11,"46,XX,inv(16)(p13.3q22)[21]","CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype. (c/w karyotype (inv 16))",NRAS (p.Q61P; MAF 15% ),Negative,Negative,,35.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,10.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,112.0,Alive,1937.0,Alive,42.0,,,,1.7,0.9,0.0,40.0,1.7,18.3,,7.8,0.2,,,,,,12.78,63.0,3.5,,,0.6,6.8,,54.0,23.0,319.0,102.5,"Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive."
C69,C69,2287,15-00723,,,,Male,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XY[20]",Normal,FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%),Positive (MAF 3%),Positive (c.860_863dup; MAF 14.5%),,51.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,762.0,Alive,78.5,71.0,,,,,,,,,,,,,,,,,12.0,,,,,,,,,,,,"CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (""atypical cells with dim CD45"" - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage that lack CD10, CD11b,  and CD16) (Myeloid (19% of leukocytes))"
C68,S237,2293,15-00734,2014.0,BA2226D,BA2226R,Female,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%),Negative,Positive (p.W288fs*12; MAF 40%),,53.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,153.0,SWOG S1203 (7+3 +/- Vorinostat),SWOG S1203 (7+3 +/- Vorinostat),Standard Chemotherapy,Induction,153.0,Alive,2204.0,Alive,93.0,80.0,,,0.0,0.0,1.7,19.3,,20.2,,13.2,0.6,,,,,,42.34,36.0,3.1,,,0.79,8.8,,47.0,37.0,977.0,92.1,"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64"
C67,S238,2295,15-00717,2513.0,BA2376D,BA2376R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XY[20]",Normal,DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%),Negative,Positive (p.W288fs*12; MAF 40%),,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Induction,6.0,Alive,3000.0,Alive,68.0,,,,0.4,0.1,3.0,17.0,,62.6,,16.9,0.1,,,,,,16.84,74.0,3.7,,,1.51,8.9,,29.0,17.0,296.0,104.9,"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive"
C71,S239,2300,15-00742,2360.0,BA2889D,BA2889R,Female,34.0,1.0,Pituitary macroadenoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]",21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.,,Negative,Negative,,34.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Induction,-1.0,Alive,1881.0,Alive,96.0,,,,0.0,0.0,4.0,60.0,,14.0,,22.0,0.0,,,,,,0.5,32.0,4.0,,,0.58,10.7,,21.0,15.0,191.0,95.9,"CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive"
C70,S240,2304,15-00755,2371.0,BA2200D,BA2200R,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,Other,"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]",,DNMT3A (c.2251T>C; MAF 36.9%)|FLT3-ITD (c.1759_1800dup; MAF 24%)|NPM1 (c.860_863dup; MAF 9.9%),Positive,Positive (c.860_863dup; MAF 9.9%),,59.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)","Azacitidine, Sorafenib",Standard Chemotherapy,Re-induction,-1.0,Dead,256.0,Dead-Disease,93.2,47.5,,,,,,,,,,,,,,,,,42.91,,,,,,,,,,,,"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64"
C72,S241,2305,15-00756,2356.0,BA2121D,BA2121R,Male,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M2,M2,Favorable,RUNX1-RUNX1T1,"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]",RUNX1T1/RUNX1: (92%),CBL (p.E369_Y371delinsH; MAF 31%),Negative,Negative,,36.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea",HiDAC,Standard Chemotherapy,Consolidation,103.0,Unknown,552.0,,25.0,38.0,,,0.0,0.0,3.4,29.1,,2.6,,23.9,0.0,,,,,,24.98,29.0,2.3,,,0.7,7.5,,32.0,39.0,,104.5,"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO"
C75,S243,2308,15-00764,2589.0,BA3064D,BA3064R,Male,38.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,,Normal,,Positive (MAF 80%; AR 4),Negative,,40.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6.0,7.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,38.0,Dead,717.0,Dead-Disease,71.0,46.0,,,,,,,,,,,,,,,,,34.0,,,,,,,,,,,,"CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase"
C73,S244,2310,15-00766,2432.0,BA2033D,BA2033R,Male,71.0,1.0,Non-Hodgkins Lymphoma,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,Other,"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2, (dic(8;11)(p12;p11.2)x2,-psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter),-10,der(10;17)(q10;q10), der(12;13)(p10;q10),der(14;17)(q10;q10),-16,-17,-18,add(20)(p11.2)[cp4])","FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.",TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%),Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Lenalidomide|Decitabine,Decitabine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,11.0,Dead-Disease,60.0,14.0,,,,,,,,7.0,,,,,,,,,21.6,17.0,,,,,,,,,,,"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry. (Aberrant CD56, unusually dim CD38 - but only 3-4% assayed cells are myeloblasts)"
C74,S245,2311,15-00767,2116.0,BA2867D,BA2867R,Male,78.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,NotDetected,"46,XY[20]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,mono,78.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Hypomethylating/Low Dose Cytarabine,,,,Decitabine,Decitabine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,347.0,Dead-Disease,25.0,4.0,,,0.2,1.0,,25.0,,10.0,,60.0,,,,,,,5.79,15.0,4.5,,,0.82,15.3,,22.0,21.0,,,"CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+) (Population #1 - 5.3%) | CD2(-), CD7(-), CD10 (-), CD11b(-), CD13(bright and variably +), CD14(-), CD15(-), CD16(-), CD22(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), and TdT (-). (Population #2 - 25%)"
C76,S246,2314,15-00777,2080.0,BA2089D,BA2089R,Male,68.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,NotDetected,"46,XY[20]",normal,ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%),Negative,Negative,,68.0,0.0,2314_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Leukapheresis,1.0,Standard Chemotherapy,2.0,2.0,Induction|Maintenance,Refractory,Standard Chemotherapy,7.0,"3+7 (Cytarabine, Daunorubicin)|Azacitidine|Decitabine",Decitabine,Standard Chemotherapy,Induction,7.0,Dead,122.0,Dead-Unknown,,83.0,,,0.0,0.0,0.8,8.1,,9.8,,1.6,0.7,,,,,,140.18,104.0,3.3,,,2.67,11.4,,29.0,137.0,3615.0,92.4,
C96,S247,2314,15-00939,2080.0,BA2034D,BA2034R,Male,68.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,NonInitial,NotDetected,"46,XY[19]",Not available,,Negative,Negative,,68.0,72.0,2314_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Maintenance,Refractory,Standard Chemotherapy,7.0,"3+7 (Cytarabine, Daunorubicin)|Azacitidine|Decitabine",Decitabine,Standard Chemotherapy,Induction,7.0,Dead,122.0,Dead-Unknown,,,,,0.8,0.9,0.0,9.3,,0.0,,0.0,0.5,,,,,,6.21,60.0,2.5,,,0.9,6.4,,12.0,14.0,,90.4,
C197,S248,2315,16-01138,2202.0,BA2470D,BA2470R,Male,62.0,0.0,,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,NonInitial,Other,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",EGR1 (73.5%) ;  TP53: (85.5%),,Negative,Negative,,63.0,412.0,,Relapse,Relapse,Relapse,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,Decitabine|Hydroxyurea,Hydroxyurea,Standard Chemotherapy,Re-induction,263.0,Dead,424.0,Dead-Disease,,,,,0.9,0.0,0.0,7.8,,1.7,,4.3,0.1,,,,,,46.79,139.0,2.8,,,1.43,8.2,,18.0,21.0,564.0,102.5,
C77,S249,2322,15-00786,2111.0,BA2972D,BA2972R,Male,40.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XY[20]",normal,CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%),Negative,Negative,bi,40.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)","Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,2163.0,Alive,80.0,27.8,,,0.0,0.0,0.0,62.6,,4.4,,5.2,0.0,,,,,,2.68,66.0,3.9,,,0.78,13.2,,26.0,22.0,,91.7,"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+."
C80,S250,2333,15-00807,2411.0,BA2978D,BA2978R,Female,14.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M2,M2,Favorable,RUNX1-RUNX1T1,"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]","All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).",FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%),Negative,Negative,,14.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,DLI|Standard Chemotherapy|Bone Marrow Transplant,8.0,4.0,Allogeneic - Sibling|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,189.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide|Clofarabine, Cytarabine",Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501),Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,2083.0,Alive,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO"
C78,S251,2337,15-00811,2238.0,BA2829D,BA2829R,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,Other,"46,XY,add(3)(p24)[cp4]/46,XY[14]",Not available,CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%),Positive,Positive (p.W288fs*12; MAF 0.7%),,54.0,7.0,2337_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,5.0,Induction|Experimental|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,49.0,Dead,168.0,Dead-Disease,9.0,,,,0.0,1.7,0.9,6.1,,8.8,,43.0,0.4,,,,,,16.65,170.0,3.4,,,0.71,9.1,,38.0,29.0,321.0,95.1,"CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)"
C94,S252,2337,15-00936,2238.0,BA2249D,BA2249R,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,RARA_re,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",Not available,DNMT3A (p.R882C; MAF 45%)FLT3 (p.D835H; VAF 14.7%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%),Positive (MAF 90%; AR 9),Positive (p.W288fs*12; MAF 40%),,54.0,63.0,2337_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,5.0,Induction|Experimental|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,49.0,Dead,168.0,Dead-Disease,48.0,,,,1.8,3.6,6.2,23.2,,18.7,,17.0,1.3,,,,,,20.77,21.0,3.6,,,1.0,6.9,,29.0,41.0,,96.3,"dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive"
C95,C95,2337,15-00938,,,,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,RARA_re,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",Not available,DNMT3A (p.R882C; MAF 45%)FLT3 (p.D835H; VAF 14.7%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%),Positive (MAF 78%),Positive (p.W288fs*12; MAF 40%),,54.0,65.0,2337_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,5.0,Induction|Experimental|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,49.0,Dead,168.0,Dead-Disease,48.0,40.0,,,0.9,0.0,1.8,11.7,,20.7,,26.1,0.4,,,,,,15.93,13.0,3.5,,,0.8,7.6,,27.0,38.0,,93.4,"dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive"
C101,S253,2337,15-00964,2238.0,BA2979D,,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,RARA_re,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",Not available,DNMT3A (p.R882C; MAF 45%)FLT3 (p.D835H; VAF 14.7%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%),Positive (MAF 95%; AR 19),Positive (p.W288fs*12; MAF 40%),,54.0,75.0,2337_3,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,5.0,Induction|Experimental|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,49.0,Dead,168.0,Dead-Disease,,,,,0.0,0.0,0.0,14.3,,2.4,,3.2,1.3,,,,,,19.3,23.0,2.6,,,0.86,7.6,,41.0,36.0,346.0,92.3,
C79,S254,2339,15-00813,2437.0,BA2851D,BA2851R,Female,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882H; MAF 45%)|FLT3 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%),Negative,Negative,,53.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,4.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)","MEC (Cytarabine, Etoposide, Mitoxantrone)",Standard Chemotherapy,Re-induction,7.0,Dead,128.0,Dead-Disease,45.0,50.0,,,0.0,0.0,19.4,6.4,,1.6,,11.3,0.0,,,,,,137.54,33.0,3.3,,,0.88,9.6,,73.0,83.0,2008.0,109.3,"partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO"
C82,S255,2350,15-00837,2049.0,BA2623D,BA2623R,Male,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",,,Negative,Negative,,72.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2.0,2.0,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Azacitidine|Momelotinib,Azacitidine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,-1.0,Dead,188.0,Dead-Disease,,58.0,,,,,,,,,,,,,,,,,8.21,,,,,,,,,,,,
C505,C505,2357,15-00849,,,,Male,62.0,1.0,Non-Hodgkins Lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",positive for rearrangement of CBFB in 60.5% of cells.,EZH2 (p.D146H; MAF 50%),Negative,Negative,,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Unknown,26.0,,50.0,20.0,,,,,,,,,,,,,,,,,52.8,32.0,,,,,,,,,,,"positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7. (Peripheral blood) | positive for CD34, CD117, HLA-DR, CD13, and CD33 (Marrow)"
C83,S256,2360,15-00855,2386.0,BA2271D,BA2271R,Male,8.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Myeloid proliferations associated with Down syndrome,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,M1,M1,Favorable,Other,"47,XY,+21c[20]",RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.,NPM1 (p.W288fs*12; MAF 50%),Negative,Positive (p.W288fs*12; MAF 50%),,8.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Intrathecal,2.0,2.0,Induction|CNS,Complete Response,Standard Chemotherapy,151.0,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine",Cytarabine,Intrathecal,CNS,151.0,Alive,2327.0,Alive,70.0,,,,10.8,0.0,1.8,8.1,,13.5,,8.1,0.0,,,,0.9,,67.53,40.0,3.2,,,0.72,9.3,,13.0,25.0,,90.5,"dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO"
C506,S257,2362,15-00858,2420.0,BA3004D,BA3004R,Female,76.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[22]",Normal,ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%),Positive,Positive (p.W288fs*12; MAF 35%),,76.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,8.0,"5+2 (Cytarabine, Idarubicin)|Decitabine","5+2 (Cytarabine, Idarubicin)",Standard Chemotherapy,Re-induction,4.0,Dead,26.0,Dead-Disease,95.0,54.0,,,0.0,0.0,0.9,16.8,,3.5,,24.8,1.1,,,,,,27.17,29.0,3.5,,,1.33,10.3,,23.0,22.0,244.0,92.6,"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive"
C86,S258,2364,15-00870,2478.0,BA3010D,BA3010R,Male,71.0,1.0,Non-Hodgkins Lymphoma,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,NotDetected,"46,XY[20]",Not Available,BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%),Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Maintenance,,,,Vidaza|Rituximab|Decitabine,Decitabine,Standard Chemotherapy,Maintenance,86.0,Dead,51.0,Dead-Disease,20.0,10.0,,,,1.0,,22.0,,48.0,,16.0,,,1.0,,,,44.8,13.0,3.7,,0.6,1.57,8.1,,6.0,33.0,,91.9,"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)"
C87,S259,2367,15-00872,2393.0,BA2662D,BA2662R,Female,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with mutated CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Intermediate,NotDetected,"46,XX[20]",Normal,CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%),Positive,Positive (p.W288fs*12; MAF 46%),,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Other,4.0,4.0,Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1962.0,Alive,74.0,60.0,,,0.0,1.9,15.1,21.7,,50.0,,11.3,0.0,,,,,,84.69,150.0,2.6,,,0.78,7.2,,23.0,32.0,905.0,100.5,
C85,S260,2416,15-00883,2044.0,BA2280D,BA2280R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XX[20]",Normal,CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%),Positive,Positive (p.W288fs*12; MAF 40%),,72.0,0.0,2416_1,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3.0,2.0,Induction|Experimental,Refractory,Standard Chemotherapy,10.0,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",Ponatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,15.0,Dead,118.0,Dead-Disease,90.0,78.0,,,0.9,0.0,0.0,2.7,,3.6,,17.3,1.4,,,,,,24.01,211.0,2.8,,,0.56,9.9,,28.0,23.0,261.0,98.1,"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO"
C100,S261,2416,15-00967,2044.0,BA2277D,BA2277R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XX[5]",Normal,CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%),Positive (MAF 39%; AR 0.639344262),Positive (p.W288fs*12; MAF 32%),,72.0,40.0,2416_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3.0,2.0,Induction|Experimental,Refractory,Standard Chemotherapy,10.0,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",Ponatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,15.0,Dead,118.0,Dead-Disease,,70.0,,,0.0,0.0,1.8,34.8,,3.6,,0.9,23.2,,,,,,6.04,32.0,3.2,,,0.55,7.5,,13.0,40.0,339.0,89.7,
C89,S262,2420,15-00900,2218.0,BA2658D,BA2658R,Male,24.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,NotDetected,"46,XY[20]",Normal,NRAS (p.G12C; MAF 40%),Negative,Negative,,24.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,7.0,7.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Venetoclax (ABT-199), Azacitidine|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Venetoclax|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide","Venetoclax (ABT-199), Azacitidine",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,3214.0,Alive,,,,,0.0,1.8,0.9,23.9,,23.0,,7.9,0.0,,,,,,21.84,102.0,3.7,,,0.95,11.3,,37.0,28.0,243.0,92.8,"dimCD13, CD33, CD34, CD56, CD117, and  CD123"
C92,S263,2421,15-00892,2257.0,BA2512D,BA2512R,Female,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,,Normal,DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%),Negative,Positive (c.860_863dup; MAF 11%),,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Targeted Therapy - Other,1.0,1.0,Induction,Complete Response,Targeted Therapy - Other,-1.0,SGN-CD33A,SGN-CD33A,Targeted Therapy - Other,Induction,-1.0,Dead,179.0,Dead-Disease,41.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"partial CD56, bright CD33,  CD13, bright CD64, HLA-DR (Monocytic cells)"
C93,S264,2423,15-00903,2381.0,BA2394D,BA2394R,Male,73.0,1.0,Lung Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"45,X,-Y[20]",Normal,,Negative,Negative,,73.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Hypomethylating/Low Dose Cytarabine,,,,Azacitidine,Azacitidine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,7.0,Dead,36.0,Dead-Disease,,79.0,,,,,,,,,,,,,,,,,19.64,,,,,,,,,,,,
C90,S265,2425,15-00909,2018.0,BA2950D,BA2950R,Female,44.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with minimal differentiation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,,M0,NonInitial,NotDetected,"46,XX[20]",This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined. (Cytogenetics),,Positive (MAF 50%; AR 1),Negative,,47.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Targeted Therapy - Other,1.0,1.0,Unknown,,,,Radiation,Radiation,Targeted Therapy - Other,Unknown,14.0,Unknown,1231.0,,90.0,45.0,,,,0.0,,28.0,,5.0,,1.0,,,1.0,,,,6.5,5.0,3.3,,0.7,0.82,9.6,,30.0,41.0,,89.9,"The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers. (Bone Marrow Immunophenotyping)"
C91,S266,2426,15-00912,2156.0,BA2981D,BA2981R,Female,76.0,1.0,Breast Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]",Not Available,,Negative,Negative,,77.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Unknown,1.0,1.0,Unknown,,,,Azacitidine,Azacitidine,Unknown,Unknown,424.0,Dead,151.0,Dead-Unknown,86.0,50.0,,,,1.0,,14.0,,5.0,1.0,20.0,,,,,,,14.3,27.0,2.9,,0.6,0.62,7.8,,32.0,20.0,,84.1,"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58."
C98,C98,2433,15-00930,,,,Female,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XX[20]","""showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).""",,Negative,Negative,,50.0,0.0,,Remission,Remission,Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,4.0,4.0,Consolidation|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC",Azacitidine,Standard Chemotherapy,Maintenance,8.0,Dead,425.0,Dead-Treatment,0.5,,,,,,,,,,,,,,,,,,10.08,,,,,,,,,,,,
C97,S267,2437,15-00942,2177.0,BA2339D,BA2339R,Female,30.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,,M5,NonInitial,KMT2A_re,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]","This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample. (Cytogenetics)",,Negative,Negative,,31.0,0.0,2437_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,93.0,Unknown,486.0,,27.0,43.0,,,,,,12.0,,40.0,,5.0,,,,,,,5.3,5.0,4.6,,0.6,1.01,8.5,,35.0,62.0,,90.6,"There are increased abnormal cells in the ""monocyte"" gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression. (Bone Marrow Immunophenotyping)"
C508,S268,2437,16-00010,2177.0,BA2786D,BA2786R,Female,30.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,,M5,NonInitial,KMT2A_re,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]","This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample. (Cytogenetics)",,Negative,Negative,,31.0,25.0,2437_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,93.0,Unknown,486.0,,79.0,64.0,,,,,,2.0,,15.0,,1.0,,,,2.0,,,20.3,69.0,4.0,,0.6,0.52,9.6,,44.0,53.0,,89.4,"POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT (Bone Marrow Immunophenotyping)"
C118,S269,2442,16-00088,2074.0,BA2256D,BA2256R,Female,25.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]",This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.,,Positive (MAF 50%; AR 1),Negative,,26.0,49.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,1.0,Standard Chemotherapy,4.0,3.0,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin","Azacitidine, Sorafenib",Standard Chemotherapy,Re-induction,67.0,Dead,324.0,Dead-Unknown,98.0,95.0,,,,,,2.0,,3.0,,,,,,0.0,,,67.7,81.0,4.1,,0.4,0.54,8.9,,46.0,30.0,,90.4,"These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)"
C112,S270,2443,16-00073,2172.0,BA2483D,BA2483R,Female,63.0,1.0,Cervical Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,KMT2A_re,"48,XX,+8,+21[16]/46,XX[4]","RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn | RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) ",,Negative,Negative,,64.0,44.0,2443_1,Residual,Residual,Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6.0,5.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,29.0,Dead,348.0,Dead-Disease,85.0,38.5,,,1.5,0.0,0.0,55.0,,3.5,,1.5,0.0,,,,,,19.76,18.0,3.8,,,1.3,7.1,,25.0,22.0,,91.3,"CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive"
C122,S271,2443,16-00118,2172.0,BA3002D,BA3002R,Female,63.0,1.0,Cervical Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,KMT2A_re,"48,XX,+8,+21[16]/46,XX[4]","RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) ",,Negative,Negative,,64.0,58.0,2443_2,Residual,Residual,Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6.0,5.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,29.0,Dead,348.0,Dead-Disease,85.0,,,,0.0,0.0,0.0,12.6,,0.0,,0.0,0.2,,,,,,49.93,21.0,3.1,,,1.57,7.0,,16.0,36.0,887.0,89.7,"CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive"
C99,S272,2444,15-00961,2251.0,BA2109D,BA2109R,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,,,,NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%),Negative,Negative,,52.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,8.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,81.0,Dead,585.0,Dead-Disease,,,,,0.0,30.0,13.0,9.0,,21.0,,19.0,0.1,,,,,,65.58,21.0,2.2,,,0.84,6.5,,54.0,50.0,,98.9,
C108,S274,2452,15-00975,2140.0,BA2132D,BA2132R,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"46,XX,del(5)(q22q35)[20]",Positive for 5q deletion in 91% of cells. (Cytogenetics),FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%),Positive (MAF 25%; AR 0.333333333),Negative,,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,37.0,Azacitidine,Azacitidine,Standard Chemotherapy,Induction,37.0,Unknown,37.0,,90.0,17.0,,,,,,20.0,,18.0,,2.0,,,,,,,7.7,35.0,3.8,,0.5,0.76,8.2,,24.0,26.0,,87.7,"POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)"
C103,S275,2453,15-00976,2498.0,BA2618D,BA2618R,Male,83.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Normal,CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%),Negative,Negative,,83.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,2.0,Induction|Experimental,Refractory,Standard Chemotherapy,-1.0,"AG-221|Azacitidine, SGN-CD33A",AG-221,Targeted Therapy - Other,Experimental,-1.0,Dead,434.0,Dead-Disease,12.0,3.0,,,0.3,0.0,9.4,26.9,,24.5,,38.9,0.0,,,,,,3.72,213.0,3.2,,,1.3,6.8,,42.0,47.0,,87.9,
C104,S276,2455,15-00979,2433.0,BA2521D,BA2521R,Female,44.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%),Positive (AR 2.333333333),Positive (p.W288fs*12; MAF 46%),,44.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6.0,5.0,Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse,Complete Response i,Standard Chemotherapy,28.0,"Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",Azacitidine,Standard Chemotherapy,Post-Transplant Relapse,81.0,Dead,319.0,Dead-Disease,75.0,80.0,,,0.0,0.0,7.7,10.3,,22.2,,6.8,0.0,,,,,,69.84,42.0,2.4,,,1.25,7.4,,21.0,25.0,705.0,96.2,"CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive"
C107,S277,2459,15-00990,2139.0,BA2885D,BA2885R,Female,81.0,1.0,Skin cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%),Negative,Positive (p.W288fs*12; MAF 40%),,81.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,Azacitidine,Azacitidine,Standard Chemotherapy,Induction,6.0,Dead,14.0,Dead-Disease,90.0,70.0,,,0.0,0.0,0.8,6.1,,72.2,,12.2,0.4,,,,,,97.26,29.0,2.9,,,4.22,7.3,,62.0,50.0,262.0,90.8,"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive"
C105,S278,2460,16-00001,2368.0,BA2639D,BA2639R,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M2,M2,Favorable,CBFB-MYH11,"46,XX,t(16;16)(p13.2;q22)[20]","CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.",KIT (p.T417_D419delinsY; MAF 33%),Negative,Negative,,36.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6.0,6.0,Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,2075.0,Alive,40.0,60.0,,,0.0,1.7,0.0,33.4,,5.1,,18.8,0.1,,,,,,20.44,24.0,3.2,,,0.53,7.6,,38.0,28.0,508.0,99.6,"Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive."
C106,S279,2461,16-00003,2138.0,BA2775D,BA2775R,Male,26.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XY[15]",Normal,IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%),Negative,Positive (p.Trp288fs; MAF 19.5%),,27.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,16.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,647.0,Alive,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"weak  CD13, CD33, partial CD117, and myeloperoxidase"
C507,S282,2467,16-00015,2590.0,BA3065D,,Male,69.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XY[18]",Normal,CEBPA (p.A240fs*83 (7 bp insertion with frameshift); MAF 19%)|CREBBP (p.P1150S; MAF 18%)|FLT3-ITD (MAF 56%)|IDH2 (p.R140Q; MAF 29%)|NPM1 (p.W288fs*12; MAF 29%)|SRSF2 (p.P95L; MAF 22%),Positive,Positive (p.W288fs*12; MAF 29%),,72.0,0.0,,Relapse,Relapse,Post-Transplant|Relapse|Post-Chemotherapy,Peripheral Blood,4.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),7.0,7.0,Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,"7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Maintenance,-1.0,Alive,3078.0,Alive,95.0,50.0,,,0.0,2.6,0.9,29.8,,0.0,,30.7,0.4,,,,3.5,,7.92,103.0,2.8,,,1.22,9.6,,15.0,18.0,230.0,96.8,"Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive."
C513,S283,2472,16-00026,2287.0,BA2661D,,Male,56.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XY[20]",Normal,DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%),Negative,Positive (p.Trp288fs; MAF 16.1%),,56.0,0.0,2472_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response i,Standard Chemotherapy,12.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,634.0,Alive,89.6,51.0,,,,,,,,,,,,,,,,,31.02,54.0,,,,,,,,,,,"84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocytes/monoblasts"
C509,C509,2472,16-00039,,,,Male,56.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XY[20]",Normal,DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%),,Positive (p.Trp288fs; MAF 16.1%),,56.0,2.0,2472_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response i,Standard Chemotherapy,12.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,634.0,Alive,89.6,89.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocytes/monoblasts"
C510,S285,2475,16-00035,2514.0,BA2103D,,Female,54.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] (AML FISH Panel)",FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%),Negative,Positive (W288FS*10+; MAF 35.0%),,54.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib",HiDAC,Standard Chemotherapy,Consolidation,88.0,Alive,671.0,Alive,92.0,97.0,,,0.0,0.0,,1.0,,0.0,,2.0,,,,,,,175.91,28.0,2.7,,0.5,0.51,6.6,,135.0,113.0,1259.0,,"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-)."
C511,S286,2477,16-00031,2210.0,BA2850D,BA2850R,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,"46,XY[20]",Not Available,,Positive (MAF 60%; AR 1.5),Negative,,50.0,0.0,2477_1,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,576.0,Alive,75.0,73.0,,,,,,6.0,,6.0,,8.0,,,,,,,17.1,26.0,3.5,,0.3,1.0,8.0,,44.0,20.0,,91.5,"These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b."
C174,C174,2477,16-00781,,,,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,"46,XY[20]",Not Available,,Negative,,,51.0,225.0,2477_2,Remission,Remission,Post-Chemotherapy|Post-Transplant,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,576.0,Alive,1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,No increased or immunophenotypically abnormal blast cell populations identified.
C109,S287,2480,16-00041,2319.0,BA2027D,,Male,70.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,,Negative,DNMT3A (p.R882H; MAF 50%)|NPM1 (p.W288fs*12;MAF 40%)|SOCS1 (p.Q210H; MAF 50%)|TET2 (p.S460F; MAF 45%),Positive (MAF 80%; AR 4),Positive (p.W288fs*12;MAF 40%),,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Hydroxyurea,Hydroxyurea,Standard Chemotherapy,Supportive/Palliative Care,1.0,Dead,4.0,Dead-Disease,65.0,,,,,,,,,,,,,,,,,,96.0,,,,,,,,,,,,"Positive (increased CD34 positive blasts (50-60%), CD71 Decreased erythroid cells (less than 5%), CD61 Few scattered megakaryocytes, E-cadherin; Scattered immature erythroid precursors, CD117: Increased immature myeloid cells and blasts (70-80%), CD3: Scattered small interstitial T-cells (less than 5%), CD20 Scattered small interstitial B-cells (less than 5%)) | Negative (AML related recurrent cytogenetic abnormalities including t(15;17)) | Positive (PAX-5: Positive in few scattered small lymhocytes, CD138: scattered interstitial and perivascular plasma cells (less than 5%), Iron strian: Storage iron present in decalcified section, Reticulin Stain: Normal reticulin fiber pattern)"
C110,S288,2483,16-00048,2341.0,BA2174D,BA2174R,Female,46.0,1.0,Anaplastic Astrocytoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,Other,"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]",Normal,DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%),Negative,Negative,,46.0,0.0,2483_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,7.0,4.0,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1.0,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,637.0,Dead-Disease,25.0,16.0,,,0.9,1.7,4.3,6.1,,32.2,,48.7,0.2,,,,0.9,,42.57,92.0,3.1,,,0.64,9.5,,14.0,15.0,440.0,80.6,"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a"
C161,S289,2483,16-00593,2341.0,BA2314D,,Female,46.0,1.0,Anaplastic Astrocytoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,NotDetected,"46,XX[19]",Normal,NRAS (p.G13R;MAF 47%),Negative,Negative,,46.0,163.0,2483_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,7.0,4.0,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1.0,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,637.0,Dead-Disease,,,,,2.6,0.6,,16.2,,14.0,,66.6,,,,,,,6.8,71.0,3.9,,,,11.7,,38.0,27.0,,94.3,
C111,S290,2490,16-00056,2344.0,BA3001D,BA3001R,Female,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,NotDetected,"46,XX[20]",Normal,CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%),Negative,Positive (p.W288fs*12; MAF ~25%),,51.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,2.0,"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,2018.0,Alive,95.0,95.0,,,0.0,0.0,0.0,7.8,,0.0,,3.1,0.1,,,,,,25.02,57.0,2.9,,,0.93,6.6,,22.0,12.0,189.0,112.6,"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive"
C116,S291,2496,16-00067,2222.0,BA2311D,BA2311R,Female,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46,XX[20]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%),Negative,Negative,,53.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,4.0,4.0,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ",Cyclophosphamide,Supportive/Palliative Care,Maintenance,1.0,Alive,653.0,Alive,20.0,8.0,,,0.0,0.0,,37.0,,20.0,,30.0,,,,,,,6.63,38.0,3.3,,,0.86,6.2,,18.0,23.0,426.0,105.3,"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-)."
C117,S292,2497,16-00070,2155.0,BA2669D,,Male,24.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XY,t(15;17)(q22;q21)[20]",Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);,,Negative,Negative,,24.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,1.0,Induction,Complete Response,Standard Chemotherapy,24.0,"Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)","APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)",Standard Chemotherapy,Induction,24.0,Unknown,388.0,,86.0,73.0,,,3.6,0.0,46.0,12.6,,2.7,,5.4,0.6,,,,,,42.35,55.0,3.5,,,1.0,8.3,,76.0,35.0,467.0,86.2,"CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+)."
C113,S293,2498,16-00075,2183.0,BA3040D,BA3040R,Male,69.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]","COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML",,Negative,Negative,,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,7.0,Dead,238.0,Dead-Disease,39.0,11.0,,,,,,,,,,,,,,,,,1.6,,,,,,,,,,,,"Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))"
C115,S294,2499,16-00078,2041.0,BA2724D,BA2724R,Female,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%),Negative,Positive (W288FS*10+; MAF 37.0%),,67.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Unknown,34.0,,85.0,7.7,,,0.8,0.0,,5.1,0.9,42.7,2.6,40.2,,,,,,,56.03,42.0,1.9,,0.5,0.66,9.5,,27.0,41.0,670.0,102.5,"CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+). (Population #1; 6.5% medium-sized cells) | CD2(dim +), CD4(dim +), CD11b(variably +), CD13(variably +), CD14(partial +), CD15(variably +), CD16(partial +), CD33(slightly bright +), CD34(-), CD36(+), CD38 (variably +), CD45(+), CD64(+), CD117(-), HLA-DR(partial +), MPO(+). (Population #2; 42% medium-sized to large monocytic cells)"
C114,S295,2500,16-00077,2322.0,BA2837D,BA2837R,Male,78.0,1.0,Esophageal Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,Other,"45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]","nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,80.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Consolidation|Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,7.0,"AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",AG-120,Targeted Therapy - Other,Experimental,-1.0,Dead,605.0,Dead-Disease,,70.0,,,0.0,0.0,,7.0,,3.0,9.0,9.0,,,,2.0,,,240.43,23.0,2.6,,0.4,1.28,8.1,,11.0,57.0,1897.0,,"CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +). (63% population)"
C119,S296,2501,16-00094,2145.0,BA2821D,BA2821R,Female,37.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML without maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",M0/M1,M0/M1,Intermediate,NotDetected,"46,XX[20]",Normal,ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%),Negative,Negative,,37.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,4.0,4.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,8.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea",Azacitidine,Standard Chemotherapy,Consolidation,-1.0,Dead,542.0,Dead-Disease,95.0,74.0,,,1.7,2.5,0.8,13.6,,14.4,,10.2,0.4,,,,,,26.57,49.0,3.1,,,0.46,9.2,,23.0,14.0,,89.4,"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR"
C131,S297,2503,16-00226,2337.0,BA2363D,BA2363R,Male,79.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[22]",Normal,,Negative,Negative,,79.0,35.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,4.0,2.0,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Azacitidine|Decitabine|Hydroxyurea|V212,Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,152.0,Dead-Disease,,35.0,,,1.7,0.0,0.0,0.9,,64.4,,8.7,0.2,,,,,,116.52,438.0,3.1,,,2.11,7.8,,9.0,22.0,722.0,95.5,"CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive"
C120,S298,2508,16-00102,2316.0,BA2233D,BA2233R,Male,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,Other,"46,XY[5]","D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)    | [5]nuc ish(D5S721,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x2)[200],(D20S108,20qter)x2[200]","FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)",Negative,Positive (p.W288fs*12;MAF ~35%),,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea,CPX-351 (Liposomal Cytarabine + Daunorubicin),Standard Chemotherapy,Induction,-1.0,Alive,95.0,Alive,97.0,96.0,,,,,,,,,,,,,,,,,125.9,,,,,,,,,,,,"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR"
C121,S299,2511,16-00109,2232.0,BA2744D,BA2744R,Male,76.0,0.0,,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XY[20]",Normal,FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%),Positive (MAF 15%; AR 0.176470588),Positive (p.W288fs*12; MAF 50%),,76.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Supportive/Palliative Care,1.0,1.0,Supportive/Palliative Care,,,,Hydroxyurea,Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,7.0,Dead,8.0,Dead-Disease,,96.0,,,0.0,0.0,0.7,4.7,0.0,0.0,0.0,1.3,0.6,,,0.0,0.0,,230.05,17.0,2.3,,,0.46,10.4,,23.0,43.0,839.0,93.9,"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive"
C125,S300,2515,16-00120,2031.0,BA2501D,BA2501R,Male,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XY,t(15;17)(q24;q21)[18]/46,XY[2]","Normal (Apparently only tested for 5q31, 7cen, 7q31, 11q23)","CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)",Positive (MAF 20%; AR 0.25),Negative,,36.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin","Methotrexate, Mercaptopurine, Tretinoin",Standard Chemotherapy,Maintenance,-1.0,Alive,604.0,Alive,91.8,95.0,,,,,,,,,,,,,,,,,55.42,,,,,,,,,,,,"weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase"
C124,C124,2519,16-00128,,,,Female,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[19]",Normal (FISH) | 60% (Percent blasts/promonocytes/atypical monocytes in PB),NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs),Negative,Positive (c.859_860insTCTG; p.W288fs),,42.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,673.0,Alive,90.0,,,1.0,0.0,0.0,,17.0,,,1.0,20.0,,,0.0,,,,18.3,71.0,3.6,,,0.98,7.3,,17.0,13.0,,,"Positive (""A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117."")"
C514,S301,2521,16-00113,2568.0,BA2880D,BA2880R,Male,85.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid sarcoma,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,,,Adverse,NotDetected,"46,XY[20]",Normal (FISH),EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X),Negative,Negative,,85.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,34.0,,2.0,,,,1.5,24.0,,11.5,,8.0,,55.0,,,0.0,,,,11.4,141.0,3.7,,,1.2,16.1,,4.0,8.0,,,
C123,S302,2522,16-00115,2347.0,BA2621D,BA2621R,Male,74.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"45,XY,-7,del(12)(p11.2p13)[20]",Monosomy 7 is detected in 87% of cells.,,Negative,Negative,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,14.0,Dead-Disease,19.0,7.0,,,,4.0,,12.0,,2.0,,51.0,,,,,,,47.5,35.0,3.7,,0.6,0.86,7.8,,29.0,38.0,,90.6,
C515,S586,2530,16-00139,2383.0,BA2133D,BA2133R,Female,73.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%),Negative,Positive (p.W288Cfs*12; MAF 35%),,73.0,0.0,2530_1,Remission,Remission,Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,4.0,Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,90.0,Ruxolitinib|AG-221|Cytarabine|Azacitidine,Cytarabine,Standard Chemotherapy,Supportive/Palliative Care,8.0,Dead,560.0,Dead-Unknown,,,,,,0.5,,39.2,,7.5,,52.5,,,,,,,3.8,6.0,4.5,,0.6,0.87,10.9,,10.0,21.0,,92.4,
C144,S587,2530,16-00358,2383.0,BA2473D,BA2473R,Female,73.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XX[20] ",This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined. (Cytogenetics),,Negative,Positive,,73.0,56.0,2530_2,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,4.0,Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,90.0,Ruxolitinib|AG-221|Cytarabine|Azacitidine,Cytarabine,Standard Chemotherapy,Supportive/Palliative Care,8.0,Dead,560.0,Dead-Unknown,5.0,,,,,,,,,,,,,,,,,,1.8,24.0,,,,,,,,,,,"CD34 positive blasts are rare, <1% (Bone Marrow Immunophenotyping)"
C126,C126,2532,16-00142,,,,Male,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"47,XY,t(8;22)(p11.2;q11.2),+19[20]","t(8;22) clone observed, consistent with a neoplastic process ","ATM (p.P604S; VAF ~50%)|PHF6 (p.G306R; VAF ~75%)|RUNX1 (p.S322fs*278 (Single base pair insertion, frame shift  mutation); MAF ~40%)",Negative,Negative,,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),4.0,4.0,Allogeneic - Sibling|Induction|Experimental|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,51.0,"Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,192.0,Alive,57.0,24.0,,,,,,,,,,,,,,,,,100.2,,,,,,,,,,,,Positive (CD34-Dim)
C127,S303,2533,16-00145,2035.0,BA2212D,BA2212R,Male,75.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]","nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%),Negative,Negative,,75.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Supportive/Palliative Care,,,,"Vidaza|Decitabine|Fludarabine, Cytarabine","Fludarabine, Cytarabine",Standard Chemotherapy,Salvage,-1.0,Dead,159.0,Dead-Disease,27.0,2.0,,,0.5,0.0,,62.0,1.0,6.2,,29.4,,,,,,,3.09,121.0,4.8,,0.8,0.98,9.3,,12.0,15.0,215.0,,"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with the following immunophenotype: CD5(- to partial dim +),CD10(-), CD19(slighty bright +), CD20(bright +), CD38(-), CD45(+), kappa(-), lambda(dim +)."
C128,S304,2538,16-00157,2219.0,BA2477D,BA2477R,Male,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,NotDetected,"46,XY[20]",Normal,DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% ),Negative,Positive (p.W288fs*12 MAF 47%),,67.0,0.0,2538_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5.0,5.0,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,864.0,Dead-Other,93.0,94.0,,,0.0,0.0,0.0,1.0,,2.8,,1.9,0.1,,,,,,125.16,30.0,2.4,,,1.23,10.1,,20.0,30.0,,96.3,"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)"
C196,S588,2538,16-01127,2219.0,BA2244D,BA2244R,Male,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,Other,"46,XY,t(4;8)(q21;p23)[2]/46,XY[18]",Normal,,Negative,Positive,,68.0,261.0,2538_2,Unknown,Unknown,Post-Chemotherapy|Unknown,Leukapheresis,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5.0,5.0,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,864.0,Dead-Other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C270,S305,2538,17-00442,2219.0,BA3089D,BA3089R,Male,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,NotDetected,"46,XY[20] ",Normal,"DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)",Negative,Positive (p.W288fs*12; MAF 41%),,68.0,429.0,2538_3,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5.0,5.0,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,864.0,Dead-Other,75.0,68.0,,,0.0,1.7,0.0,17.4,,0.9,,12.2,0.0,,,,,,20.31,91.0,3.4,,,0.9,13.6,,21.0,22.0,,95.8,"CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+ "
C129,S306,2569,16-00217,2057.0,BA2659D,BA2659R,Male,86.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"47,XY,+8[20]","(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ",BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%),Negative,Negative,mono,86.0,0.0,,Residual,Residual,Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,3.0,3.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental,,,,AG-221|Azacitidine|Hydroxyurea,Hydroxyurea,Standard Chemotherapy,Consolidation,55.0,Dead,596.0,Dead-Disease,23.0,,,,0.0,0.0,0.8,8.6,,19.0,,59.5,0.0,,,,,,10.0,299.0,3.4,,,1.52,9.0,,16.0,15.0,398.0,97.5,"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive"
C130,S307,2571,16-00220,2310.0,BA2124D,BA2124R,Male,67.0,1.0,Skin cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XY[20]","Normal (Full AML panel (3q21.3q26.2, 5q31, 7cen, t(8;21)(q22;q22), 11q21, 16q22)",NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%),Negative,Positive (p.Trp288fs; MAF 16.4%),,67.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|IDAC",IDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,579.0,Alive,71.5,56.0,,,,,,,,,,,,,,,,,16.24,,,,,,,,,,,,"CD33, CD38, CD56, CD117, and myeloperoxidase"
C132,S308,2581,16-00249,2276.0,BA2369D,BA2369R,Male,75.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Not Available,,Negative,Negative,,75.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Vidaza,Vidaza,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Alive,302.0,Alive,60.0,50.0,,,,,,,,,,,,,,,,,25.0,,,,,,,,,,,,"These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers"
C134,S309,2593,16-00269,2426.0,BA2400D,BA2400R,Female,44.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,,Normal,FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%),Negative,Positive (p.W288fs*12; MAF 44%),,44.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,8.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)",HiDAC,Standard Chemotherapy,Consolidation,99.0,Alive,2080.0,Alive,65.0,11.2,,,0.0,3.5,0.0,76.7,,0.0,,8.6,0.0,,,,,,2.41,222.0,2.8,,,0.53,7.8,,19.0,11.0,197.0,100.4,"CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)"
C135,S310,2594,16-00271,2061.0,BA2762D,BA2762R,Female,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XX[20]","nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]",FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MAF 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%),Positive (MAF 40%; AR 0.666666667),Positive (K292FS*6+; MFA 35.0%),,22.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Allogeneic - Sibling|Induction|Experimental,Complete Response,Standard Chemotherapy,39.0,"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,603.0,Alive,63.0,39.0,,,0.0,0.0,,32.7,,4.4,,26.6,,,2.0,,,,22.01,176.0,3.1,,,0.68,6.0,,27.0,39.0,,,"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +)."
C136,S311,2595,16-00273,2537.0,BA2312D,BA2312R,Female,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NotDetected,"46,XX[20]",Normal,CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%),Negative,Negative,mono,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,7.0,Dead,169.0,Dead-Disease,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"partial weak  CD7, CD13, CD33, CD34, CD117, myeloperoxidase, and partial  HLA-DR"
C137,S312,2597,16-00278,2206.0,BA2813D,BA2813R,Male,64.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XY[20]",Normal (FISH),DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs),Positive (MAF 30%; AR 0.428571429),Positive (c.859_860insTCTG; p.W288fs),,64.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,41.0,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,636.0,Alive,83.0,74.0,,,0.0,0.0,,13.0,,0.0,,13.0,,,0.5,,,,53.3,39.0,4.0,,,1.27,8.7,,15.0,45.0,,,"Positive (""The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxidase, and a smaller subset shows dim aberrant expression of CD19. The blasts are almost entirely negative for CD34."")"
C138,S313,2606,16-00289,2471.0,BA2211D,BA2211R,Female,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",normal,FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%),Positive (MAF 50%; AR 1),Positive (p.W288fs*12; MAF 45%),,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response i,Standard Chemotherapy,17.0,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib",Azacitidine,Standard Chemotherapy,Consolidation,34.0,Dead,142.0,Dead-Treatment,95.0,92.9,,,0.0,0.0,0.7,3.6,,1.4,,1.4,0.1,,,,,,166.91,42.0,3.2,,,0.83,12.4,,101.0,55.0,697.0,95.1,"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive"
C516,S314,2607,16-00292,2321.0,BA2171D,BA2171R,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%),Positive (MAF 30%; AR 0.428571429),Positive (p.W288fs*12; MAF 40%),,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,3.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,3.0,Dead,4.0,Dead-Disease,90.0,98.4,,,0.0,0.0,0.0,0.8,,0.0,,0.8,0.1,,,,,,122.89,19.0,2.9,,,1.44,8.2,,18.0,36.0,,90.6,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO"
C139,S315,2611,16-00303,2522.0,BA2746D,BA2746R,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XX[19]",Normal (FISH),ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs),Positive (MAF 10%; AR 0.111111111),Positive (c.859_860insTCTG; p.W288fs),,56.0,0.0,2611_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","GCLAC (GCSF, Clofarabine & Cytarabine)",Standard Chemotherapy,Salvage,-1.0,Dead,323.0,Dead-Disease,1.5,2.0,,2.0,0.0,0.0,,23.0,,57.0,2.0,13.0,,,0.0,0.0,,,58.7,28.0,3.0,,,1.87,9.5,,67.0,33.0,,,"Positive (""Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)"
C145,C145,2611,16-00310,,,,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XX[19]",Normal (FISH),ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs),Positive (MAF 10%; AR 0.111111111),Positive (c.859_860insTCTG; p.W288fs),,56.0,1.0,2611_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","GCLAC (GCSF, Clofarabine & Cytarabine)",Standard Chemotherapy,Salvage,-1.0,Dead,323.0,Dead-Disease,1.5,2.0,,2.0,0.0,0.0,,23.0,,57.0,2.0,13.0,,,0.0,0.0,,,50.0,28.0,3.0,,,1.87,9.5,,67.0,33.0,,,"Positive (""Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)"
C194,C194,2611,16-01119,,,,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XX[19]",Normal (FISH),,,,,56.0,224.0,2611_3,Relapse,Relapse,Relapse|Post-Transplant,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","GCLAC (GCSF, Clofarabine & Cytarabine)",Standard Chemotherapy,Salvage,-1.0,Dead,323.0,Dead-Disease,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C517,C517,2612,16-00306,,,,Male,71.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"46,XY,del(7)(q32),add(13)(p11.2)[15]","This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.",ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%),Negative,Negative,,71.0,0.0,2612_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Salvage|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,32.0,"AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,77.0,Dead,548.0,Dead-Unknown,75.0,26.0,,,,2.0,,15.0,,8.0,,43.0,,,,,,,5.0,24.0,3.8,,0.7,1.26,7.7,,118.0,53.0,,81.8,"These are positive for CD34, CD117, HLADR, CD33 and CD13 (Bone Marrow Immunophenotyping)"
C227,S589,2612,17-00083,2395.0,BA3342D,,Male,71.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,del(7)(q32),add(13)(p11.2)[20]","Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)",,Negative,Negative,,72.0,315.0,2612_2,Remission,Remission,Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Salvage|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,32.0,"AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,77.0,Dead,548.0,Dead-Unknown,,,,,,8.0,,5.0,,,,85.0,,,,,,,14.3,229.0,4.4,,0.5,1.13,6.8,,64.0,36.0,,105.9,
C141,C141,2628,16-00345,,,,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XY[20]",Normal,DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%),Negative,Positive (p.W288fs*12 ; MAF 40%),,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,5.0,3.0,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Re-induction,4.0,Dead,597.0,Dead-Disease,30.0,10.5,,,0.0,0.0,0.0,19.7,,0.9,,71.4,0.0,,,,,,4.4,101.0,3.4,,,1.01,8.9,,77.0,27.0,479.0,96.4,"CD13, CD33, CD117, CD123, and HLA-DR"
C518,C518,2630,16-00350,,,,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Favorable,NotDetected,"46,XX[19] ",Normal,CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%),,Negative,,46.0,0.0,2630_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,120.0,Alive,1950.0,Alive,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR "
C519,S319,2630,16-00351,2497.0,BA2296D,BA2296R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Favorable,NotDetected,"46,XX[19] ",Normal,CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%),Negative,Negative,bi,46.0,0.0,2630_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,120.0,Alive,1950.0,Alive,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR "
C142,S320,2632,16-00354,2037.0,BA2300D,BA2300R,Male,79.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]",5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present ,KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%),Negative,Negative,,79.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,1.0,Dead-Disease,86.0,87.0,,,,,,,,,,,,,,,,,70.01,27.0,,,,,,,,,,,
C143,S321,2633,16-00356,2161.0,BA2903D,BA2903R,Male,59.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,,,,"NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%)",Negative,Negative,,59.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,6.0,5.0,Salvage|Induction|Experimental|Frontline|Re-induction,Refractory,Standard Chemotherapy,8.0,"HiDAC|Lenalidomide|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Etoposide, Mitoxantrone|Cytarabine, OXi4503","Cytarabine, OXi4503",Targeted Therapy - Other,Experimental,4.0,Dead,207.0,Dead-Unknown,,1.0,,,,9.0,,1.0,,6.0,,58.0,,,,,,,9.1,22.0,3.2,,0.5,0.79,7.3,,135.0,44.0,,85.0,
C146,S324,2678,16-00410,2535.0,BA2646D,BA2646R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]","PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.",,Negative,Negative,,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Induction,-1.0,Alive,1719.0,Alive,90.0,,,,0.0,0.9,3.5,35.7,,1.7,,5.2,0.7,,,,,,9.87,38.0,2.8,,,1.12,7.0,,28.0,24.0,519.0,85.7,"CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)"
C520,S325,2685,16-00466,2591.0,BA3067D,BA3067R,Male,59.0,1.0,Bladder Cancer,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Adverse,Other,"45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]","EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, | 56/100 cells (56%) had a 2 red/ 4 green signal pattern, reflecting 4 copies of RUNX1 on 21q and consistent with the tetrasomy 21 observed in the metaphase karyotype. ",GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%),Negative,Negative,,59.0,6.0,,Initial Diagnosis,Diagnosis,Post-Chemotherapy|Post-Transplant|Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance,,,,"Fludarabine, Melphalan|Azacitidine|Sorafenib",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,12.0,Dead,78.0,Dead-Disease,30.0,25.0,,,0.0,0.9,0.0,23.2,,11.6,,36.6,0.0,,,,,,4.54,11.0,2.7,,,,8.6,,39.0,22.0,,97.2,"CD13, dim CD33, CD43, CD117"
C147,S327,2687,16-00459,2181.0,BA2240D,BA2240R,Female,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,,,,,Positive (MAF 90%; AR 9),Positive,,61.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Experimental,61.0,Dead,263.0,Dead-Disease,,,,,0.0,0.0,0.0,30.8,,10.3,,0.0,0.3,,,,4.7,,73.28,49.0,3.6,,,0.68,8.2,,195.0,75.0,1033.0,95.5,
C148,S328,2690,16-00465,2052.0,BA2272D,BA2272R,Male,12.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,Other,"47,XY,+8[19]/46,XY[1]",RUNX1T1 signal consistent with the trisomy 8 clone ,FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%),Positive (MAF 35%; AR 0.538461538),Negative,,12.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4.0,4.0,Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction,Refractory,Standard Chemotherapy,27.0,"Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,1905.0,Alive,70.0,85.0,,,0.0,0.0,1.8,14.7,,51.4,,8.3,50.0,,,,,,214.49,49.0,3.7,,,0.64,4.6,,28.0,150.0,,132.4,"dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR"
C149,S329,2694,16-00474,2085.0,,BA2306R,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,,,Favorable,RUNX1-RUNX1T1,"46,XY,t(8;21)(q22;q22)[20]",,"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)",Negative,Negative,,50.0,0.0,2694_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Refractory,Standard Chemotherapy,20.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)",HiDAC,Standard Chemotherapy,Consolidation,182.0,Alive,424.0,Alive,70.0,91.0,,,,0.0,,7.0,,2.0,,0.0,,,0.0,,,,71.1,28.0,2.4,,1.1,0.66,8.7,,23.0,25.0,,94.7,
C159,S330,2694,16-00538,2085.0,BA2842D,BA2842R,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,,,NonInitial,RUNX1-RUNX1T1,"46,XY,t(8;21)(q22;q22)[20]",RUNX1/RUNX1T1 fusion positive in 6.5% of cells,,Negative,Negative,,50.0,21.0,2694_2,Residual,Residual,Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Refractory,Standard Chemotherapy,20.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)",HiDAC,Standard Chemotherapy,Consolidation,182.0,Alive,424.0,Alive,8.0,0.0,,,,0.0,,12.0,,29.0,4.0,54.0,,,0.0,,,,6.8,224.0,2.3,,0.5,0.51,7.5,,19.0,9.0,,88.7,
C163,S331,2695,16-00611,2592.0,BA3071D,BA3071R,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,NotDetected,"46,XY[19]",Normal,,Negative,Positive,,51.0,46.0,2695_1,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,4.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7.0,6.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,13.0,"HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Decitabine,Supportive/Palliative Care,Supportive/Palliative Care,115.0,Dead,972.0,Dead-Disease,,,,,0.0,0.0,0.0,4.2,,1.7,,6.8,0.6,,,,,,162.21,31.0,3.5,,,,10.8,,91.0,102.0,,85.4,
C535,S332,2695,16-00883,2592.0,BA3072D,BA3072R,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]","Positive (Cells Scored: 200 Probe(s): Leica DEK (SG) / NUP 214 (SO) t(6;9) DC, DF)",,Negative,Positive,,51.0,129.0,2695_2,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,4.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7.0,6.0,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,13.0,"HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Decitabine,Supportive/Palliative Care,Supportive/Palliative Care,115.0,Dead,972.0,Dead-Disease,,,,,0.0,6.1,0.0,7.9,,0.0,,6.1,0.1,,,,1.8,,39.25,32.0,3.1,,,,8.9,,30.0,26.0,,84.5,
C150,S333,2697,16-00479,2550.0,BA2765D,BA2765R,Female,39.0,1.0,Leiomyosarcoma,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,MECOM_re,"46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]",,,Negative,Negative,,40.0,0.0,,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,5.0,Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,30.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",Azacitidine,Standard Chemotherapy,Salvage,4.0,Dead,232.0,Dead-Treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Increased atypical CD34 positive, CD7 positive myeloblasts"
C151,S334,2699,16-00481,2450.0,BA2904D,BA2904R,Female,60.0,1.0,Adenocarcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,NonInitial,CBFB-MYH11,"46,XX,inv(16)(p13q22)[20]",,,Negative,Negative,,61.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Unknown,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|IDAC",IDAC,Standard Chemotherapy,Consolidation,-1.0,Dead,336.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.
C521,C521,2704,16-00492,,,,Female,29.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Fanconi anaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Adverse,Other,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",Normal,,Negative,Positive,,29.0,1.0,2704_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5.0,3.0,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,2.0,Dead,129.0,Dead-Disease,98.0,,,,0.6,0.6,15.1,41.0,,30.1,,12.6,1.2,,,,,,1.66,63.0,3.0,,,0.49,6.9,,251.0,165.0,,105.4,"CD11b, CD13, CD14, CD33, CD56 and bright CD64+"
C173,S335,2704,16-00765,2309.0,BA3076D,BA3076R,Female,29.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Fanconi anaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,NonInitial,Other,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",Normal,,Negative,Positive,,29.0,82.0,2704_2,Relapse,Relapse,Post-Chemotherapy|Relapse|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5.0,3.0,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,2.0,Dead,129.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C536,S336,2704,16-00886,2309.0,BA3077D,BA3077R,Female,29.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Fanconi anaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,NonInitial,Other,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",Normal,,Negative,Positive,,29.0,126.0,2704_3,Residual,Residual,Post-Chemotherapy|Residual Disease|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5.0,3.0,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,2.0,Dead,129.0,Dead-Disease,,,,,0.0,0.0,0.0,0.0,,79.2,,1.0,0.2,,,,,,12.98,43.0,3.3,,,0.68,9.7,,65.0,152.0,9928.0,90.4,
C152,S337,2705,16-00494,2247.0,BA2234D,BA2234R,Female,72.0,1.0,Non-Hodgkins Lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Adverse,KMT2A_re,"46,XX,t(1;11)(p32;q23)[20]",MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal,DNMT3A (p.E283*; MAF 30%),Negative,Negative,,72.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)","FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Standard Chemotherapy,Salvage,5.0,Dead,148.0,Dead-Disease,90.0,90.0,,,0.0,1.9,0.0,4.6,,89.8,,3.7,0.2,,,,,,104.44,33.0,2.8,,,0.93,11.9,,,,,96.6,"dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive"
C153,S338,2706,16-00498,2318.0,BA2022D,BA2022R,Female,33.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,,This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.,FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%),Positive (MAF 48%; AR 0.923076923),Negative,,33.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Consolidation,-1.0,Alive,559.0,Alive,,,,,,,,,,,,,,,,70.0,,,12.75,26.0,,,,,,,,,,,"Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML."
C156,S340,2712,16-00510,2182.0,BA2037D,BA2037R,Male,34.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M1,M1,Adverse,MECOM_re,"46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]",D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.,NRAS (p.Q61H; MAF 45%),Negative,Negative,,34.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine",anti-CD33,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,291.0,Dead-Disease,60.0,40.0,,,0.0,0.0,2.1,44.3,,8.2,,16.5,5.5,,,,,,6.13,916.0,3.9,,,1.0,11.7,,117.0,61.0,424.0,96.0,"CD2, CD11b, CD13, CD33, CD34, CD38, CD56, CD58, CD117,  CD123, and HLA-DR positive"
C154,S341,2713,16-00519,2320.0,BA2184D,BA2184R,Male,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XY[20]",Normal,CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%),Negative,Negative,bi,47.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,5.0,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)","Cyclophosphamide, Fludarabine, TBI",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Dead,582.0,Dead-Disease,75.0,,,,0.0,0.0,0.0,20.3,,3.4,,3.4,6.9,,,,,,8.98,34.0,3.5,,,1.08,15.0,,49.0,21.0,353.0,86.8,"CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,"
C155,S343,2715,16-00525,2213.0,BA3009D,BA3009R,Female,26.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,Adverse,Other,"46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]","CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.",PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%),Negative,Negative,,26.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,6.0,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)","Cyclophosphamide, Fludarabine, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,1610.0,Alive,75.0,,,,0.0,0.0,0.0,45.5,,9.8,,4.5,0.2,,,,,,9.27,154.0,3.1,,,0.69,7.4,,32.0,58.0,,97.8,"CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+"
C295,C295,2716,17-00667,,,,Female,82.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,MYELOPROLIFERATIVE NEOPLASMS,Primary myelofibrosis,,,Adverse,Other,"46,XX,add(11)(q23)[1]/47,sl,+21[19]",,JAK2 (p.Val617Phe; MAF 96.2%)|NRAS (p.Gly12Ser; MAF 45.7%)|RUNX1 (p.Asp198Asn; MAF 54.9%)|SRSF2 (p.Pro95Arg; MAF 45.7%)|TET2 (p.Glu1555fs; MAF 30.5%)|TET2 (p.Phe1287Ser; MAF 44.5%),Negative,Negative,,82.0,406.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,46.0,Dead-Disease,34.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C158,S344,2721,16-00540,2549.0,BA2442D,BA2442R,Female,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,Other,"47,XX,+8[18]",Normal,FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%),Positive (MAF 30%; AR 0.428571429),Negative,,66.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,13.0,Dead-Treatment,,16.0,,,,,,,,,,,,,,,,,129.5,,,,,,,,,,,,"Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML."
C166,S346,2747,16-00701,2440.0,BA2347D,BA2347R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46, XY [20]",The abnormalities normally seen in MDS are not detected. (Cytogenetics),,Negative,Negative,,62.0,34.0,2747_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Unknown|Allogeneic - Matched Unrelated Donor,,,,"Azacitidine|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,281.0,Alive,,1.0,,,,0.0,,22.0,,28.0,,42.0,,,,,,,16.4,237.0,4.7,,1.5,1.03,12.4,,37.0,29.0,,91.0,
C527,S347,2747,16-00822,2440.0,BA2379D,BA2379R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,M4,M4,NonInitial,NotDetected,"46,XY[12]",Not Available,,Negative,Negative,,62.0,81.0,2747_2,Residual,Residual,Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Unknown|Allogeneic - Matched Unrelated Donor,,,,"Azacitidine|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,281.0,Alive,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.
C230,S348,2747,17-00096,2440.0,BA2180D,,Male,62.0,0.0,,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,M4,M4,NonInitial,NotDetected,"46,XY[12]",Not Available,,Negative,Negative,,63.0,232.0,2747_3,Residual,Residual,Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Unknown|Allogeneic - Matched Unrelated Donor,,,,"Azacitidine|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,281.0,Alive,,,,,,0.1,,13.8,,9.9,,74.1,,,,,,,8.0,410.0,4.9,,1.1,1.0,12.9,,9.0,17.0,,82.2,
C162,S349,2754,16-00595,2462.0,BA2967D,,Male,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2] ",,,Negative,Negative,,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)","CLAG (Cladribine, Cytarabine, Filgrastim)",Standard Chemotherapy,Re-induction,-1.0,Dead,63.0,Dead-Disease,60.0,25.0,,,,,,,,,,,,,,,,,6.69,75.0,,,,,,,,,,,"Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML"
C522,C522,2780,16-00619,,,,Female,64.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,KMT2A_re,"46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]",MLL Rearrangment,GATA2 (c.1145G>A; p.R382Q)|TET2 (c.5162T>G; p.L1721W (SNP)),Negative,Negative,,65.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,2.0,Induction|Experimental,Complete Response,Standard Chemotherapy,-1.0,"FLX925|7+3 (Cytarabine, Idarubicin)|Azacitidine",FLX925,Targeted Therapy - Other,Experimental,-1.0,Dead,385.0,Dead-Disease,35.0,40.0,,,0.0,0.0,,30.0,,14.0,,12.0,,,,,,,42.9,35.0,2.7,,,,6.6,,11.0,23.0,369.0,,"Negative (CD10, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD14, CD15, CD64, CD117, HLA-DR, TdT) | Positive (CD38, CD11b, CD13, CD33, CD34, Dim CD45, MPO,)"
C165,S350,3975,16-00699,2367.0,BA2570D,BA2570R,Male,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NotDetected,"46,XY[20]","nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,46.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,9.0,Dead-Disease,92.0,75.0,,,,,,5.0,,19.0,,1.0,,,,,,,151.6,31.0,2.8,,0.6,1.13,6.2,,,,,113.6,"CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)"
C523,S595,3976,16-00702,2209.0,BA2764D,BA2764R,Male,77.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,MECOM_re,,Translocation between the long arm of chromosome 3 and short arm of chromosome 12.,FLT3-ITD|NPM1,Positive,Positive,,79.0,0.0,,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,Decitabine,Decitabine,Standard Chemotherapy,Induction,-1.0,Unknown,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C167,S351,3978,16-00705,2363.0,BA2209D,BA2209R,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"47,XY,+13[2]/94,slx2[2]/46,XY[19]","5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter) | AML1 (21q22.12)/ETO (8q22), 5'MLL (KMT2a, 11q23)/ 3'MLL (KMT2A,11q23), PML (15q24)/ RARA (17q21), 5'CBFB (16q22)/3'CBFB (16q22), 5'RARA (17q21)/ 3'RARA (17q21)",,Negative,Negative,,64.0,0.0,,Relapse,Relapse,Relapse,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ","Fludarabine, Cyclophosphamide, TBI ",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,1824.0,Dead-Disease,59.5,12.0,,,0.0,0.0,,55.0,,3.0,,29.0,,,,,,,,46.0,4.1,,,,8.3,,37.0,22.0,,,"Negative (CD10, CD19, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD11b, CD14, CD15, CD33, CD64, MPO) | Positive (CD38, CD13, CD34, Dim CD45, Dim CD117, HLA-DR, TdT)"
C168,S352,3979,16-00708,2332.0,BA2989D,BA2989R,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"47,XY,+21[19]/46,XY[1]","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],",BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX1 (Foundation; I366fs*114+; MAFs: 57%)|TET2 (Foundation; Q742*; MAFs: 41%),Positive (MAF 8%; AR 0.086956522),Negative,,71.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,1.0,Hypomethylating/Low Dose Cytarabine,,,,Azacitidine|Decitabine,Azacitidine,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,98.0,Unknown,305.0,,44.0,31.0,,,0.0,2.0,,46.0,4.0,0.0,2.0,14.0,,,4.0,1.0,,,5.05,35.0,3.7,,0.6,0.91,7.1,,41.0,18.0,91.0,,"CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-) | In addition, there is a 0.92% population of CD117(bright +)/CD34(-)/CD45(dim +)/CD33(- to dim +) small cells with low orthogonal light scatter. The exact identity of these cells is uncertain"
C170,S353,3986,16-00724,2528.0,BA2261D,BA2261R,Female,62.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[","nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",TP53 (R213fs; MAF 34%),Negative,Negative,,62.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Supportive/Palliative Care,4.0,3.0,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,7.0,"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea",Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,198.0,Dead-Disease,34.0,3.3,,,0.8,1.6,,14.9,4.1,5.0,1.7,68.6,,,2.0,,,,8.35,36.0,2.6,,0.5,0.5,10.7,,13.0,11.0,304.0,,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with the following immunophenotype: CD5(+), CD10(-), CD19(+), CD20(dim+), CD38(-), CD45(+), lambda(dim +), and kappa(-)."
C171,C171,3989,16-00728,,,,Male,74.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,add(4)(q35),der(17)t(11;17)(q13;q25)[13]/46,XY[","nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522) x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[196],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[181/200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Positive (MAF 18%),Negative,,74.0,0.0,,Relapse,Relapse,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,1.0,Standard Chemotherapy,4.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Mitoxantrone, Crenolanib","Cytarabine, Mitoxantrone, Crenolanib",Standard Chemotherapy,Salvage,-1.0,Dead,351.0,Dead-Disease,,20.0,,,,,,42.0,1.0,3.0,,34.0,,,,,,,5.18,47.0,,,,,7.0,,,,,93.0,
C169,S354,3990,16-00731,2556.0,BA2721D,BA2721R,Female,69.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,NotDetected,"46,XX[20]",normal,CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%),Positive (MAF 50%; AR 1),Negative,,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,8.0,4.0,Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,38.0,"7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib",IMGN779 (Immunogen Trial),Targeted Therapy - Other,Salvage,-1.0,Dead,565.0,Dead-Disease,,40.0,,,1.8,0.9,8.8,10.5,,9.6,,26.3,2.8,,,,,,61.22,12.0,3.4,,,0.64,7.1,,27.0,22.0,399.0,103.5,"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +"
C172,C172,4001,16-00751,,,,Female,58.0,1.0,Basal Cell Carcinoma|Squamous cell carcinoma,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M2,M2,Adverse,MECOM_re,"46,XX,t(3;3)(q21;q26)[20]",Abnormal (RPN1/MECOM fusion),NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%),Negative,Negative,,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Induction|Maintenance,Complete Response,Standard Chemotherapy,70.0,"Azacitidine|SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide",Azacitidine,Standard Chemotherapy,Maintenance,102.0,Alive,1911.0,Alive,21.0,0.0,,,0.0,0.0,2.3,41.7,,25.9,,30.1,0.1,,,,,,13.83,360.0,,,,,11.0,,,,,107.0,"variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123"
C534,S356,4006,16-00882,2192.0,BA2116D,BA2116R,Male,81.0,0.0,,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5] (.ish der(6)t(5;6)(D5S2064+,D5S630+),der(8)(RUNX1T1++),der(22)t(16;22)(5’CBFB con3’CBFB dimx1)[3])",Not available,,Negative,Negative,,81.0,41.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Supportive/Palliative Care,2.0,2.0,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Vidaza|Decitabine,Decitabine,Supportive/Palliative Care,Supportive/Palliative Care,3.0,Dead,97.0,Dead-Disease,,70.0,,,0.0,0.0,,3.0,,1.0,,36.0,,,,,,,39.12,74.0,4.1,,,1.26,8.1,,25.0,33.0,853.0,98.0,negative (not done)
C524,S357,4007,16-00770,2530.0,BA2469D,BA2469R,Female,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML without maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,,M1,NonInitial,NotDetected,"46,XX[20]",Not Available,"BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)",Negative,Negative,,51.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Unknown|Induction|Re-induction,Unknown,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib","Busulfan, Fludarabine",Bone Marrow Transplant,Unknown,-1.0,Alive,716.0,Alive,12.0,,,,,,,,,,,,,,,,,,1.5,16.0,,,,,,,,,,,"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO."
C525,S358,4008,16-00771,2033.0,BA2269D,BA2269R,Female,34.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,,M5,NonInitial,NotDetected,"46,XX[20]",Not Available,"CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)",Negative,Negative,,34.0,0.0,4008_1,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Intrathecal,3.0,3.0,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",Cytarabine,Intrathecal,Unknown,6.0,Dead,157.0,Dead-Unknown,15.0,,,,,,,,,,,,,,,,,,26.4,426.0,,,,,,,,,,,Not Available
C175,C175,4008,16-00788,,,,Female,34.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,,M5,NonInitial,NotDetected,"46,XX[20]",Not Available,"CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)",Negative,,,34.0,10.0,4008_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Intrathecal,3.0,3.0,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",Cytarabine,Intrathecal,Unknown,6.0,Dead,157.0,Dead-Unknown,,0.0,,,,0.0,,3.0,,12.0,,85.0,,,,,,,9.9,76.0,3.9,,0.9,0.33,9.3,,51.0,33.0,,84.7,
C176,C176,4028,16-00811,,,,Female,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%),Negative,Positive (p.W288fs*12; MAF 40%),,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1980.0,Alive,83.0,,,,0.0,0.0,0.9,16.7,,63.1,,15.8,0.1,,,,2.6,,50.17,137.0,3.0,,,0.87,11.7,,69.0,35.0,337.0,96.3,"Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes account for 13% of WBCs and include 74% T cells, 19% B cells and 7% NK cells. T cells show a CD4:CD8 ratio of 5:1 without aberrant antigen expression.) | Positive (B cells are polytypic by surface light chain expression with a kappa to lambda ratio of 1.2:1.)"
C526,S360,4029,16-00818,2228.0,BA2951D,BA2951R,Female,65.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,,,Adverse,MECOM_re,"47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]",evidence of monosomy 7 in 191/200 (95.5 percent) cells scored,CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%),Negative,Negative,,65.0,3.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,27.0,,59.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C177,S361,4030,16-00815,2083.0,BA2778D,BA2778R,Female,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%),Negative,Positive (p.W288fs*12; MAF 40%),,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6.0,6.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea",Ruxolitinib,Targeted Therapy - Kinase Inhibitor(s),Maintenance,496.0,Alive,1965.0,Alive,75.0,44.0,,,0.0,0.0,0.9,28.7,,46.1,,24.3,0.0,,,,,,31.22,175.0,2.9,,,1.19,8.8,,18.0,13.0,222.0,96.4,"Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)"
C531,S362,4037,16-00834,2664.0,BA3153D,BA3153R,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,"Mixed-phenotype acute leukaemia, T/myeloid",,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",,,Unknown,NotDetected,"46,XY[20] ",Normal,CEBPA ([c.937A>C; c.940G>A; c.941T>A;c.943C>G] p.K313_V314_L315delinsQKV),Negative,Negative,mono,49.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,455.0,Alive,15.0,50.0,,,0.0,1.0,,10.0,,2.0,,40.0,,,,,,,7.9,210.0,3.4,,,,12.2,,37.0,34.0,,,"Positive (CD38, CD7, CD2) | Negative (CD10, CD19, CD22, CD16, CD56, CD13, CD14, CD15, CD33, CD34, CD117, MPO, HLA-DR) | Dim Positive (cCD3, CD11b, CD64)"
C530,S363,4038,16-00831,2557.0,BA2817D,BA2817R,Male,73.0,1.0,Prostate Cancer,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]","nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]",IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss),Negative,Negative,,77.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Supportive/Palliative Care|Targeted Therapy - Other,6.0,3.0,Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care,,,,Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine,AG-221,Targeted Therapy - Other,Experimental,267.0,Dead,1490.0,Dead-Disease,95.0,48.0,,,,1.0,,42.0,1.0,6.0,,2.0,,,,,,,3.0,23.0,3.5,,3.2,1.1,9.4,,14.0,14.0,453.0,,"92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +)."
C532,S364,4039,16-00836,2542.0,BA2820D,BA2820R,Male,73.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XY[20]",normal,DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%),Positive (MAF 50%; AR 1),Positive (p.W288fs*12; MAF 43%),,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Supportive/Palliative Care,Unknown,Standard Chemotherapy,21.0,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea","S0919 Trial (Pravastatin, Idarubicin, Cytarabine)",Standard Chemotherapy,Induction,21.0,Dead,28.0,Dead-Disease,88.0,38.0,,,0.0,0.0,1.7,20.9,,60.9,,1.7,0.1,,,,,,58.97,55.0,3.0,,,1.2,11.2,,27.0,40.0,,105.8,"Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))"
C528,C528,4042,16-00844,,,,Female,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%),Positive (MAF ~50%),Positive (p.W288fs*12; MAF ~50%),,61.0,0.0,4042_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,8.0,Hydroxyurea,Hydroxyurea,Standard Chemotherapy,Induction,8.0,Dead,8.0,Dead-Disease,93.0,,,,0.0,0.9,,7.1,,0.9,,0.9,0.0,,,,,,91.16,27.0,2.6,,,0.81,6.1,,25.0,34.0,608.0,87.3,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO"
C529,S365,4042,16-00867,2255.0,BA2704D,BA2704R,Female,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%),Positive (MAF 46%; AR 0.851851852),Positive (p.W288fs*12; MAF ~50%),,61.0,3.0,4042_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,8.0,Hydroxyurea,Hydroxyurea,Standard Chemotherapy,Induction,8.0,Dead,8.0,Dead-Disease,93.0,85.0,,,0.0,0.8,0.0,16.5,,0.8,,1.6,0.2,,,,,,30.54,43.0,2.7,,,0.78,7.1,,19.0,21.0,360.0,84.4,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO"
C186,S366,4043,16-01017,2390.0,BA2492D,BA2492R,Male,25.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",Not Available,,Negative,Negative,,26.0,28.0,4043_1,Residual,Residual,Post-Chemotherapy|Residual Disease|Post-Transplant,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7.0,"Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine",Decitabine,Standard Chemotherapy,Salvage,9.0,Dead,463.0,Dead-Disease,70.0,8.0,,,,,,,,,,,,,,,,,30.2,10.0,,,,,,,,,,,"MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR "
C187,C187,4043,16-01046,,,,Male,25.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",Not Available,,,,,26.0,32.0,4043_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7.0,"Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine",Decitabine,Standard Chemotherapy,Salvage,9.0,Dead,463.0,Dead-Disease,70.0,7.0,,,,1.0,,18.0,,63.0,,4.0,,,,,,,14.1,1.0,3.4,,0.7,0.58,9.3,,35.0,10.0,,85.2,"MYELOBLASTS 18%. These are positive for CD34, CD33, CD13, and CD11b."
C533,S367,4055,16-00880,2095.0,BA2614D,,Female,55.0,1.0,Multiple Sclerosis,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with mutated CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",Normal,CEBPA (p.Ala40fs; MAF 20.3%)|CEBPA (p.Lys304Thr; MAF 26.5%)|DNMT3A (p.Arg882His; MAF 39.1%)|NPM1 (p.Trp288fs; MAF 9.6%)|TET2 (p.Gln1501*; MAF 39%),Negative,Positive (p.Trp288fs; MAF 9.6%),bi,55.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,383.0,Alive,40.0,57.0,,,,,,,,,,,,,,,,,16.43,75.0,,,,,,,,,,,"Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML."
C572,S368,4057,18-00048,2618.0,BA3139D,BA3139R,Male,30.0,1.0,Dyskeratosis congenita,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,MYELODYSPLASTIC SYNDROMES,Unknown,,,NonInitial,Other,"40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1] ","84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously. ",BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%),Negative,Negative,,31.0,504.0,4057_1,Relapse,Relapse,Post-Chemotherapy|Post-Transplant|Relapse,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Induction|Maintenance|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine","Fludarabine, Cytarabine",Standard Chemotherapy,Re-induction,5.0,Dead,475.0,Dead-Disease,87.0,,,,0.0,0.0,,10.4,,3.5,,1.7,0.4,,,,,,19.23,36.0,3.3,,,0.77,8.0,,23.0,29.0,532.0,102.1,
C345,S369,4057,18-00149,2618.0,BA3285D,BA3285R,Male,30.0,1.0,Dyskeratosis congenita,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,MYELODYSPLASTIC SYNDROMES,Unknown,,,NonInitial,Other,"39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5] ","84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously. ",,Negative,Negative,,31.0,573.0,4057_2,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Induction|Maintenance|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine","Fludarabine, Cytarabine",Standard Chemotherapy,Re-induction,5.0,Dead,475.0,Dead-Disease,,,,,1.8,1.8,,14.7,,8.3,,0.0,0.0,,,,,,10.63,9.0,2.2,,,0.77,7.5,,65.0,64.0,,90.5,
C178,S371,4075,16-00951,2422.0,BA2584D,BA2584R,Male,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,KMT2A_re,"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]",11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short arm of chromosome 10;  a translocation between chromosomes 3 and 17;  | (first cell line cont.) added material on the long arm of chromosome 4 and on the short arm of chromosome 5; an unbalanced whole arm rearrangement between the long arms of chromosomes 12 and 18. | The remaining cell (1/20; 5%) showed a normal male chromosome complement. ,,Negative,Negative,,42.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,427.0,Alive,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C179,S372,4076,16-00952,2599.0,BA3132D,,Male,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"47, XY, del (6) (q13q23), +8, der(20) t (20;?) (q11.2-13.1;?) [6]","There are only 6 metaphase cells available for analysis. All have clonal abnormalities including 6q deletion, trisomy 8 and rearrangement involving 20q. This karyotype is consistent with the clinical diagnosis of AML. (Cytogenetics)","IDH2 (p.R140Q, MAF 46%)|NRAS (p.Q61K, MAF 45%)|SRSF2 (p.P95H, MAF 47%)",Negative,Negative,,72.0,0.0,,Residual,Residual,Residual Disease,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Alive,8.0,Alive,92.0,,,,,,,,,,,,,,,,,,32.2,19.0,,,,,,,,,,,"Positive for CD34, HLADR, MPO, CD14 and CD33. Negative for CD117, CD11b, cd13 and CD64. (Bone Marrow Immunophenotyping)"
C181,S373,4082,16-00980,2830.0,BA3079D,BA3079R,Male,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,RARA_re,"45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4]","5p15.2 (D5S23): gain present  5q31 (EGR1): deletion present  7cen (D7Z1), 7q31 (D7S486): deletion and monosomy present  | t(8;21)(q22;q22) (RUNX1T1;RUNX1): gain present  11q23 (KMT2A; also known as MLL): gain present  16q22 (CBFB): gain present  17q21 (RARA): gain present  ",TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%),Negative,Negative,,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Unknown,23.0,,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C182,S374,4083,16-00981,2439.0,BA2547D,,Female,69.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,,,,,Negative,Negative,,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,255.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits."
C183,S375,4195,16-01004,2333.0,BA2417D,BA2417R,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,,M4,NonInitial,,not performed,Not available,,Negative,Negative,,70.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC",Vidaza,Standard Chemotherapy,Hypomethylating/Low Dose Cytarabine,4.0,Alive,486.0,Alive,85.0,77.8,,,0.0,0.0,,7.4,0.9,0.0,2.8,11.1,,,,,,,25.85,103.0,2.8,,0.4,0.62,7.0,,12.0,32.0,1195.0,,"CD11b(partial +), CD13(equivocal), CD15(bright +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(bright +), CD45(bright +), CD56(+),CD64(bright+), CD117(-), and HLA-DR(+)."
C180,S377,4197,16-01010,2284.0,BA2450D,BA2450R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,Other,,"Positive (metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid)",,Positive (MAF 20%; AR 0.25),Positive,,46.0,0.0,4197_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,5.0,4.0,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",Sunitinib,Standard Chemotherapy,Consolidation,2.0,Dead,269.0,Dead-Disease,,,,,0.0,0.0,0.0,20.4,,0.0,,66.7,1.0,,,,,,6.18,14.0,3.3,,,1.04,8.1,,58.0,44.0,401.0,88.5,
C189,S378,4197,16-01061,2284.0,BA2994D,BA2994R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,Other,,"Positive (metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid)",,Negative,Positive,,47.0,14.0,4197_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Supportive/Palliative Care,5.0,4.0,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32.0,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",Sunitinib,Standard Chemotherapy,Consolidation,2.0,Dead,269.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C184,S380,4201,16-01022,2224.0,BA2987D,,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882C; MAF 45%)|FLT3 (p.D835A; MAF 4%)|FLT3 (p.N841K; MAF; 7%)|NPM1 (p.W288fs*12; MAF 46%)|NRAS (p.G12D; 17%)|TET2 (p.G1137D; MAF 31%),Negative,Positive (p.W288fs*12; MAF 46%),,52.0,0.0,4201_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",Idarubicin and Cytarabine,Standard Chemotherapy,Salvage,3.0,Dead,559.0,Dead-Disease,51.5,72.0,,,0.0,0.0,0.0,13.2,,79.8,,4.4,0.0,,,,,,116.57,45.0,3.6,,,1.16,10.2,,52.0,25.0,608.0,102.3,"CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive"
C185,C185,4201,16-01023,,,,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882C; MAF 45%)|FLT3 (p.D835A; MAF 4%)|FLT3 (p.N841K; MAF; 7%)|NPM1 (p.W288fs*12; MAF 46%)|NRAS (p.G12D; 17%)|TET2 (p.G1137D; MAF 31%),Negative,Positive (p.W288fs*12; MAF 46%),,52.0,0.0,4201_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",Idarubicin and Cytarabine,Standard Chemotherapy,Salvage,3.0,Dead,559.0,Dead-Disease,51.5,72.0,,,0.0,0.0,0.0,13.2,,79.8,,4.4,0.0,,,,,,116.57,45.0,3.6,,,1.16,10.2,,52.0,25.0,608.0,102.3,"CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive"
C200,S598,4201,16-01192,2224.0,BA2079D,BA2079R,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,NonInitial,NotDetected,"46,XX[20]  | 46,XX[20]",Not available,DNMT3A (p.R882C; MAF 14%),Negative,Negative,,52.0,34.0,4201_2,Remission,Remission,Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",Idarubicin and Cytarabine,Standard Chemotherapy,Salvage,3.0,Dead,559.0,Dead-Disease,1.5,,,,1.4,0.2,,9.2,,24.3,,64.9,,,,,,,6.5,395.0,3.2,,,0.76,9.2,,119.0,151.0,380.0,93.4,
C312,S381,4201,17-00963,2224.0,BA3099D,BA3099R,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,NonInitial,Other,"46,X,t(X;7)(q21;q32)[20] ",Normal,DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%),Positive (MAF 93%; AR 13.28571429),Positive (p.W288fs*12; MAF 44%),,53.0,383.0,4201_3,Relapse,Relapse,Post-Chemotherapy|Relapse,Peripheral Blood,1.0,Standard Chemotherapy,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",Idarubicin and Cytarabine,Standard Chemotherapy,Salvage,3.0,Dead,559.0,Dead-Disease,,78.0,,,0.0,0.0,0.0,14.9,,7.0,,10.5,0.0,,,,,,7.66,5.0,2.3,,,0.43,8.5,,40.0,99.0,,94.1,"variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)"
C537,S382,4207,16-01049,2546.0,BA2472D,BA2472R,Male,78.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]","nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,78.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Supportive/Palliative Care,5.0,4.0,Induction|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Supportive/Palliative Care,-1.0,"7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine","Etoposide, Cytarabine",Standard Chemotherapy,Supportive/Palliative Care,-1.0,Dead,372.0,Dead-Disease,20.0,3.8,,,0.0,7.8,,40.0,,5.2,7.0,40.0,,,,,,,4.9,30.0,3.1,,1.0,1.41,8.5,,9.0,49.0,675.0,,"CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-)."
C188,S383,4210,16-01055,2028.0,BA2144D,,Female,56.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,NotDetected,"46,XX[20]",Normal,ASXL1 (p.T601A; MAF 45%)|BCOR (p.Y1350fs*1; MAF 43%)|DNMT3A (p.R882H; MAF 46%)|FLT3 (p.A680V; MAF 37%)|IDH2 (p.R140Q; MAF 43%)|NRAS (p.Q61K; MAF 9%)|PRDM1 (p.I117M; MAF 49%)|RUNX1 (p.N434fs*166; MAF 37%)|RUNX1 (p.R201*; MAF 45%),Negative,Negative,,56.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|ME (Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1731.0,Alive,80.0,68.0,,,0.0,0.0,0.8,19.3,,7.6,,3.4,0.1,,,,,,40.02,53.0,3.4,,,0.74,5.9,,46.0,25.0,,91.9,"CD13, CD34, CD38, CD117, and dim HLA-DR +."
C191,S385,4230,16-01098,2555.0,BA2284D,,Female,44.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,Other,"45,XX,der(13;14)(q10;q10)?c[20]","nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Positive (MAF 46%; AR 0.851851852),Positive,,44.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,369.0,Alive,64.0,74.0,,,,,,,,,,,,,,,,,99.87,90.0,,,,,,,21.0,34.0,,,
C192,S386,4231,16-01100,2481.0,BA2456D,BA2456R,Male,65.0,1.0,Skin cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,,"nuc ish (PML,RARA)x2[199]",,Negative,Positive,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Cytarabine,Cytarabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Dead,2.0,Dead-Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C193,S387,4232,16-01102,2382.0,BA2175D,BA2175R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]","nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]",,Negative,Negative,,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Alive,373.0,Alive,30.0,5.0,,,,,,,,,,,,,,,,,44.63,16.0,,,,,,,37.0,93.0,,,
C201,S388,4235,16-01109,2377.0,BA2507D,BA2507R,Male,33.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",Positive for CBFB rearrangment for 91% of cells (FISH),TET2 (c.652G>A; p.V218M; MAF 50%),Negative,Negative,,33.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,402.0,Alive,72.0,95.0,,,0.0,0.0,,3.0,,0.0,,1.0,,,,,,,93.2,31.0,3.4,,,,6.5,,29.0,24.0,,,"Positive (CD38, CD13, CD33, CD34, CD45, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD64, TdT)"
C195,C195,4239,16-01120,,,,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XY[20]",Normal,DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%),Positive (MAF 45%),Positive (p.Trp288fs; MAF 20.7%),,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,398.0,Alive,86.0,89.0,,,,,,,,,,,,,,,,,115.15,57.0,,,,,,,,,,,
C540,S390,4240,17-00215,2194.0,BA3164D,BA3164R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/46,sl,der(1)t(1;2)(p13;q11.2),-2, (der(3)t(3;5)(q12;p15),del(6)(q13q23),+22[2]/46,XX[1])",Normal,DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%),Positive (MAF 92%; AR 11.5),Positive (p.W288fs*12; MAF 36%),,47.0,124.0,4240_1,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),7.0,6.0,Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,360.0,Dead-Disease,85.0,50.0,,,0.0,0.0,0.0,7.1,,4.4,,41.6,0.4,,,,,,23.68,63.0,3.7,,,1.0,10.5,,25.0,56.0,1199.0,93.0,"partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +"
C264,C264,4240,17-00339,,,,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]",Not available,FLT3-ITD (ITD; MAF 60%),Positive (MAF 60%),,,47.0,159.0,4240_2,Residual,Residual,Residual Disease,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),7.0,6.0,Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,360.0,Dead-Disease,83.0,90.0,,,0.1,0.2,1.4,5.1,,89.3,,3.9,2.4,,,,,,20.31,17.0,3.5,,,1.2,8.6,,59.0,57.0,,92.1,"CD7, CD13, CD33, partial CD34, partial  CD117, CD123 and HLA-DR-positive"
C267,S391,4240,17-00436,2194.0,BA3235D,BA3235R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]",Not available,,Positive (MAF 94%; AR 15.666666667),Positive,,47.0,168.0,4240_3,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),7.0,6.0,Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,360.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C274,C274,4240,17-00448,,,,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]",Not available,,Positive (MAF 60%),,,47.0,172.0,4240_4,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),7.0,6.0,Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction,Complete Response i,Standard Chemotherapy,-1.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate",Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,360.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C539,S393,4248,16-01151,2520.0,BA2984D,BA2984R,Male,81.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,NotDetected,"46,XY[19]",Normal,CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%),Negative,Positive (p.W288fs*12; MAF: 39%),,81.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Vidaza, BI836858 (anti-CD33)","Vidaza, BI836858 (anti-CD33)",Standard Chemotherapy,Induction,-1.0,Dead,581.0,Dead-Disease,80.0,80.0,,,0.0,0.0,7.0,7.8,,0.0,,6.9,0.5,,,,,,33.81,16.0,3.2,,,1.3,8.8,,31.0,42.0,665.0,85.1,"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive"
C198,S394,4252,16-01185,2307.0,BA2414D,BA2414R,Male,50.0,1.0,Hodgkin Lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,Other,"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ",Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells,BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N),Positive (MAF 45%; AR 0.818181818),Negative,,50.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Dead,201.0,Dead-Unknown,75.0,82.0,,,0.0,2.0,,4.0,,0.0,,8.0,,,,,,,119.6,12.0,3.7,,,,6.5,,39.0,45.0,,,"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT"
C199,S395,4256,16-01191,2168.0,BA2697D,BA2697R,Female,65.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"45,XX,-7[20]","7cen (D7Z1), 7q31 (D7S486): monosomy present ",DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%),Negative,Negative,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,338.0,Alive,20.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C202,S396,4260,16-01201,2117.0,BA2999D,BA2999R,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ","42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML",DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%),Negative,Negative,,54.0,0.0,4260_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,7.0,5.0,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",Incyte trial (azacitidine and JAK 1 inhibitor),Standard Chemotherapy,Salvage,-1.0,Dead,543.0,Dead-Disease,75.0,90.0,,,0.0,0.0,0.0,22.1,,6.2,,1.8,0.0,,,,,,118.0,25.0,1.8,,,0.84,8.1,,19.0,33.0,706.0,91.4,"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive "
C253,C253,4260,17-00310,,,,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,t(4;12)(q12;p13)[19]/46,XY[1]","91/100 (91%)  interphase cells scored were positive for ETV6 rearrangement, as seen previously and consistent with the 4;12 translocation observed in the metaphase karyotype. ","DNMT3A (p.R882H; MAF 50%)|IDH1 (p.R132S; MAF 51%)|RUNX1 (p.R166*, MAF 51%)|SRSF2 (p.P95H; MAF 53%)|ZRSR2 (p.H330Y; MAF 59%)",Negative,Negative,,55.0,129.0,4260_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,7.0,5.0,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",Incyte trial (azacitidine and JAK 1 inhibitor),Standard Chemotherapy,Salvage,-1.0,Dead,543.0,Dead-Disease,90.0,25.0,,,0.0,0.9,0.9,63.6,,5.5,,3.6,0.3,,,,,,63.69,65.0,3.7,,,0.6,12.4,,19.0,29.0,,103.2,"partial CD7, CD13, CD33, CD34, CD38, CD71, CD117, CD123, and HLA-DR + "
C203,S397,4263,16-01216,2280.0,BA2011D,BA2011R,Male,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,NotDetected,"46,XY[11] ",Normal,BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%),Negative,Negative,,63.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Child,-1.0,Alive,306.0,Alive,26.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C204,S398,4271,16-01219,2538.0,BA2217D,BA2217R,Male,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XY[20]",,"CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)",Negative,Negative,bi,47.0,0.0,4271_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,116.0,Unknown,214.0,,83.0,82.0,,,0.0,3.4,0.0,23.1,,3.4,,0.0,1.6,,,,,,18.71,24.0,3.5,,,0.95,10.2,,23.0,11.0,290.0,88.9,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO "
C205,C205,4271,16-01220,,,,Male,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XY[20]",,"CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)",Negative,Negative,,47.0,0.0,4271_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,116.0,Unknown,214.0,,83.0,82.0,,,0.0,3.4,0.0,23.1,,3.4,,0.0,1.6,,,,,,18.71,24.0,3.5,,,0.95,10.2,,23.0,11.0,290.0,88.9,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO "
C206,S399,4273,16-01223,2234.0,BA2454D,BA2454R,Male,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]","nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Dead,31.0,Dead-Unknown,83.0,59.0,,,,,,,,,,,,,,,,,24.23,22.0,,,,,,,21.0,23.0,,,
C207,S400,4274,16-01225,2431.0,BA2776D,BA2776R,Female,61.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%),Positive (MAF 90%; AR 9),Positive (p.W288fs*12; MAF 45%),,61.0,0.0,4274_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Supportive/Palliative Care,1.0,1.0,Supportive/Palliative Care,,,,Hydroxyurea,Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,316.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive"
C212,C212,4274,16-01259,,,,Female,61.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XX[20]",Normal,FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%),Positive (30 bp insertion; MAF 70%),Positive (p.W288fs*12; MAF 45%),,61.0,12.0,4274_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Supportive/Palliative Care,1.0,1.0,Supportive/Palliative Care,,,,Hydroxyurea,Hydroxyurea,Supportive/Palliative Care,Supportive/Palliative Care,-1.0,Dead,316.0,Dead-Disease,,96.0,,,0.8,0.0,0.0,5.5,,0.8,,0.8,0.3,,,,,,100.76,11.0,,,,,7.1,,,,,70.2,
C208,S401,4275,16-01227,2282.0,BA2218D,BA2218R,Female,39.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M4,NonInitial,,,,,Negative,Positive,,40.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,4.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,39.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine",Decitabine,Standard Chemotherapy,Salvage,69.0,Dead,433.0,Dead-Unknown,,91.0,,,,,,9.0,,,,,,,,,,,73.0,66.0,3.8,,0.4,0.49,9.9,,21.0,34.0,,93.6,
C209,S402,4291,16-01237,2547.0,BA2135D,BA2135R,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,,Negative,Negative,,73.0,0.0,4291_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Alive,122.0,Alive,71.0,3.0,,,,1.0,,68.0,,8.0,,11.0,,,,,,,63.4,95.0,2.9,,0.2,0.51,7.8,,11.0,23.0,,110.7,"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo."
C210,C210,4291,16-01238,,,,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,,Negative,Negative,,73.0,0.0,4291_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Alive,122.0,Alive,71.0,3.0,,,,1.0,,68.0,,8.0,,11.0,,,,,,,63.4,95.0,2.9,,0.2,0.51,7.8,,11.0,23.0,,110.7,"BLASTS HAVE A MYELOID IMMUNOPHENOTYPE; THEY ARE POSITIVE FOR HLA-DR, CD34, CD117, CD33 AND  CD43 AND ARENEGATIVE FOR CD13, CD14, CD64, CD11B, MPO, TDT B AND T CELL MARKERS. (Peripheral Blood Flow Cytometry)"
C211,C211,4299,16-01253,,,,Female,38.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,NotDetected,"46,XX[20]",Normal,DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%),Negative,Positive (p.W288fs*12; MAF 51%),,38.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,106.0,Alive,1586.0,Alive,47.0,,,,,,,,,,,,,,,,,,46.27,,,,,,,,,,,,"CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)"
C213,S404,4303,16-01262,2120.0,BA2500D,BA2500R,Female,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XX,t(15;17)(q22;q21)[20]",86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. ,ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%),Negative,Negative,,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"ATRA, Arsenic Trioxide, Idarubicin","ATRA, Arsenic Trioxide, Idarubicin",Standard Chemotherapy,Induction,-1.0,Unknown,28.0,,90.0,90.0,,,0.9,1.7,44.0,8.6,,0.0,,6.0,1.5,,,,,,46.3,38.0,2.4,,,0.86,6.7,,110.0,255.0,,88.0,"CD13, CD33, CD58, CD64, CD117, CD123, MPO"
C215,S405,4307,16-01267,2315.0,BA2519D,,Female,61.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XX[20]",,CUX1 (VAF: 43.9%)|DNMT3A (VAF: 42.8%)|NPM1 (VAF: 44.9%)|WT1 (VAF: 23.2%),Negative,Positive (VAF: 44.9%),,62.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Alive,361.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C214,S406,4317,16-01270,2268.0,BA2830D,BA2830R,Female,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,,,,Negative,Negative,,74.0,0.0,4317_1,Relapse,Relapse,Relapse,Peripheral Blood,1.0,Targeted Therapy - Kinase Inhibitor(s),1.0,1.0,Experimental,,,,Dasatinib,Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,16.0,Unknown,808.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C216,C216,4317,17-00006,,,,Female,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,"46,XX,inv(16)(p13q22)[cp20]",CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.,KIT (p.D816H; MAF 44%),Negative,Negative,,74.0,7.0,4317_2,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Targeted Therapy - Kinase Inhibitor(s),1.0,1.0,Experimental,,,,Dasatinib,Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,16.0,Unknown,808.0,,91.0,80.0,,,0.0,3.4,0.8,5.8,,8.3,,2.5,0.0,,,,,,40.25,30.0,2.9,,,0.61,8.5,,19.0,42.0,1612.0,85.9,"CD13, CD33, CD34, variable CD38, CD58, CD117, dim HLA-DR, and dim MPO"
C217,C217,4317,17-00007,,,,Female,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,"46,XX,inv(16)(p13q22)[cp20]",CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.,KIT (p.D816H; MAF 44%),Negative,Negative,,74.0,8.0,4317_3,Relapse,Relapse,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,1.0,Targeted Therapy - Kinase Inhibitor(s),1.0,1.0,Experimental,,,,Dasatinib,Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,16.0,Unknown,808.0,,91.0,80.0,,,0.0,3.4,0.8,5.8,,8.3,,2.5,0.0,,,,,,40.25,30.0,2.9,,,0.61,8.5,,19.0,42.0,1612.0,85.9,"CD13, CD33, CD34, variable CD38, CD58, CD117, dim HLA-DR, and dim MPO"
C226,S407,4317,17-00077,2268.0,BA2353D,BA2353R,Female,72.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,"46,XX,inv(16)(p13q22)[18]/46,XX[2] ",CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype. ,,Negative,Negative,,74.0,33.0,4317_4,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,1.0,Targeted Therapy - Kinase Inhibitor(s),1.0,1.0,Experimental,,,,Dasatinib,Dasatinib,Targeted Therapy - Kinase Inhibitor(s),Experimental,16.0,Unknown,808.0,,90.0,74.0,,,2.6,0.0,0.0,6.0,,2.6,,2.6,0.0,,,,,,34.76,9.0,2.7,,,0.69,6.5,,12.0,22.0,807.0,86.7,"CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +."
C218,S408,4324,17-00021,2475.0,BA2924D,BA2924R,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,,,,,Negative,Positive,,67.0,0.0,4324_1,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,23.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,63.0,Alive,300.0,Alive,,8.0,,,,1.0,,14.0,,19.0,,46.0,,,1.0,,,,9.0,165.0,4.3,,0.2,0.88,12.5,,15.0,22.0,,97.2,
C249,S409,4324,17-00281,2475.0,BA3192D,BA3192R,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]",Not Available (Cytogenetics),DNMT3A (c.2645G>A; p.R882H; MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V; MAF 81%)|NPM1 (c.860_863dupTCTG; p.W288Cfs*12; MAF 51%)|SETBP1 (c.3209C>T; p.P1070L; MAF 46%)|TET2 (c.3638T>G; p.V1213G; MAF 87%),Positive,Positive (NPM1  c.860_863dupTCTG; p.W288Cfs*12; MAF 51%),,67.0,80.0,4324_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,23.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,63.0,Alive,300.0,Alive,90.0,,,,,,,,,,,,,,,,,,13.0,41.0,,,,,,,,,,,"POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)"
C219,S410,4325,17-00025,2570.0,BA2303D,BA2303R,Female,39.0,1.0,Cervical Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,Intermediate,NotDetected,"46,XX[20]",,DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%),Positive (MAF 85%; AR 5.666666667),Positive (p.Trp288fs; MAF 21.2%),,39.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI","Fludarabine, TBI",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,296.0,Alive,70.0,80.0,,,,,,,,,,,,,,,,,190.0,,,,,,,,,,,,"Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation."
C220,C220,4336,17-00028,,,,Female,44.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,,,,FLT3-ITD|IDH2 (c.419G>A; p.R140Q; MAF 39%)|NF1 (c.5225A>G; p.N17425; MAF 10%)|PHF6 (c.901T>G; p.Y301D; MAF 29%)|RAD21 (c.482-3T>C; MAF 8%)|RUNX1 (c.318G>A; p.W106* MAF 37% c.319C>T; p.R107C MAF 37%)|SMC1A (c.3391G>A; p.G1131R; MAF 29%),Positive,,,45.0,1.0,,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,7.0,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Clofarabine, Cytarabine",Azacitidine,Standard Chemotherapy,Salvage,4.0,Dead,768.0,Dead-Unknown,83.0,80.0,,,,,,16.0,,,,4.0,,,,,,,85.8,60.0,4.1,,0.2,0.93,9.9,,19.0,20.0,,96.1,"POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.  | POSITIVE FOR DIM CD45, CD34, HLADR, CD117, CD13, CD38, NEGATIVE FOR CD33."
C221,S411,4359,17-00033,2216.0,BA2160D,BA2160R,Male,74.0,1.0,Bladder Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",Normal,,Negative,Positive,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Re-induction,-1.0,Dead,58.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML."
C538,S412,4363,17-00064,2131.0,BA2590D,BA2590R,Male,55.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Adverse,NotDetected,"46,XY[19]",Normal,FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%),Positive (MAF 50%; AR 1),Positive (c.863_864insTCTG; p.W288fs; MAF 42%),,55.0,0.0,4363_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib",Midostaurin,Targeted Therapy - Kinase Inhibitor(s),Maintenance,44.0,Dead,282.0,Dead-Disease,88.5,64.0,,,0.0,0.0,,25.0,,4.0,,7.0,,,,,,,24.9,54.0,3.3,,,,10.9,,34.0,36.0,,,"Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)"
C223,C223,4363,17-00065,,,,Male,55.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Adverse,NotDetected,"46,XY[19]",Normal,FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%),Positive (MAF 50%; AR 1),Positive (c.863_864insTCTG; p.W288fs; MAF 42%),,55.0,0.0,4363_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib",Midostaurin,Targeted Therapy - Kinase Inhibitor(s),Maintenance,44.0,Dead,282.0,Dead-Disease,88.5,64.0,,,0.0,0.0,,25.0,,4.0,,7.0,,,,,,,24.9,54.0,3.3,,,,10.9,,34.0,36.0,,,"Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)"
C224,S413,4364,17-00066,2827.0,BA3195D,BA3195R,Male,77.0,0.0,,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,NotDetected,"46,XY[19]",Normal,DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434Â£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%),Negative,Negative,,77.0,0.0,4364_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Experimental,Refractory,Targeted Therapy - Kinase Inhibitor(s),-1.0,"Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb",Enasidenib,Targeted Therapy - Kinase Inhibitor(s),Salvage,-1.0,Alive,322.0,Alive,90.0,92.0,,,0.0,0.0,,4.0,,1.0,,3.0,,,,,,,224.2,72.0,3.8,,,,7.4,,17.0,22.0,,,"Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)"
C225,C225,4364,17-00067,,,,Male,77.0,0.0,,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,NotDetected,"46,XY[19]",Normal,DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434Â£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%),Positive (<1% MAF),Negative,,77.0,0.0,4364_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Experimental,Refractory,Targeted Therapy - Kinase Inhibitor(s),-1.0,"Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb",Enasidenib,Targeted Therapy - Kinase Inhibitor(s),Salvage,-1.0,Alive,322.0,Alive,90.0,92.0,,,0.0,0.0,,4.0,,1.0,,3.0,,,,,,,224.2,72.0,3.8,,,,7.4,,17.0,22.0,,,"Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)"
C222,S414,4366,17-00072,2500.0,BA2516D,BA2516R,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,"46,XY[20]",Normal,BCOR (p.S1024; MAF 5%)|NRAS (p.G13D; MAF 34%)|PTPN11 (p.G60V; MAF 3%)|SRSF2 (p.P95H; MAF 40%),Negative,Negative,,70.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,61.0,"Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine","MEC (Cytarabine, Etoposide, Mitoxantrone)",Standard Chemotherapy,Salvage,-1.0,Dead,362.0,Dead-Disease,,15.0,,,0.0,0.0,16.2,16.2,,8.1,,6.3,4.5,,,,,,92.55,14.0,4.6,,,1.5,9.8,,19.0,45.0,851.0,92.6,
C228,S415,4379,17-00093,2372.0,BA3036D,BA3036R,Female,43.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NotDetected,"46,XX[20]","nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",FLT3-D835,Positive (MAF 33%; AR 0.492537313),Negative,,43.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Unknown,35.0,,,48.0,,,,,,,,,,,,,,,,,41.91,27.0,,,,,,,30.0,21.0,,,
C229,S416,4380,17-00094,2086.0,BA2971D,BA2971R,Male,57.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]",Not Available,DNMT3A (c.2644C>T; p.R882C; MAF 47%)|JAK2 (c.1849G>T; p.V617F; MAF 91%)|RUNX1 (c.338C>T; p.P113L; MAF 42% )|RUNX1 (c.592G>A; p.D198N; MAF 46%)|SETBP1 (c.883G>A; p.V1295M; MAF 47%)|SRSF2 (c.284C>A; p.P95H; MAF 47%),Negative,Negative,,57.0,0.0,4380_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)","Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,13.0,Alive,307.0,Alive,20.0,,,,,,,,,,,,,,,,,7.05,19.3,49.0,,,,,,,,,,,"THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33."
C233,C233,4380,17-00117,,,,Male,57.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]",Not Available,DNMT3A (c.2644C>T; p.R882C; MAF 47%)|JAK2 (c.1849G>T; p.V617F; MAF 91%)|RUNX1 (c.338C>T; p.P113L; MAF 42% )|RUNX1 (c.592G>A; p.D198N; MAF 46%)|SETBP1 (c.883G>A; p.V1295M; MAF 47%)|SRSF2 (c.284C>A; p.P95H; MAF 47%),Negative,,,57.0,11.0,4380_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)","Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,13.0,Alive,307.0,Alive,,20.0,,,,11.0,,9.0,,15.0,,39.0,,,,,,,21.1,27.0,4.7,,1.0,1.01,13.4,,38.0,92.0,,70.3,
C232,S417,4389,17-00111,2709.0,BA3118D,BA3118R,Female,45.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Myeloid sarcoma,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,,,Favorable,CBFB-MYH11,"46,XX[20]",,MYH11 (CBFB-MYH11 fusion)|NRAS (G12D),Negative,Negative,,45.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,92.0,Alive,279.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C231,S418,4390,17-00113,2668.0,BA3206D,BA3206R,Female,35.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M2,M2,Favorable,RUNX1-RUNX1T1,"45,X,-X,t(8;21)(q22;q22)[20] ","RUNX1T1(8q21.3)/RUNX1(21q22):   64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21).",FLT3-ITD (MAF 5%),Negative,Negative,,35.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,4.0,Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax","Decitabine, Venetoclax",Standard Chemotherapy,Salvage,165.0,Dead,1220.0,Dead-Disease,60.0,10.0,,,0.0,0.0,0.9,88.7,,0.9,,9.5,0.0,,,,,,4.73,34.0,3.0,,,0.8,7.8,,34.0,12.0,334.0,93.2,"CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+ "
C235,S419,4395,17-00123,2624.0,BA3217D,BA3217R,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]",Normal,"FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))",Positive (MAF 49%; AR 0.960784314),Negative,,60.0,0.0,4395_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,293.0,Alive,95.0,70.0,,,,,,27.0,,1.0,,2.0,,,,,,,25.5,48.0,3.2,,,,9.9,,37.0,32.0,,,"Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)"
C234,C234,4395,17-00124,,,,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[20]",Normal,"FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))",Positive (MAF 38%),Negative,,60.0,0.0,4395_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,293.0,Alive,95.0,70.0,,,,,,27.0,,1.0,,2.0,,,,,,,25.5,48.0,3.2,,,,9.9,,37.0,32.0,,,"Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)"
C236,S420,4406,17-00177,2811.0,BA3306D,BA3306R,Female,26.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,,Normal,"FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))",Positive (MAF 95%; AR 19),Positive (c.863_864insTCTG; p.W288fs; MAF 43%),,26.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,289.0,Alive,89.5,88.0,,,0.0,0.0,,7.0,,2.0,,3.0,,,,,,,138.2,19.0,3.0,,,,7.6,,10.0,21.0,,,"Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)"
C237,C237,4418,17-00190,,,,Female,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,,,Adverse,Other,"46,XX,del(9)(q13q22)[5]/46,sl,del(11)(q13q23)[14]  /46,sdl,t(2;4;7)(q33;q21;p15),add(8)(p11.2)[2]",,CEBPA (p.Ala111fs; MAF 44.5%)|CEBPA (p.Ser319_Asp320del; MAF 32.9%)|CSF3R (p.Thr618Ile; MAF 1.6%)|GATA2 (p.Arg330Gln; MAF 46%),Negative,Negative,,31.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine|CLAG (Cladribine, Cytarabine, Filgrastim)|7+3 (Cytarabine, Idarubicin, Dexamethasone)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,153.0,Alive,80.0,69.0,,,,,,,,,,,,,,,,,11.23,18.0,,,,,,,,,,,
C238,S421,4421,17-00195,2615.0,BA3411D,BA3411R,Female,48.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,Adverse,Other,"47,XX,+8,del(8)(q11.2q22)[20]","CEP 8:  73/100 cells (73%) had three signals, consistent with the extra chromosome 8 in the metaphase karyotype",ASXL1 (p.L823; MAF 47%),Negative,Negative,,48.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Unknown,351.0,,25.0,7.0,,,0.0,0.0,2.6,47.0,,9.6,,36.5,0.0,,,,,,4.8,21.0,,,,,6.7,,,,,89.4,"CD13, CD33, CD34, CD38, CD56, CD58, variable CD64, CD71, CD117, dim CD123, HLA-DR, MPO  (Myeloid Blasts) | CD11b, CD13, CD15, CD33, CD56, CD64, HLA-DR (Abnormal Monocytes)"
C239,S422,4428,17-00210,2747.0,BA3133D,BA3133R,Male,61.0,1.0,Skin cancer,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8] ","TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1.  No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2):  33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes.  No evidence for MECOM/RPN1 fusion. ",BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%),Negative,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,Vidaza,Vidaza,Standard Chemotherapy,Induction,-1.0,Dead,51.0,Dead-Disease,25.0,26.0,,,0.0,0.0,11.5,9.7,,7.1,,43.4,0.1,,,,,,19.22,166.0,3.6,,,0.8,7.0,,23.0,33.0,855.0,116.4,"CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR + "
C242,C242,4429,17-00227,,,,Male,69.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with minimal differentiation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,Intermediate,NotDetected,"46,XY[20]",Negative,JAK2,Negative,Negative,,69.0,5.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,3.0,3.0,Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response i,Standard Chemotherapy,8.0,"7+3 (Cytarabine, Idarubicin)|Cytarabine, Cyclophosphamide, TBI|Methotrexate","Cytarabine, Cyclophosphamide, TBI",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,512.0,Dead-Disease,18.0,,,,,,,87.0,,1.0,,,,,,,,,0.9,,,,,,,,,,,,"CD34, CD117, dim CD33, CD13, HLA-DR, variable intracytoplasmic MPO"
C240,C240,4438,17-00229,,,,Female,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%),Negative,Positive (p.W288fs*12; MAF 44%),,47.0,0.0,4438_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,95.0,Alive,1679.0,Alive,85.0,70.0,,,0.0,0.4,0.4,27.1,,63.8,,5.3,0.1,,,,2.6,,58.66,48.0,2.8,,,1.39,6.5,,14.0,15.0,355.0,97.5,"CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +"
C241,S423,4438,17-00230,2780.0,BA3451D,BA3451R,Female,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%),Negative,Positive (p.W288fs*12; MAF 44%),,47.0,0.0,4438_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,95.0,Alive,1679.0,Alive,85.0,70.0,,,0.0,0.4,0.4,27.1,,63.8,,5.3,0.1,,,,2.6,,58.66,48.0,2.8,,,1.39,6.5,,14.0,15.0,355.0,97.5,"CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +"
C243,S424,4442,17-00248,2645.0,BA3286D,BA3286R,Female,45.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML without maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Intermediate,NotDetected,"46,XX[20] ",Normal,FLT3-ITD (123 bp insertion; MAF 50%),Positive (MAF 23%; AR 0.298701299),Negative,,45.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib",HIDAC + Sorafenib,Standard Chemotherapy,Consolidation,-1.0,Unknown,104.0,,85.0,70.0,,,0.0,0.0,2.6,6.0,,25.6,,4.3,0.1,,,,,,185.9,59.0,3.8,,,0.8,7.4,,110.0,114.0,2504.0,104.0,"dimCD7, dimCD13, CD33, CD34, CD38, variable CD64, dimCD117, CD123, HLA-DR, and MPO positive "
C244,S425,4443,17-00252,2727.0,BA3212D,BA3212R,Female,0.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,RARA_re,"46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3] ","EGR-1/ D5S23, D5S721: 175/200 cells had a 1 red/ 2 green signal  pattern, indicating a deleted 5q. Five cells had a 2 red/ 4 green signal pattern consistent with the  two normal chromosomes 5 and the two derivative chromosomes (5;9),  resulting in loss of 5q, present in the near-triploid clone. | RUNX1T1/ RUNX1: 155/200 cells had a 3 chromosome 8 signals,  consistent with the trisomy 8 observed in the metaphase karyotype.  Four cells had 4 chromosome 21 signals (in addition to trisomy 8),  consistent with the tetrasomy 21 observed in the near-triploid clone. No evid for RUNX1T1/RUNX1 fusion. | ETV6/ RUNX1:   5/200 cells (2.5%) had a 4 red/ 3 green signal pattern,  consistent with the near-triploid clone with trisomy 8 and tetrasomy 21.  There was no evidence for ETV6/ RUNX1 fusion. ",NRAS (p.G12D; MAF 29%)|NRAS (p.Q61K; MAF 6%),Negative,Negative,,0.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,5.0,Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide|Etoposide, Cytarabine","FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Standard Chemotherapy,Re-induction,4.0,Dead,855.0,Dead-Disease,,82.0,,,0.0,0.0,,23.1,0.0,63.1,,5.8,0.6,,,0.0,0.0,,133.39,28.0,3.2,,,0.26,5.6,,55.0,179.0,8707.0,85.2,"CD4, CD7, partial CD13, CD33, CD71, partial CD117, CD123 and dim HLA-DR-positive "
C245,C245,4447,17-00257,,,,Female,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XX,inv(16)(p13.1q22)[18]/46,XX[2]",,KIT|KRAS|MYH11 (CBFB-MYH11 fusion),Negative,Negative,,49.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,225.0,Alive,58.0,44.0,,,,,,,,,,,,,,,,,57.75,32.0,,,,,,,,,,,
C246,S426,4449,17-00262,2792.0,BA3271D,BA3271R,Female,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M4,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%),Positive (MAF 40%; AR 0.666666667),Positive (p.W288fs*12; MAF 41%),,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,23.0,Dead-Disease,81.0,43.0,,,0.0,7.5,,20.6,,16.8,,8.4,0.8,50.0,,,,,28.53,73.0,2.3,,,2.79,8.6,,21.0,33.0,487.0,106.4,"dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)"
C247,S427,4450,17-00264,2758.0,BA3152D,BA3152R,Male,74.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,Other,"43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]","Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21. ",TP53 (p.Y220C;  MAF 91%),Negative,Negative,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Azacitidine,Azacitidine,Standard Chemotherapy,Supportive/Palliative Care,3.0,Dead,5.0,Dead-Disease,42.0,4.0,,,0.0,0.0,9.1,3.8,,44.7,,38.6,0.5,,,,,,29.15,93.0,2.3,,,1.64,7.7,,27.0,23.0,387.0,93.3,"partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)"
C248,C248,4453,17-00280,,,,Female,27.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML without maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Intermediate,Other,"47,XX,+8[19]/46,XX[1]",RUNX1T1 (8q21.3):   93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.,FLT3-ITD (ITD; MAF 50% ),Positive (MAF 50%),Negative,,27.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),7.0,5.0,Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib",Ruxolitinib,Targeted Therapy - Kinase Inhibitor(s),Maintenance,-1.0,Alive,1512.0,Alive,61.0,82.0,,,0.0,0.0,0.0,11.5,,0.9,,1.8,1.9,,,,,,24.3,53.0,3.5,,,0.64,7.1,,17.0,33.0,440.0,96.2,"dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+ "
C250,S430,4456,17-00287,2815.0,BA3251D,BA3251R,Female,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%),Positive (MAF 36%; AR 0.5625),Negative,,75.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,4.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,4.0,Dead,14.0,Dead-Disease,80.5,60.0,,,0.0,0.0,,16.0,,22.0,,1.0,,,,,,,142.8,35.0,3.7,,,,11.1,,61.0,75.0,,,"Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)"
C292,C292,4458,17-00649,,,,Male,68.0,1.0,Dupuytren's|Skin cancer,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(9;22)(q34;q11); BCR::ABL1 fusion,"AML, myelodysplasia-related",MYELODYSPLASTIC SYNDROMES,Unknown,,,NonInitial,BCR-ABL1,"49,X,-Y,add(3)(q21),t(3;12)(q25;q24.1),add(8)(q22),t(9;22)(q34;q11.2),+19,+21,+der(22)t(9;22)(q34;q11.2),+mar[2]/48~49,idem,+12,-der(12)t(3;12)(q25;q24.1)[cp12]/46,XY[6] ",43/200 cells (21.5%) had a fusion signal pattern consistent with BCR/ABL fusion and the Philadelphia rearrangement plus extra derivative 22 observed in the metaphase karyotype.,,Negative,Negative,,71.0,1308.0,,Residual,Residual,Post-Transplant|Residual Disease|Post-Chemotherapy,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction,Complete Response,Standard Chemotherapy,912.0,"Fludarabine, Melphalan|Dasatinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine",Decitabine,Supportive/Palliative Care,Experimental,-1.0,Dead,827.0,Dead-Disease,,73.0,,,0.0,0.0,1.7,0.9,,11.0,,38.1,0.9,,,,,,32.56,36.0,2.9,,,0.79,8.4,,19.0,48.0,1654.0,97.8,"CD13, CD33, HLA-DR, dim CD117, CD34, CD123, CD56,  CD38, CD58 and cytoplasmic MPO+"
C251,S431,4461,17-00300,2655.0,BA3362D,BA3362R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,Other,"46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]","In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)",FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%),Negative,Negative,,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"3+7 (Cytarabine, Daunorubicin)","3+7 (Cytarabine, Daunorubicin)",Standard Chemotherapy,Induction,-1.0,Dead,24.0,Dead-Disease,85.0,75.0,,,0.0,0.0,0.0,14.8,,7.8,,1.7,0.5,,,,,,95.49,144.0,3.4,,,0.89,7.7,,31.0,63.0,4853.0,96.7,"CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive"
C254,S432,4464,17-00313,2733.0,BA3135D,BA3135R,Male,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Adverse,,,,FLT3-ITD,Positive (MAF 24%; AR 0.315789474),Positive,,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,7.0,Unknown,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dim CD56 | dim CD15 | dim CD123
C255,S433,4468,17-00322,2823.0,BA3187D,BA3187R,Male,76.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,NonInitial,CBFB-MYH11,"46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4]",POSITIVE for CBFB gene locus rearrangement (separated by chromosome 16 inversion),,Negative,Negative,,78.0,0.0,,Relapse,Relapse,Relapse,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",Decitabine,Standard Chemotherapy,Salvage,81.0,Unknown,901.0,,10.0,,,,,,,,,,,,,,,,,,13.3,47.0,,,,,14.6,,,,,97.7,
C256,S434,4470,17-00325,2630.0,BA3098D,BA3098R,Male,44.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]","7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present",KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%),Negative,Negative,,44.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1.0,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC","Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,119.0,Alive,74.8,83.0,,,,,,,,,,,,,,,,,102.09,23.0,,,,,,,,,,,
C258,C258,4471,17-00331,,,,Male,79.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,Other,"47,XY,+8[18]/46,XY[2] ","CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis.",FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%),Positive (MAF 16%),Negative,,79.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,50.0,"Decitabine|Azacitidine, BI 836858 (anti-CD33)",Decitabine,Standard Chemotherapy,Salvage,37.0,Dead,135.0,Dead-Disease,85.0,49.0,,,0.0,0.0,0.0,42.4,,0.8,,6.8,0.1,,,,,,20.17,97.0,3.6,,,1.6,9.0,,19.0,19.0,,89.0,"partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO"
C257,S435,4472,17-00328,2633.0,BA3261D,BA3261R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Adverse,Other,"45,X,-Y,del(11)(q12)[20]","95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement.","ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)",Negative,Negative,bi,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,289.0,Dead-Treatment,40.0,25.0,,,0.0,0.0,0.0,27.0,,0.0,,46.0,0.0,,,,,,4.17,35.0,3.9,,,0.84,8.1,,30.0,14.0,,98.3,"CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO "
C259,S436,4475,17-00337,2767.0,BA3203D,BA3203R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"nuc ish(RUNX1T1x3,RUNX1x1)[56/100]    nuc ish(PMLx2,RARAx1)[62/100]    nuc ish(5'RARA,3'RARA)x1(5'RARA con 3'RARAx1)[56/100]   nuc ish(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[100]    nuc ish(5'MLL,3'MLL)x3-6(5'MLL con 3'MLLx3-6)[82/100]    nuc ish(DEK,NUP214)x2[100]   nuc ish(ABL1x2,BCRx3)[17/200]",The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of cells.,,Negative,Negative,,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,7.0,"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,6.0,Dead,310.0,Dead-Disease,35.0,39.0,,,,1.0,,36.0,,2.0,,9.0,,,,,,,44.8,50.0,2.8,,0.7,0.99,7.0,,83.0,69.0,,102.9,"THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)"
C263,S437,4479,17-00346,2652.0,BA3174D,BA3174R,Male,61.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,M2,NonInitial,Other,"46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1]",POSITIVE for chromosome 5q copy number loss,,Negative,Negative,,61.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,4.0,3.0,Salvage|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1.0,"Vidaza|7+3 (Cytarabine, Idarubicin)|Cytarabine, OXi4503|Velcade",Velcade,Standard Chemotherapy,Salvage,41.0,Dead,283.0,Dead-Disease,14.0,,,,,,,,,,,,,,,,,,6.5,34.0,,,,,9.2,,,,,81.5,
C261,S438,4482,17-00360,2608.0,BA3299D,BA3299R,Female,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]","An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution. ",,Negative,Positive,,47.0,0.0,4482_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,11.0,Alive,263.0,Alive,70.0,,,,,2.3,,18.3,,72.7,,6.2,,,,,,,66.7,237.0,3.1,,0.2,0.62,9.5,,17.0,17.0,,97.7,"positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)"
C262,C262,4482,17-00361,,,,Female,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]","An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution. ",,Negative,Positive,,47.0,0.0,4482_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)","Busulfan, Fludarabine",Bone Marrow Transplant,Allogeneic - Sibling,11.0,Alive,263.0,Alive,70.0,,,,,2.3,,18.3,,72.7,,6.2,,,,,,,66.7,237.0,3.1,,0.2,0.62,9.5,,17.0,17.0,,97.7,"positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)"
C265,S439,4487,17-00423,2708.0,BA3347D,BA3347R,Female,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20] ",Normal,DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%),Negative,Positive (c.863_864insTCTG; p.W288fs; MAF 38%),,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,-1.0,Alive,233.0,Alive,85.0,30.0,,,0.0,3.0,,35.0,,21.0,,11.0,,,,,,,22.0,131.0,2.8,,,,10.3,,16.0,15.0,,,"Negative (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)"
C266,C266,4491,17-00432,,,,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XY[20]",MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.,FLT3 (p.D835Y; MAF 35%),Negative,Negative,,66.0,0.0,4491_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,1580.0,Alive,61.0,72.5,,,0.0,0.0,,4.2,,89.8,,2.5,0.4,,,,,,109.24,53.0,2.2,,,2.58,6.7,,30.0,40.0,680.0,91.7,"CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive "
C268,S440,4491,17-00438,2686.0,BA3126D,BA3126R,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XY[20]",MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.,FLT3 (p.D835Y; MAF 35%),Negative,Negative,,66.0,2.0,4491_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Alive,1580.0,Alive,61.0,,,,0.0,0.0,1.5,3.6,,87.8,,7.1,0.2,,,,,,67.35,14.0,1.7,,,1.52,7.8,,22.0,39.0,607.0,87.8,"CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive "
C269,S441,4511,17-00441,2766.0,BA3380D,BA3380R,Male,21.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,Normal,Not available,,Positive (MAF 85%; AR 5.666666667),Negative,,23.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,520.0,,,96.0,,,,,,,,,,,,,,,,,55.0,,,,,,,,,,,,
C271,S600,4513,17-00444,2631.0,BA3114D,BA3114R,Female,75.0,1.0,Endometrial cancer|Lobular carcinoma in situ,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.),CEBPA (biallelic)|NPM1|PTPN11|TET2,Negative,Positive,mono,75.0,0.0,,Initial Diagnosis,Diagnosis,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,4.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)","FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Standard Chemotherapy,Induction,4.0,Dead,93.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C358,S443,4514,18-00251,2835.0,BA3452D,BA3452R,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]",,,Negative,Negative,,64.0,455.0,4514_1,Relapse,Relapse,Relapse,Peripheral Blood,1.0,Standard Chemotherapy,4.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib","Azacitidine, Trametinib",Standard Chemotherapy,Salvage,-1.0,Alive,2929.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C584,S601,4514,19-00436,2835.0,BA3343D,,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,NonInitial,Other,"46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]",,,Negative,Negative,,66.0,893.0,4514_2,Unknown,Unknown,,Peripheral Blood,1.0,Standard Chemotherapy,4.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib","Azacitidine, Trametinib",Standard Chemotherapy,Salvage,-1.0,Alive,2929.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C542,S444,4515,17-00446,2824.0,BA3418D,BA3418R,Male,72.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,,,Adverse,MECOM_re,"45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2]",,,Negative,Negative,,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,7.0,Dead,24.0,Dead-Disease,50.0,,,,,,,,,,,,,,,,,,2.2,40.0,,,,,10.3,,,,,85.5,
C273,S446,4532,17-00463,2596.0,BA3128D,BA3128R,Male,33.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,NotDetected,Normal,Normal,,Positive,Negative,,33.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CECA (Cyclophosphamide, Etoposide, Carboplatin, Cytosine)|Cytarabine, OXi4503","Cytarabine, OXi4503",Standard Chemotherapy,Salvage,-1.0,Unknown,255.0,,,18.0,,,,,,,,,,,,,,,,,5.8,59.0,,,,,8.4,,,,,,
C272,S447,4533,17-00464,2605.0,BA3423D,BA3423R,Female,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,FLT3-TKD,Negative,Positive,,50.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Unknown,Standard Chemotherapy,28.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,114.0,Alive,345.0,Alive,90.0,96.0,,,,,,2.0,,,,2.0,,,,,,,19.0,78.0,3.7,,0.1,0.67,8.7,,43.0,32.0,,84.8,"Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)"
C275,S448,4535,17-00467,2719.0,BA3171D,BA3171R,Male,55.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,Adverse,Other,"43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5] ","RUNX1T1/RUNX1:  86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21.  No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721:  89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA:  Signal patterns were within normal limits with no evidence for  PML/RARA fusion.  One metaphase cell shows the PML (15q22) signal on the derivative 17, consistent with the metaphase karyotype | BCR/ABL/ASS:  72/100 cells (72%) consistent the trisomy 9 in the metaphase karyotype.  No evidence  for BCR/ABL fusion.  | D7S486/ CEP 7:  79/100 cells (79%) consistent with missing 7q in the derivative 7 | DEK/NUP:  79/100 cells (79%) reflecting the trisomy 9 in the metaphase karyotype.  No evidence for  DEK/NUP fusion. | MLL:  61/100 cells (61%) had three intact MLL signals. One metaphase cell  shows two signals on the duplicated 11q.  There was no evidence for MLL rearrangement.",KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%),Negative,Negative,,55.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,9.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,402.0,Dead-Treatment,60.0,,,,0.0,0.0,6.8,19.7,,20.5,,15.4,1.5,,,,,,17.99,21.0,,,,,9.6,,,,,101.4,"CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117, HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)"
C543,S449,4539,17-00478,2818.0,BA3277D,BA3277R,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,NotDetected,"46,XY[20] ",Normal,IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%),Negative,Positive (C.863_864insTCTG; p.W288fs; MAF 34%),,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,-1.0,Alive,211.0,Alive,66.5,37.0,,,0.0,2.0,,24.0,,6.0,,31.0,,,,,,,8.6,101.0,2.6,,,,8.1,,23.0,25.0,,,"positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)"
C276,S450,4542,17-00482,2644.0,BA3210D,BA3210R,Female,74.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,M2,NonInitial,Other,"47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8]",,BCORL1 (K632fs*33)|CSF3R (T6181)|ETV6 (MN1-ETV6 fusion)|IDH2 (R140Q)|IDH2 (p.Arg140Gln)|PHF6|PTPN11 (E69K)|RUNX1 (L429fs*171),Negative,Negative,,75.0,0.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,-1.0,"3+7 (Cytarabine, Daunorubicin)","3+7 (Cytarabine, Daunorubicin)",Standard Chemotherapy,Induction,-1.0,Unknown,305.0,,65.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C544,S451,4544,17-00485,2614.0,BA3157D,BA3157R,Male,60.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,Other,"46,XY,del(9)(q13q22)[20]",Normal,NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%),Negative,Positive (p.W288fs*12; MAF 41%),,60.0,0.0,4544_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1754.0,Alive,87.0,83.0,,,0.0,0.0,0.0,13.4,,0.8,,8.3,0.3,,,,,,23.32,146.0,2.3,,,0.79,9.2,,125.0,74.0,823.0,89.5,"CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO"
C277,C277,4544,17-00489,,,,Male,60.0,1.0,Basal Cell Carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,Other,"46,XY,del(9)(q13q22)[20]",Normal,NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%),Negative,Positive (p.W288fs*12; MAF 41%),,60.0,1.0,4544_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1754.0,Alive,87.0,83.0,,,0.0,0.0,0.0,13.4,,0.8,,8.3,0.3,,,,,,23.32,146.0,2.3,,,0.79,9.2,,125.0,74.0,823.0,89.5,"CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO"
C278,S452,4545,17-00491,2681.0,BA3433D,BA3433R,Male,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M0,M0,Favorable,NotDetected,"46,XY[20]",Normal,FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%),Negative,Positive (c.863_864insTCTG; p.W288fs; MAF 45%),,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,215.0,Alive,92.0,96.0,,,0.0,0.0,,3.0,,0.0,,1.0,,,,,,,52.1,51.0,3.3,,,,8.5,,30.0,16.0,,,"negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)"
C279,S453,4548,17-00499,2617.0,BA3374D,BA3374R,Male,21.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"47~49,XY,+8[cp13]/46,XY[7]",RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copies of a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.,KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%),Negative,Negative,,21.0,0.0,4548_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Intrathecal,6.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,26.0,Dead,316.0,Dead-Disease,91.0,90.0,,,0.0,0.0,0.0,27.3,,0.0,,2.7,0.0,,,,,,55.69,54.0,2.2,,,1.35,6.8,,70.0,152.0,2767.0,96.6,"CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+"
C280,C280,4548,17-00500,,,,Male,21.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"47~49,XY,+8[cp13]/46,XY[7]",RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copies of a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.,KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%),Negative,Negative,,21.0,1.0,4548_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Intrathecal,6.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,26.0,Dead,316.0,Dead-Disease,91.0,90.0,,,0.0,1.8,0.0,60.5,,0.0,,2.6,0.0,,,,,,12.97,29.0,2.0,,,1.4,4.8,,57.0,192.0,4605.0,96.0,"CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+"
C307,S454,4548,17-00831,2617.0,BA3403D,BA3403R,Male,21.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,NonInitial,KMT2A_re,"49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8] ","RUNX1T1/CEP8:  95/100 cells (95%) had an abnormal 3 red/ 3 aqua signal  pattern, reflecting the trisomy 8 in the metaphase karyotype and previously  observed. There was no evidence for RUNX1T1/RUNX1 fusion. | MLL:  93/100 cells (93%) had a variant abnormal 0 red/ 1 green/ 1 yellow  (red/small green)/ 1 yellow (red/green) signal pattern, reflecting MLL rearrangement and previously observed. | MECOM/RPN1:  84/100 cells (84%) had an abnormal 5-6 red/ 2 green signal  pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q.  Metaphase FISH shows the extra signals to be on the two markers. There was  no evidence for MECOM/RPN1 fusion.",KRAS (p.G13R; MAF 52%)|U2AF1 (p.S34F; MAF 49%),Negative,Negative,,22.0,99.0,4548_3,Relapse,Relapse,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Intrathecal,6.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,26.0,Dead,316.0,Dead-Disease,95.0,95.0,,,0.0,0.0,0.0,4.5,,6.3,,0.0,0.0,,,,,,60.51,42.0,3.1,,,0.8,9.9,,31.0,75.0,1612.0,92.9,"CD4, CD11b, CD13, variable CD14, CD15, CD33, CD34,  variable CD38,CD56, CD58, CD64, variable CD117, and HLA-DR"
C331,S455,4548,18-00043,2617.0,BA3222D,BA3222R,Male,21.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,NonInitial,KMT2A_re,"49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1] ","51% had an abnormal signal pattern, reflecting the trisomy 8 in the metaphase karyotype and previously observed.  There was no evidence for RUNX1T1/RUNX1 fusion.  | 61% had a variant abnormal signal pattern, reflecting MLL rearrangement and previously observed.  | 72% had an abnormal signal pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q, previously observed.  Metaphase FISH shows the extra signals to be on  two markers.  There was no evidence for MECOM/RPN1 fusion. ",KRAS (p.G13R; MAF 24%)|U2AF1 (p.S34F; MAF 24%),Negative,Negative,,22.0,267.0,4548_4,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Intrathecal,6.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4.0,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,26.0,Dead,316.0,Dead-Disease,43.0,0.0,,,0.0,1.7,,13.3,,13.3,,70.0,0.0,,,,,,0.6,57.0,3.5,,,0.9,8.5,,41.0,26.0,229.0,85.2,"dim CD4, CD13, CD33, CD34, dim CD56, CD64, HLA-DR+"
C281,C281,4556,17-00512,,,,Female,68.0,1.0,Breast Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,Other,"46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1]",Not available,JAK2|TP53,Negative,Negative,,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,22.0,Dead-Unknown,74.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"positive for CD13, CD33, CD34, CD38, partial HLA-DR, CD117, and a minor population is also positive for MPO"
C282,S456,4557,17-00514,2704.0,BA3167D,BA3167R,Male,38.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,,,Intermediate,KMT2A_re,"46,XY,t(9;11)(p22;q23),inv(9)(p11q12)",,BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion),Negative,Negative,,38.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,162.0,Alive,94.0,55.0,,,,,,,,,,,,,,,,,25.29,,,,,,,,,,,,
C283,C283,4558,17-00519,,,,Female,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M0,M0,Favorable,NotDetected,"46,XX[19] ",Normal,DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%),Negative,Positive (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%),,66.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2.0,2.0,Induction|Supportive/Palliative Care,Refractory,Targeted Therapy - Kinase Inhibitor(s),26.0,AG-221|Azacitidine,Azacitidine,Standard Chemotherapy,Supportive/Palliative Care,6.0,Dead,61.0,Dead-Disease,75.0,86.0,,,0.0,0.0,,10.0,,2.0,,2.0,,,,,,,70.1,66.0,2.4,,,,7.7,,14.0,28.0,,,"negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)"
C596,C596,4559,17-00521,,,,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute megakaryoblastic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute megakaryoblastic leukaemia,,M7,NonInitial,,,,,,,,3.0,0.0,,Unknown,Unknown,,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C284,S602,4567,17-00536,2713.0,BA3110D,BA3110R,Male,51.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,Intermediate,NotDetected,"46,XY[20]",Normal,,Negative,Negative,,51.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,121.0,Dead-Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C287,S457,4573,17-00551,2734.0,BA3226D,BA3226R,Female,75.0,1.0,Breast Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Intermediate,NotDetected,"46,XX[20]",Normal,FLT3-ITD (MAF 44%)|IKZF1 (p.L161P; VAF 38.2%)|NPM1 (p.W288fs*12; VAF 45.3%),Positive (MAF 49%; AR 0.960784314),Positive (p.W288fs*12; VAF 45.3%),,75.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,37.0,Dead-Disease,73.0,79.0,,,0.0,0.0,0.0,11.4,,1.8,,7.9,0.4,,,,,,88.2,45.0,2.8,,,0.66,7.5,,42.0,41.0,,97.9,"dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive"
C288,S458,4575,17-00556,2659.0,BA3421D,BA3421R,Female,52.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,,Normal/Negative Rearrangement,"DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)",Positive (MAF 42%; AR 0.724137931),Positive (MAF 44%),,52.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Allogeneic - Sibling|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide",Midostaurin,Targeted Therapy - Kinase Inhibitor(s),Maintenance,13.0,Alive,181.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C285,S459,4592,17-00613,2714.0,BA3232D,BA3232R,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Adverse,NotDetected,"46,XX[20]",Normal,BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%),Positive (MAF 21%; AR 0.265822785),Positive (p.W288fs*12; MAF 48%),,36.0,0.0,4592_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other,6.0,5.0,Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate",SY-1425 (Tamibarotene) plus Daratumumab,Targeted Therapy - Other,Experimental,28.0,Dead,370.0,Dead-Disease,30.0,40.0,,,0.0,0.0,9.6,13.9,,0.9,,36.5,0.1,,,,,,59.05,58.0,3.5,,,0.77,4.6,,14.0,25.0,,100.0,"dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive"
C286,C286,4592,17-00615,,,,Female,36.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Adverse,NotDetected,"46,XX[20]",Normal,BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%),Positive (MAF 15%),Positive (p.W288fs*12; MAF 48%),,36.0,1.0,4592_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other,6.0,5.0,Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate",SY-1425 (Tamibarotene) plus Daratumumab,Targeted Therapy - Other,Experimental,28.0,Dead,370.0,Dead-Disease,30.0,40.0,,,0.0,0.0,9.6,13.9,,0.9,,36.5,0.1,,,,,,59.05,58.0,,,,,4.6,,,,,100.0,"dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive"
C545,S460,4599,17-00618,2671.0,BA3365D,,Male,29.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,,,NonInitial,KMT2A_re,"46,XY,t(9;11)(p21;q23)[1]/46,idem,t(5;12)(q33;p13)[19]    ",,,Negative,Negative,,30.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Alive,401.0,Alive,,91.0,,,,,,,,,,,,,,,,,54.0,,,,,,,,,,,,"Population 1: Immature blasts (80%) expressed dim CD45+, partial CD34+ (68% of total cells), CD117+, HLA DR+, CD13+, CD33++, CD123+, and CD64neg /dim+ | Population 2:  Monoblasts (11%) expressed bright CD33 ++, intermediate SSC, brighter CD45, brCD64++, CD33++, and HLA DR++"
C290,S461,4603,17-00634,2677.0,BA3289D,BA3289R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with minimal differentiation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Intermediate,NotDetected,,Normal,DNMT3A|FLT3-ITD|TET2,Positive (MAF 37%; AR 0.587301587),Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,177.0,Alive,65.0,,,,,,,,,,,,,,,,,,111.5,179.0,,,,,,,,,,,
C291,C291,4605,17-00638,,,,Female,60.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Intermediate,KMT2A_re,t(9;11)(p22;q23),,,Negative,Negative,,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,1.0,Dead-Disease,90.0,87.0,,,,,,,,,,,,,,,,,166.8,,,,,,,,,,,,"positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO"
C546,C546,4612,17-00645,,,,Male,2.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"45,XY,-7[20]","D7S486/ CEP 7:  97/100 cells (97%) had a 1 red/ 1 green signal pattern,  indicating monosomy 7, consistent with the metaphase karyotype. ",ABL1 (p.K454del; VAF 51%)|ETV6 (p.R125fs*82; MAF 44%)|PTPN11 (p.G503D; MAF 45%),Negative,Negative,,2.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,43.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide, Melphalan","Busulfan, Cyclophosphamide, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,748.0,Alive,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD34, CD117, variable MPO  positive "
C296,C296,4623,17-00671,,,,Male,87.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Germline DDX41 P/LP variant,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,,,,FLT3-ITD,Positive (MAF 43%; AR 0.639344262),Negative,,87.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,Entospletinib,Entospletinib,Standard Chemotherapy,Supportive/Palliative Care,-1.0,Dead,40.0,Dead-Disease,90.0,70.0,,,,,,,,,,,,,,,,,1.4,,,,,,,,,,,,"positive for dim CD7, CD11b, CD13, CD33, CD34, CD38, CD45, dim CD64, CD117, HLA-DR, and MPO"
C293,S464,4624,17-00678,2736.0,BA3384D,BA3384R,Female,39.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,KMT2A_re,"47,XX,del(11)(q23),+21[20]","MLL:  97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1:  95/100 cells (95%) had a 2 red/ 3 green signal pattern, consistent with the trisomy 21 in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1fusion.",MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%),Negative,Negative,,39.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,4.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Other,7.0,5.0,Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Venetoclax (ABT-199), Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Radiation|Busulfan, Cyclophosphamide|IDAC",IDAC,Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,2494.0,Dead-Disease,91.0,90.0,,,0.0,0.0,0.0,9.7,,28.3,,0.0,0.0,,,,,,173.2,12.0,2.4,,,0.57,6.7,,,,540.0,109.6,"partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+ "
C297,S465,4627,17-00676,2609.0,BA3449D,BA3449R,Male,55.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,,,Adverse,MECOM_re,"49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20]",POSITIVE for RUNX1T1 and RUNX1 copy number gains,,Negative,Negative,,55.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Supportive/Palliative Care,,,,Vidaza|Decitabine,Decitabine,Standard Chemotherapy,Salvage,-1.0,Dead,1.0,Dead-Disease,80.0,67.0,,,,,,,,,,,,,,,,,43.7,31.0,,,,,10.4,,,,,83.7,
C294,C294,4629,17-00683,,,,Female,43.0,1.0,Breast Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Intermediate,KMT2A_re,"46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]","MLL:  57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1:  6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8:  5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype.",DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%),Negative,Negative,,43.0,0.0,4629_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Azacitidine|Mitoxantrone,Mitoxantrone,Standard Chemotherapy,Supportive/Palliative Care,0.0,Dead,62.0,Dead-Disease,80.0,55.0,,,0.0,0.9,2.5,8.5,,61.0,,25.4,0.3,,,,,,91.72,120.0,2.7,,,1.18,11.4,,198.0,685.0,5919.0,99.1,"dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+"
C547,S466,4629,17-00685,2638.0,BA3163D,BA3163R,Female,43.0,1.0,Breast Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Intermediate,KMT2A_re,"46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]","MLL:  57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1:  6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8:  5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype.",DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%),Negative,Negative,,43.0,0.0,4629_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,Azacitidine|Mitoxantrone,Mitoxantrone,Standard Chemotherapy,Supportive/Palliative Care,0.0,Dead,62.0,Dead-Disease,80.0,55.0,,,0.0,0.9,2.5,8.5,,61.0,,25.4,0.3,,,,,,91.72,120.0,2.7,,,1.18,11.4,,198.0,685.0,5919.0,99.1,"dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+"
C298,S467,4631,17-00687,2646.0,BA3158D,BA3158R,Male,68.0,1.0,Non-Hodgkins Lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Favorable,RUNX1-RUNX1T1,"46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2] ","This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus. ",,Negative,Negative,,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,0.0,,90.8,,,,,,,,,,,,,,,,,,27.1,,,,,,,,,,,,
C422,C422,4633,20-00037,,,,Female,23.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,NotDetected,"46,XX[20]",Normal,CEBPA (p.A199fs*114; VAF ~50-60% (low depth))|DNAH9 (p.V3194L; VAF 51%)|DOCK8 (p.E1104D; VAF 50%)|DOCK8 (p.R1008Q; VAF 50%)|EGFR (p.A1040T; VAF 51%)|EZH2 (p.R288*; VAF 45%)|GATA2 (p.A372T; VAF 45%)|NPM1 (p.W288fs*12; VAF 42%),Negative,Positive (p.W288fs*12; VAF 42%),,25.0,918.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"FLAG-IDA, Gemtuzumab Ozogamicin|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1923.0,Alive,89.0,90.0,,,0.9,0.0,,19.5,,0.9,,2.7,0.6,,,,,,29.33,23.0,3.2,,,0.63,10.5,,13.0,11.0,233.0,97.8,"CD13, CD33, dim CD34, CD117, variable MPO"
C299,S469,4635,17-00694,2768.0,BA3154D,BA3154R,Female,29.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,"Mixed-phenotype acute leukaemia, B/myeloid",,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, B/myeloid, NOS",,,Adverse,Other,"30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]",Negative for 9;22 and MLL,CREBBP|NF1|TP53,Negative,Negative,,29.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,256.0,Dead-Other,95.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)"
C300,S470,4641,17-00741,2740.0,BA3162D,BA3162R,Male,20.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,AML with mutated NPM1,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.,KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%),Negative,Positive,,20.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,99.0,Alive,50.0,,,,,,,,,,,,,,,,,,68.59,16.0,,,,,,,,,,,"CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), and surface kappa lambda light chain(-).,"
C301,S472,4652,17-00748,2705.0,BA3081D,,Female,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"50-55,XX,+X,+6,+8,+10,+12,+13,+14,+21,+22[cp 18]/46,XX[2].",POSITIVE for RUNX1T1 and RUNX1 copy number gains,,Negative,Negative,,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"HiDAC|7+3 (Cytarabine, Idarubicin, Dexamethasone)|Fludarabine, Melphalan, ATG","Fludarabine, Melphalan, ATG",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,188.0,Dead-Disease,20.0,,,,,,,,,,,,,,,,,,6.7,53.0,,,,,8.5,,,,,119.2,
C302,S473,4654,17-00755,2699.0,BA3352D,BA3352R,Male,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,NotDetected,"46,XY[20]",Normal,,Positive (MAF 55%; AR 1.222222222),Positive,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,-1.0,Dead,22.0,Dead-Disease,90.0,94.0,,,,,,,,,,,,,,,,,64.4,,,,,,,,,,,,"CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -)."
C548,S474,4659,17-00761,2694.0,BA3084D,BA3084R,Male,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,KMT2A_re,"46,XY,t(10;11)(p13;q23)[20]","MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe.  This result is consistent with MLL rearrangement and with the t(10;11) seen on metaphase analysis.",FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%),Negative,Negative,,22.0,0.0,4659_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,328.0,Dead-Disease,92.0,91.0,,,0.0,0.9,0.0,9.8,,1.8,,0.0,0.1,,,,,,82.99,95.0,2.5,,,0.71,9.5,,22.0,35.0,1186.0,102.2,"Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123"
C567,C567,4659,17-00911,,,,Male,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,NonInitial,NotDetected,"46,XY[19]",Normal,,Negative,Negative,,22.0,64.0,4659_2,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,328.0,Dead-Disease,1.5,0.0,,,0.9,0.0,0.6,33.7,,26.1,,38.7,1.2,,,,,,3.41,408.0,3.5,,,1.1,9.5,,100.0,47.0,,97.6,
C549,C549,4663,17-00769,,,,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,,Normal,,Negative,Negative,,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Supportive/Palliative Care,,,,"Azacitidine, BI 836858 (anti-CD33)","Azacitidine, BI 836858 (anti-CD33)",Standard Chemotherapy,Supportive/Palliative Care,6.0,Dead,27.0,Dead-Disease,85.0,54.0,,,,,,,,,,,,,,,,,9.4,,,,,,,,,,,,"positive for CD13, CD33, CD34, dim CD45, CD38, CD117, HLA-DR and MPO"
C303,S475,4664,17-00770,2662.0,BA3169D,BA3169R,Female,88.0,1.0,Uterine Sarcoma,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,KMT2A_re,"47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]",MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells,,Negative,Positive,,88.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,5.0,Dead-Disease,80.0,24.0,,,,,,,,,,,,,,,,,23.4,,,,,,,,,,,,"positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR"
C550,C550,4665,17-00773,,,,Male,27.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Intermediate,,,,FLT3-ITD|IDH2,Positive (MAF 47%; AR 0.886792453),Positive,,27.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine","Fludarabine, Cyclophosphamide, Thiotepa, TBI",Bone Marrow Transplant,Double Umbilical Cord Blood Transplant (DUCBT),-1.0,Alive,116.0,Alive,,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C304,C304,4666,17-00775,,,,Male,55.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M0,M0,Intermediate,NotDetected,"46,XY[20] ",Normal,DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%),Positive (p.E598delinsDYVDFREYE; MAF 60%),Positive (p.W290fs*10; MAF 45%),,55.0,3.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide","Decitabine, Sorafenib ",Standard Chemotherapy,Salvage,61.0,Dead,272.0,Dead-Disease,90.0,,,,0.0,0.0,3.4,17.1,,8.5,,7.7,0.3,,,,,,66.78,160.0,2.5,,,0.98,7.0,,19.0,22.0,946.0,86.0,"dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+ "
C306,S477,4673,17-00779,2834.0,BA3438D,BA3438R,Male,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,KMT2A_re,"47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1] ","EGR1:  90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):   97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On available metaphase  cells, there was clustering of amplified fused signals on two chromosomes:  in the first clone, amplified signals clustered on the der(15) and on the  marker chromosome; in the second clone, amplified signals clustered on the  der(15) and on the der(10).) | CBFB (16q22):   94% of cells were missing a signal for CBFB, consistent  with del(16q) as seen on metaphase. | RUNX1/RUNX1T1+CEP8: 92% of cells had three signals for chromosome 8 probes (CEP8 and RUNX1T1) and only one signal for RUNX1 (21q22), consistent with trisomy 8. Results with the RUNX1 probe on chromosome 21 suggest that the interpretation of the chrom results as der(20;21) may be more complicated.",MLL |TP53 (p.R248Q; MAF 82%),Negative,Negative,,53.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)","5+2 (Cytarabine, Idarubicin)",Standard Chemotherapy,Re-induction,4.0,Dead,65.0,Dead-Disease,95.0,,,,3.5,1.7,,69.8,,0.9,,15.5,4.5,,,,,,3.81,23.0,3.3,,,0.87,8.4,,30.0,24.0,399.0,88.4,"CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO"
C551,S478,4675,17-00781,2775.0,BA3345D,BA3345R,Female,59.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M5,M5,Adverse,Other,"47,XX,+8[20]",POSITIVE for RUNX1T1 copy number gain,,Negative,Negative,,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,4.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,4.0,Unknown,57.0,,2.0,,,,,,,,,,,,,,,,,,3.7,51.0,,,,,7.4,,,,,87.2,
C305,S479,4678,17-00834,2647.0,BA3431D,BA3431R,Female,45.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,M5,Favorable,NotDetected,46[XX],Not available,FLT3-TKD (MAF 1%)|NPM1 (MAF 39%)|PTPN11 (likely pathogenic),Negative,Positive (MAF 39%),,45.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,68.0,,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"positive for CD11b, CD11c, CD14, CD64, CD33, CD38, HLA-DR and partial for CD13, CD15, cMPO"
C552,S480,4679,17-00838,2667.0,BA3181D,BA3181R,Female,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid sarcoma,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,M5,M5,Adverse,NotDetected,"46,XX[20]",Normal,,Negative,Negative,,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,7.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin, Dexamethasone)","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Unknown,212.0,,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C553,S481,4682,17-00843,2628.0,BA3341D,BA3341R,Female,62.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,Other,"46,XX,del(7)(q22q32)[cp4]/46,XX[16]",Evidence of deletion of the BCR (22q11.2) gene in 7% of the cells examined.,DNMT3A|IDH2 (p.172Arg>Lys)|KMT2A,Negative,Negative,,62.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Targeted Therapy - Other,1.0,1.0,Induction,Refractory,Targeted Therapy - Other,-1.0,Enasidenib,Enasidenib,Targeted Therapy - Other,Induction,-1.0,Alive,52.0,Alive,48.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C554,S482,4684,17-00848,2700.0,BA3191D,BA3191R,Male,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,Not available ,"Positive for CBFB rearrangement. (96/100 cells (96%) reflected a loss of the distal green portion of one break-apart signal. Presence of an  inverted chromosome 16 was confirmed.  In addition, metaphase FISH showed a  normal chromosome 16 with a yellow (red/green) signal in the long arm and the inverted chromosome 16 with the proximal red signal in the short arm and the green signal missing.)",GATA2 (p.T356A; MAF 41%)|NRAS (p.Q61K; MAF 41%),Negative,Negative,,46.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Consolidation|Salvage|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|Azacitidine|Gemtuzumab|MiDAC|Decitabine",Gemtuzumab,Targeted Therapy - Kinase Inhibitor(s),Salvage,-1.0,Dead,546.0,Dead-Disease,36.0,28.0,,,1.7,1.7,2.5,21.8,,34.5,,21.8,0.0,,,,,,47.64,42.0,3.1,,,0.88,12.7,,24.0,16.0,593.0,82.9,"CD13, dim CD33, CD34, CD38, CD117, CD123, HLA-DR  and dim MPO+. (Blast Immunophenotype) | CD11b, CD13, dim CD14, CD33, CD38, CD64,  HLA-DR, dim CD117, CD123 and dim MPO+ (Monocytic Immunophenotype)"
C308,S483,4685,17-00849,2738.0,BA3197D,BA3197R,Female,47.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,Not available ,PML/RARA: Negative,FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%),Positive (MAF 44%; AR 0.785714286),Positive (p.W288fs*12; MAF 50%),,47.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,10.0,Dead-Disease,,95.0,,,0.0,0.0,0.0,1.7,,0.0,,0.0,0.1,,,,,,134.63,22.0,3.4,,,0.83,10.3,,190.0,80.0,730.0,93.5,"partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive "
C555,C555,4688,17-00855,,,,Female,27.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,KMT2A_re,"46,XX,t(6;11)(q27;q23)[25] ","MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 rearrangement.",KRAS (p.G12D; MAF 16%)|MLL (PTD),Negative,Negative,,27.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC",Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501),Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1455.0,Alive,90.0,85.0,,,0.0,0.0,0.0,30.2,,0.0,,0.0,0.0,,,,,,22.95,16.0,2.2,,,0.81,8.3,,23.0,16.0,496.0,91.1,"CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive"
C556,C556,4689,17-00858,,,,Female,76.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",,,Negative,Positive,,76.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Targeted Therapy - Kinase Inhibitor(s),1.0,1.0,Supportive/Palliative Care,,,,Decitabine,Decitabine,Targeted Therapy - Kinase Inhibitor(s),Supportive/Palliative Care,9.0,Unknown,19.0,,91.0,85.0,,,,,,,,,,,,,,,,,44.4,,,,,,,,,,,,"A large blastic population, positive for CD13, CD15, CD33, CD38, dim CD45, dim CD64, CD117, HLA-DR, and MPO"
C557,S485,4691,17-00862,2796.0,BA3406D,BA3406R,Male,33.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46, XY[20]",Normal,BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%),Positive (MAF 33%; AR 0.492537313),Negative,,33.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Alive,30.0,Alive,69.0,28.0,,,,,,,,,,,,,,,,,4.52,70.0,,,,,,,,,,,
C558,S486,4692,17-00867,2772.0,BA3308D,BA3308R,Male,78.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4] ","RUNX1T1:  22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal.  The  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel:  6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype. ",IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%),Negative,Negative,,78.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s),4.0,3.0,Salvage|Maintenance|Supportive/Palliative Care,,,,AG-221|Imatinib|Midostaurin|Interferon,AG-221,Targeted Therapy - Kinase Inhibitor(s),Salvage,191.0,Dead,319.0,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C559,S487,4701,17-00878,2743.0,BA3186D,BA3186R,Male,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,KMT2A_re,"45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2] ","MLL:  97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17:  99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1:  93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1.  There was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB:  96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7:  99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8:  66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8. ",JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%),Negative,Negative,,70.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,3.0,3.0,Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,,,,"Fludarabine, Melphalan|Azacitidine|MiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,980.0,Dead-Disease,79.0,56.0,,,0.0,0.0,0.0,14.6,,4.5,,8.2,2.6,,,,,,49.48,28.0,2.9,,,0.69,11.8,,31.0,58.0,3293.0,92.5,"dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive"
C560,S488,4703,17-00881,2640.0,BA3334D,BA3334R,Female,76.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,,Normal,ASXL1|FLT3 (N841K)|SRSF2|STAG2,Negative,Negative,,76.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Targeted Therapy - Other,1.0,1.0,Experimental,,,,Entospletinib,Entospletinib,Targeted Therapy - Other,Experimental,-1.0,Alive,47.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C561,C561,4704,17-00884,,,,Male,67.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,NotDetected,46XY,Not available,FLT3-ITD (MAF not available)|NRAS|U2AF1,Positive,Negative,,67.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,249.0,Dead-Disease,82.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)"
C562,C562,4706,17-00888,,,,Female,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,,,,ASXL1|TET2,Negative,,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Azacitidine, BI 836858 (anti-CD33)","Azacitidine, BI 836858 (anti-CD33)",Standard Chemotherapy,Induction,-1.0,Alive,83.0,Alive,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C563,S489,4709,17-00896,2769.0,BA3185D,BA3185R,Male,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"47,XY,+13[20]/47,XY,+8[1]",Low level gain of chromosome 8 sequences (trisomy). Loss of 21q22 sequences (monosomy),ASXL1|RUNX1|SRSF2|TET2,Negative,Negative,,75.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2.0,2.0,Induction|Re-induction,Refractory,Targeted Therapy - Kinase Inhibitor(s),-1.0,"Entospletinib, Azacitidine|Entospletinib","Entospletinib, Azacitidine",Standard Chemotherapy,Re-induction,-1.0,Alive,75.0,Alive,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, HLA-DR, and CD34"
C564,C564,4711,17-00899,,,,Male,84.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,84.0,0.0,,Unknown,Unknown,,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C565,S490,4712,17-00901,2660.0,BA3094D,BA3094R,Male,23.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,KMT2A_re,"46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20]","MLL:  60% of cells had a split signal pattern consistent with MLL rearrangement. On available metaphase cells, there was a distal signal on chromosome 10p and the proximal signal was close to the chromosome 11 centromere, consistent with t(10;11) and inv(11), as seen on chromosome analysis.",NRAS (p.G12A; MAF 4%)|NRAS (p.Q61H; MAF 30%),Negative,Negative,,23.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1386.0,Alive,95.0,85.0,,,0.0,0.0,0.0,12.4,,0.9,,1.8,0.0,,,,,,98.29,56.0,2.8,,,0.78,8.6,,68.0,83.0,2144.0,87.9,"CD4, variable CD13, CD33, CD38, variable CD56, CD58,  CD64, dim CD71, dim CD117, dim CD123 and HLA-DR+ "
C566,S491,4718,17-00908,2593.0,BA3318D,BA3318R,Female,83.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10]",67.5% of cells had an extra copy of MLL(11q23),IDH2 (p.172Arg>Lys),Negative,Negative,,83.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,13.0,,80.0,,,,,,,,,,,,,,,,,,14.17,78.0,,,,,,,,,,,
C309,S492,4722,17-00915,2632.0,BA3216D,BA3216R,Female,73.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,,,,FLT3-ITD (suspicious for D835 as well),Positive (MAF 30%; AR 0.428571429),Negative,mono,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,16.0,Dead-Disease,85.0,79.0,,,,,,,,,,,,,,,,,123.2,44.0,,,,,,,,,,,
C568,S493,4726,17-00926,2748.0,BA3332D,BA3332R,Female,26.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX",,,Negative,Positive,,26.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,8.0,"7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin","7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin",Standard Chemotherapy,Induction,8.0,Alive,720.0,Alive,41.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD117(+) myeloid precursors comprise 26% of total events and are positive for dim CD7, CD13, CD33, CD38, CD117, HLA-DR, and cyMPO.  They are negative for CD34.  "
C310,C310,4732,17-00932,,,,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,51.0,0.0,4732_1,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C569,S603,4732,17-00933,2820.0,BA3214D,BA3214R,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Negative,Negative,,51.0,0.0,4732_1,Unknown,Unknown,,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C311,S494,4734,17-00953,2802.0,BA3204D,,Male,58.0,1.0,Lung Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,,,Adverse,Other,"44-45,XY,-3,-5,der(7)del(7)(q22)inv(7)(p13q22),del(12)9p11.2),add(19)(q13.1),+mar[cp20]",,TP53,Negative,Negative,,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Targeted Therapy - Other,1.0,1.0,Experimental,,,,BP1001 plus LDAC,BP1001 plus LDAC,Targeted Therapy - Other,Experimental,28.0,Dead,80.0,Dead-Disease,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Myeloid blasts comprise 16% of total events and are positive for CD13, CD33, CD34, CD38 (reduced), CD117, HLA-DR and cyMPO. They are negative for CD11b, CD11c, CD14, CD15, CD56, CD64, TdT, B- and other T-cell markers"
C317,S495,4762,17-01021,2680.0,BA3373D,BA3373R,Female,67.0,0.0,,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M1,M1,Adverse,MECOM_re,"45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]","EGR-1/ D5S23, D5S721:  96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7:  98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent with the metaphase karyotype. | MECOM/ RPN1:  97/100 cells (97%) had a 1 red/ 1 green/ 2 yellow signal  pattern, reflecting MECOM/RPN1 fusion, consistent with the 3;3  translocation in the metaphase karyotype. ",DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%),Negative,Negative,,67.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,49.0,Dead-Unknown,70.0,88.0,,,0.0,2.6,0.9,14.8,,0.0,,3.5,0.0,,,,,,44.52,85.0,3.2,,,0.81,9.1,,21.0,24.0,643.0,88.5,"dim CD5, CD7,  partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58,  dim CD71, CD117, dim CD123, dim HLA-DR and MPO+"
C313,S496,4763,17-01023,2707.0,BA3319D,BA3319R,Male,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13;q22)[20]","CBFB:   39% of cells had a 1r/1g/1f split signal pattern consistent with CBFB disruption and inv916), as seen on metaphase analysis. ",KIT (p.D816Y; MAF 6%)|NRAS (p.Q61H; MAF 32%),Negative,Negative,,22.0,0.0,4763_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,106.0,Alive,1409.0,Alive,61.0,12.0,,,0.0,2.7,0.0,16.1,,72.3,,2.7,0.2,,,,,,99.89,50.0,2.3,,,0.87,8.2,,63.0,28.0,482.0,94.5,"Myeloid blast immunophenotype: CD13, CD33, CD34, CD38, CD58, CD117,  CD123, dim HLA-DR and MPO+  | Monocytic blast immunophenotype: CD11b, CD13, CD14, partial CD16, CD33,  dim CD34, CD38, CD58, CD64, CD117, dim CD123, HLA-DR and MPO+ "
C315,C315,4763,17-01027,,,,Male,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13;q22)[20]","CBFB:   39% of cells had a 1r/1g/1f split signal pattern consistent with CBFB disruption and inv916), as seen on metaphase analysis. ",KIT (p.D816Y; MAF 6%)|NRAS (p.Q61H; MAF 32%),Negative,Negative,,22.0,1.0,4763_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,106.0,Alive,1409.0,Alive,61.0,,,,0.8,3.4,1.7,33.6,,46.2,,4.2,0.1,,,,,,46.72,57.0,2.1,,,0.83,7.7,,47.0,29.0,539.0,95.0,"Myeloid blast immunophenotype: CD13, CD33, CD34, CD38, CD58, CD117,  CD123, dim HLA-DR and MPO+  | Monocytic blast immunophenotype: CD11b, CD13, CD14, partial CD16, CD33,  dim CD34, CD38, CD58, CD64, CD117, dim CD123, HLA-DR and MPO+ "
C314,S497,4765,17-01024,2741.0,BA3328D,BA3328R,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[15]",Normal,DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%),Positive (MAF 43%; AR 0.754385965),Positive (p.W288fs*12; MAF 48%),,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,167.0,Dead-Treatment,95.0,86.0,,,0.0,0.0,32.0,13.0,,0.0,,6.0,0.8,,,,,,59.23,60.0,3.5,,,0.98,8.5,,15.0,25.0,563.0,93.0,"dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+"
C316,S498,4770,17-01038,2711.0,BA3240D,BA3240R,Female,79.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,BCR-ABL1,"51~52,XX,+2,+6,add(7)(q31),+8,+9,+10,+15[cp14]/50~52,idem,del(19)(q11.2)[cp 5]/46,XX[1]","BCR/ABL/ASS: 72/100 cells had a variant abnormal fusion reflecting a single BCR/ABL fusion. The Philadelphia rearrangement was not visible in the metaphase karyotype  and is, thus, likely a cryptic rearrangement involving at least three chromosomes.    (Twenty-one cells (21%) had three signals for ASS and ABL with  no fusion signal.) | RUNX1T1:  89/100 cells (89%) had three signals, consistent with the trisomy  8 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1  fusion.  In addition, 80% of cells had three chromosome 8 centromere  signals, also consistent with trisomy 8. | DEK/NUP21:  96/100 cells (96%) had three signals for both probes,  consistent with trisomies 6 and 9 in the metaphase karyotype.  There was no evidence for DEK/NUP21 fusion | PML:  41/100 cells (41%) had three signals, consistent with the trisomy 15  in the metaphase karyotype.  Fifty-two cells (52%) had four PML signals –  the chromosomal context of the fourth signal was not apparent in the  metaphase karyotype.  There was no evidence for PML/RARA fusion. ",DNMT3A (p.R882C; MAF 64%)|FLT3 (p.D835H; MAF 5%)|IDH1 (p.R132L; MAF 54%),Negative,Negative,,79.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"Vyxeos (Daunorubicin, Cytarabine - liposomal)","Vyxeos (Daunorubicin, Cytarabine - liposomal)",Standard Chemotherapy,Induction,-1.0,Dead,20.0,Dead-Disease,90.0,,,,0.0,0.0,0.0,2.9,,1.5,,1.4,0.1,,,,,,130.45,126.0,2.9,,,1.02,6.2,,25.0,29.0,483.0,108.2,"CD13, variable CD34, CD38, dim CD58, CD117, CD123, HLA-DR and dim MPO+"
C318,S500,4782,17-01054,2746.0,BA3333D,BA3333R,Male,,1.0,Prostate Cancer,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XY[20]",Normal,FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%),Negative,Positive (W288Cfs*12; VAF 46%),,,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,2.0,Dead-Disease,93.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C321,C321,4785,17-01059,,,,Male,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,Adverse,NotDetected,"46,XY[20]",Normal,"ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)",Positive ( Allelic Ratio .03),Negative,,51.0,0.0,4785_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,6.0,"HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax","Decitabine, Venetoclax",Standard Chemotherapy,Re-induction,-1.0,Dead,486.0,Dead-Treatment,14.0,21.0,,,4.3,0.9,6.1,7.0,,25.2,,52.2,0.6,,,,,,80.58,17.0,3.4,,,1.36,6.3,,19.0,34.0,1116.0,106.5,"CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+ "
C322,S501,4785,17-01060,2754.0,BA3381D,BA3381R,Male,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,Adverse,NotDetected,"46,XY[20]",Normal,"ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)",Negative,Negative,,51.0,0.0,4785_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,5.0,Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,6.0,"HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax","Decitabine, Venetoclax",Standard Chemotherapy,Re-induction,-1.0,Dead,486.0,Dead-Treatment,14.0,21.0,,,4.3,0.9,6.1,7.0,,25.2,,52.2,0.6,,,,,,80.58,17.0,3.4,,,1.36,6.3,,19.0,34.0,1116.0,106.5,"CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+ "
C319,S502,4820,17-01081,2753.0,BA3290D,BA3290R,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"46,XY,del(12)(p11.2)[9]/46,XY[11]",Normal,RUNX1 (p.D198N; MAF 6%)|SF3B1 (p.K666N; MAF 45%)|SRSF2 (p.P95H; MAF 46%),Negative,Negative,,67.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,232.0,Dead-Disease,17.0,22.0,,,0.9,7.1,8.0,38.0,,7.1,,22.1,0.3,,,,,,6.21,16.0,2.9,,,1.04,8.3,,43.0,30.0,287.0,94.7,"dim partial CD7, CD13, CD33, CD34, dim CD38, CD58,  CD117, dim CD123, HLA-DR and partial TdT+"
C320,S503,4821,17-01083,2641.0,BA3207D,BA3207R,Male,65.0,1.0,Melanoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46,XY[20]",Normal,IDH1 (p.R132H; MAF 46%)|MLL (Partial tandem duplication )|NRAS (p.Q61R; MAF 45%)|RUNX1 (p.F396fs*204; MAF 46%)|SRSF2 (p.P95L; MAF 28%),Negative,Negative,,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,2.0,Standard Chemotherapy|Intrathecal,2.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|Methotrexate",Methotrexate,Intrathecal,Induction,6.0,Dead,21.0,Dead-Disease,90.0,96.0,,,0.0,0.0,0.0,3.6,0.0,92.8,0.0,0.9,0.4,,,0.0,0.0,,89.55,18.0,2.2,,,6.73,6.6,,15.0,60.0,2285.0,90.4,"CD11b, variable CD14, CD15, CD33, CD38, variable CD56,  CD58, CD64, CD123, HLA-DR, variable MPO"
C323,S504,4837,17-01106,2634.0,BA3305D,BA3305R,Male,84.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"47,XY,+8[12]/47,XY,+15[8]/46,XY[5]",Gain of 8q22 and 15q22 sequences,IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%),Negative,Negative,,84.0,0.0,4837_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,344.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,344.0,Dead,394.0,Dead-Disease,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C324,C324,4837,17-01107,,,,Male,84.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,Other,"47,XY,+8[12]/47,XY,+15[8]/46,XY[5]",Gain of 8q22 and 15q22 sequences,IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%),Negative,,,84.0,0.0,4837_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,344.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,344.0,Dead,394.0,Dead-Disease,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C570,S505,4838,17-01110,2651.0,BA3434D,BA3434R,Female,78.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"46,XX,del(9)(q22q22)[20] ","With the TP53 probe set, 7/200 cells (3.5%) were missing a TP53  signal, within normal limits, but also this patient's previous abnormal  pattern.  ","DNMT3A (p.A644fs*7; MAF 37%)|ETV6 (p.L205fs*12; MAF 30%)|IKZF1 (p.N159S; MAF 35%)|NRAS (p.Q61H; MAF 31%)|RUNX1 (c.58+2T>C, Donor-splice-site mutation in intron 1; MAF 46%)|RUNX1 (p.T196fs*17; MAF 46%)|SF3B1 (p.K700E; MAF 51%)",Negative,Negative,,78.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Induction|Maintenance,Refractory,Standard Chemotherapy,4.0,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|Azacitidine,CPX-351 (Liposomal Cytarabine + Daunorubicin),Standard Chemotherapy,Induction,4.0,Dead,79.0,Dead-Disease,35.0,23.0,,,0.0,0.0,,27.8,,1.8,,40.9,0.9,,,,,,6.5,11.0,2.7,,,0.74,7.1,,128.0,52.0,396.0,88.0,"CD13, CD33, CD34, CD38, CD58, CD117, HLA-DR, partial  MPO "
C325,S506,4841,17-01117,2676.0,BA3189D,BA3189R,Male,20.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,Other,"46,XY,del(2)(q11.2q21)[3]",Normal,"FLT3-ITD (p.E608delinsDPVDFREYEYDLKWEFPRE; p.E598delinsDLSYVDFREYE;  ratio: ~1.0; Two visible FLT3 ITD insertions, one  of ~ 10 amino acids (predominating, with a high mutant allele ratio) and  one of ~18 amino acids (smaller sub-clone).)",Positive (MAF 50%; AR 1),Negative,,20.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Allogeneic - Sibling|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide",Sorafenib,Targeted Therapy - Kinase Inhibitor(s),Maintenance,317.0,Alive,1356.0,Alive,80.0,75.0,,,0.0,0.9,,11.3,,0.0,,11.3,0.1,,,,,,34.16,102.0,2.5,,,0.77,8.3,,16.0,17.0,,98.4,"CD13, CD33, CD34, CD38, CD58, dim CD64, CD117,  variable MPO "
C326,S507,4849,18-00007,2603.0,BA3264D,BA3264R,Male,41.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XY,t(15;17)(q24;q21)[20]",PML/RARA (92% of  cells had the dual fusion signal pattern consistent with PML/RARA fusion and t(15;17).),FLT3-ITD (Mutant Allele Ratio:  0.85),Positive (MAF 53%; AR 1.127659574),Negative,,41.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,26.0,"ATRA, Arsenic Trioxide, Idarubicin|ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Consolidation,200.0,Alive,1253.0,Alive,72.0,86.0,,,0.0,0.0,,14.3,,4.4,,2.7,0.1,,,,,,39.57,55.0,4.1,,,0.84,13.5,,87.0,65.0,588.0,81.5,"partial CD11b, CD13, CD33, CD34, CD38, CD58, variable  CD64, CD117, CD123, partial HLA-DR and bright MPO"
C571,S606,4853,18-00014,2600.0,BA3417D,BA3417R,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,BCR-ABL1,,,,Negative,Negative,,50.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C327,S607,4854,18-00016,2730.0,BA3367D,BA3367R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Negative,Negative,,34.0,0.0,4854_1,Unknown,Unknown,,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C328,C328,4854,18-00017,,,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,34.0,0.0,4854_1,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C329,S509,4859,18-00029,2658.0,BA3225D,BA3225R,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"N/A (Only six metaphase cells were found in all available material, an insufficient number to establish the karyotype. All cells appeared normal male.)",Normal,"GNA13 (p.T365S; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PHF6 (c.730-2A>G, Acceptor-splice-site mutation in intron 6; MAF 89%)|TET2 (c.3594+1G>T, Donor-splice-site mutation in intron 3; MAF 46%)|TET2 (p.D1242fs*11; MAF 42%)",Negative,Positive (p.W288fs*12; MAF 43%),,65.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,4.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,4.0,Dead,16.0,Dead-Disease,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Monocytic blast immunophenotype (75%):  CD11b, CD13, CD14, CD33, CD38, CD58, CD64, dim CD117, CD123, and dim HLA-DR+. | Myeloid blast immunophenotype (13%): dim CD13, CD33, CD38, CD58 dim CD117, dim CD123 and MPO+.           | Monoclonal plasma cell population immunophenotype (approximately10% involvement): CD138 and kappa+. "
C330,S510,4864,18-00039,2798.0,BA3183D,BA3183R,Male,64.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XY[20]",Normal,"ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)",Negative,Positive (p.W288fs*12; MAF 49%),,64.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,337.0,Dead-Treatment,51.0,65.0,,,0.0,0.9,,12.3,,3.5,,15.8,0.1,,,,,,15.38,46.0,2.6,,,1.2,8.2,,20.0,13.0,,103.0,"CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+"
C332,S511,4871,18-00053,2674.0,BA3397D,BA3397R,Male,79.0,1.0,Prostate Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Adverse,Other,"44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20] ","ETV6 (12p13): 93.5% of cells were missing a signal for ETV6, consistent with 12p deletion resulting from dic(10;12).  | CEP17: 98.5% of cells were missing a signal for CEP17, consistent with monosomy 17.  | PML/RARA: 189/200 cells (94.5%) were missing a signal for RARA (17q21.2).",TP53 (p.L194R; MAF 80%),Negative,Negative,,79.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,54.0,Dead-Disease,60.0,74.0,,,0.0,0.0,,10.7,,22.9,,9.0,0.4,,,,,,13.72,92.0,2.2,,,1.36,9.2,,22.0,27.0,219.0,97.9,"CD13, CD33, CD34, variable CD38, CD117, CD123, HLA-DR, partial MPO"
C573,S512,4872,18-00055,2720.0,BA3311D,BA3311R,Male,74.0,1.0,Prostate Cancer,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Adverse,Other,"48,XY,+11,+13[17]/46,XY[3]","MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis. ",CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%),Negative,Negative,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,Azacitidine,Azacitidine,Standard Chemotherapy,Induction,6.0,Dead,24.0,Dead-Disease,21.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT. "
C370,S513,4873,18-00361,2783.0,BA3175D,BA3175R,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]","MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fusion. ","BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P350R; VAF 5%)",Positive (AR 0.234567901),Negative,,63.0,248.0,4873_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin",Mitoxantrone,Standard Chemotherapy,Salvage,0.0,Dead,373.0,Dead-Disease,25.0,,,,0.9,0.0,,6.8,,58.1,,16.2,0.1,,,,,,39.59,20.0,3.5,,,1.0,9.5,,55.0,53.0,,83.4,"CD7, CD13, CD33, CD34, CD117, and HLA-DR positive"
C577,C577,4873,18-00386,,,,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]","MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fusion. ","BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P350R; VAF 5%)",Positive (VAF 19%; AR 0.24),Positive (p.H30Q; VAF 3%),,63.0,262.0,4873_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin",Mitoxantrone,Standard Chemotherapy,Salvage,0.0,Dead,373.0,Dead-Disease,,,,,0.0,0.0,,9.5,,28.4,,2.6,3.9,,,,,,21.62,17.0,3.6,,,1.0,8.8,,56.0,58.0,1500.0,85.6,
C372,C372,4873,18-00389,,,,Male,62.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]","MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fusion. ",,Positive (VAF 19%; AR 0.24),Positive (p.H30Q; VAF 3%),,63.0,267.0,4873_3,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin",Mitoxantrone,Standard Chemotherapy,Salvage,0.0,Dead,373.0,Dead-Disease,,,,,0.0,0.9,,9.4,,16.8,,1.0,3.2,,,,,,48.57,15.0,3.6,,,0.8,7.9,,33.0,58.0,2017.0,86.1,
C334,S514,4885,18-00073,2636.0,BA3422D,BA3422R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",Normal,GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%),Negative,Positive (W288Cfs*12; VAF 39%),,72.0,0.0,4885_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,-1.0,Alive,521.0,Alive,97.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C335,C335,4885,18-00074,,,,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20]",Normal,GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%),Negative,Positive (W288Cfs*12; VAF 39%),,72.0,0.0,4885_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,-1.0,Alive,521.0,Alive,97.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C333,S515,4887,18-00077,2717.0,BA3228D,BA3228R,Female,68.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"46,XX,i(14)(q10)[8]/46,XX[12] ","IGH (14q32) breakapart probe set, as listed  below.  4/200 interphase cells had three intact signals, but one abnormal  metaphase was found, which had an IGH signal on either end of the  i(14)(q10). ",,Positive,Negative,,69.0,0.0,,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,11.0,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Cytarabine, Midostaurin","Cytarabine, Midostaurin",Standard Chemotherapy,Re-induction,-1.0,Unknown,494.0,,,,,,2.1,0.0,,6.2,,29.4,,3.4,1.1,,,,,,105.01,482.0,,,,0.99,7.8,,,,1036.0,91.5,
C336,S516,4890,18-00082,2817.0,BA3213D,BA3213R,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2]",Positive for a CBFB rearrangement,CBL (L399V; VAF 50%)|KIT (N587_R588ins16; VAF 34%),Negative,Negative,,50.0,0.0,4890_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin","7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin",Standard Chemotherapy,Induction,7.0,Alive,536.0,Alive,73.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C337,C337,4890,18-00083,,,,Male,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2]",Positive for a CBFB rearrangement,CBL (L399V; VAF 50%)|KIT (N587_R588ins16; VAF 34%),Negative,Negative,,50.0,0.0,4890_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin","7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin",Standard Chemotherapy,Induction,7.0,Alive,536.0,Alive,73.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C341,S518,4894,18-00103,2825.0,BA3415D,BA3415R,Female,79.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]","EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  | RUNX1T1/RUNX1:  92/100 cells (92%) had a 3 red/ 3 green signal pattern, reflecting the extra copies of chromosome 8 and chromosome 21 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion.  | BCR/ABL:  95/100 cells (95%) had a 3 red/ 2-3 green signal pattern, reflecting the extra copies of chromosome 9q and chromosome 22 in the metaphase karyotype.  There was no evidence for BCR/ABL fusion. | DEK/NUP214:  184/200 cells (92%) had a 3 red/ 2 green signal pattern, reflecting an extra copy of NUP214 (9q34),consistent with the extra chromosome 9q material in the metaphase karyotype.  There was no evidence for DEK/NUP214 fusion.  | TP53/CEP 17:  93/100 cells (93%) had a 1 red/ 2 green signal pattern, reflecting TP53 deletion and consistent with the deleted chromosome 17 short arm in the metaphase karyotype. ",CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%),Negative,Negative,,79.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,14.0,Dead-Disease,65.0,15.0,,,0.0,0.0,,25.2,,0.9,,24.3,1.7,,,,,,11.5,31.0,,,,,8.3,,,,,92.6,"partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO"
C338,S519,4896,18-00101,2814.0,BA3270D,BA3270R,Female,47.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,Favorable,NotDetected,"46,XX[20",Normal,DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12D; MAF 46%),Negative,Positive (p.W288fs*12; MAF 48%),,47.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,100.0,Alive,2237.0,Alive,18.0,9.0,,,0.0,0.0,,13.3,,16.8,,46.0,0.6,,,,,,65.11,189.0,2.7,,,0.7,7.4,,16.0,23.0,470.0,98.7,
C339,S520,4898,18-00105,2625.0,BA3324D,BA3324R,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,Other,"46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4] ","EGR-1/ D5S23, D5S721:  193/200 cells (96.5%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | D7S522/ CEP 7:  191/200 cells (95.5%) had a 1 red/ 2 green signal pattern, indicating deleted 7q, consistent with the metaphase karyotype.  | MLL:  150/200 cells (75%) had three intact signals, consistent with the trisomy 11 in the metaphase karyotype. An additional 18 cells (9%) had four intact MLL signals.  There was no evidence for MLL rearrangement.  | CBFB:  195/200 cells (97.5%) had a single intact signal, consistent with the monosomy 16 in the metaphase karyotype.  There was no evidence for CBFB rearrangement. ",PTPN11 (p.S502P; MAF 34%)|TP53 (p.L194R; MAF 87%),Negative,Negative,,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Induction|Re-induction,Complete Response,Standard Chemotherapy,15.0,"Decitabine, MGB453|7+3 (Cytarabine, Idarubicin) plus Sorafenib","Decitabine, MGB453",Standard Chemotherapy,Re-induction,84.0,Dead,200.0,Dead-Disease,85.0,72.0,,,0.0,0.9,,14.6,,32.8,,4.3,0.1,,,,,,62.69,133.0,2.5,,,1.2,9.1,,12.0,37.0,1498.0,107.4,"variable CD4, dim CD7, dim CD11b, CD13, variable CD14, variable CD15, CD33, variable CD34, CD38, dim CD56, partial CD64, CD117, HLA-DR, MPO positive."
C340,S521,4901,18-00110,2808.0,BA3401D,,Male,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XY[4]",,CEBPA (p.G242S; MAF 57%)|FLT3 (p.A680V; MAF 2%)|IDH1 (p.R132S; MAF 34%)|MPL (p.R102P; MAF 55%)|NPM1 (p.W288fs*12; MAF 35%)|PTPN11 (p.S502L; MAF 28%)|TCF3 (p.Q169K; MAF 50%),Negative,Positive (p.W288fs*12; MAF 35%),,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,88.0,Alive,1459.0,Alive,65.0,50.0,,,0.0,0.0,,40.2,,0.0,,6.0,0.2,,,,,,10.53,31.0,4.0,,,1.03,10.1,,49.0,21.0,236.0,94.2,"variable CD11b, CD33, CD38, CD117, MPO positive"
C342,S523,4911,18-00131,2724.0,BA3199D,BA3199R,Male,69.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,NotDetected,"46,XY[19] ",Normal,ASXL1 (A619*; VAF 47%)|CEBPA (H24Afs*84; VAF 44%)|CEBPA (R165Afs*153; VAF 48%)|RUNX1 (VAF 45%)|SRSF2 (P95H; VAF 53%)|TET2 (S1486*; VAF 48%),Negative,Negative,mono,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,7.0,Dead,156.0,Dead-Disease,94.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C343,S524,4912,18-00135,2797.0,BA3326D,BA3326R,Male,63.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,M5,Adverse,Other,"47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]","Gain of 8q22, 8 centromere and 16q22 sequences",ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%),Negative,Negative,,63.0,0.0,4912_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,29.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,29.0,Dead,52.0,Dead-Disease,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C344,C344,4912,18-00136,,,,Male,63.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,M5,Adverse,Other,"47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]","Gain of 8q22, 8 centromere and 16q22 sequences",ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%),Negative,,,63.0,0.0,4912_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,29.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,29.0,Dead,52.0,Dead-Disease,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C574,S525,4930,18-00173,2657.0,BA3297D,BA3297R,Female,46.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XX[20] ",Normal,IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 40%),Negative,Positive (p.W288fs*12; VAF 40%),,46.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,102.0,Alive,1292.0,Alive,81.0,84.0,,,0.0,0.0,,12.1,,16.1,,8.9,0.2,,,,,,61.13,220.0,2.9,,,0.41,9.9,,45.0,29.0,,95.2,"dim CD13, CD33, CD38, CD117 and MPO+"
C410,S526,4934,18-00179,2650.0,BA3227D,BA3227R,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%),Positive (MAF 13%; AR 0.149425287),Positive (p.W288fs*12; VAF 69%),,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,6.0,"MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)","Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1188.0,Alive,95.0,96.0,,,0.0,0.0,,2.7,,0.0,,0.0,0.2,,,,,,159.73,45.0,3.1,,,0.78,5.6,,163.0,68.0,469.0,106.3,"dim CD13, CD33, CD38, CD117, and MPO +"
C346,S608,4937,18-00184,2653.0,BA3394D,BA3394R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Negative,Negative,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,12.0,,,,,,,,,,,,
C347,S527,4943,18-00190,2833.0,BA3412D,BA3412R,Female,74.0,1.0,Breast Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Adverse,Other,"46,XX,t(8;16)(p11.2;p13.3)[19] /46,XX[1] ",Normal,KMT2D (p.R1918C; VAF 50%)|PTPN11 (p.S502P; VAF 41%),Negative,Negative,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,90.0,"Vidaza, BI836858 (anti-CD33)","Vidaza, BI836858 (anti-CD33)",Standard Chemotherapy,Induction,90.0,Dead,149.0,Dead-Disease,81.0,85.0,,,,,,,,,,,,,,,,,43.06,111.0,2.5,,,1.1,6.3,,13.0,23.0,1017.0,102.6,"dim CD4, dim CD11b, CD15, bright CD33, CD38, variable CD56, bright CD64, partial CD117, HLA-DR, MPO, and dim TdT+"
C348,S528,4944,18-00192,2685.0,BA3293D,BA3293R,Female,53.0,1.0,Cervical Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,NotDetected,"46,XX[20]",,,Positive (MAF 92%; AR 11.5),Positive,,55.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Leukapheresis,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Mismatched Unrelated Donor,-1.0,Dead,835.0,Dead-Disease,,90.0,,,,,,,,,,,,,,,,,43.57,34.0,,,,,8.8,,,,,97.5,"variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO"
C349,C349,4951,18-00203,,,,Male,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13q22)[20] ","CBFB/MYH11:  165/200 cells (82.5%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion and consistent with the inverted chromosome 16 observed in the metaphase karyotype. ",CARD11 (p.N191S; VAF 45%)|KRAS (p.G12V; VAF 4%),Negative,Negative,,58.0,0.0,4951_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,22.0,Dead-Disease,82.0,63.0,,,,,,,,,,,,,,,,,22.83,30.0,,,,,6.6,,,,,100.0,"23% myeloid blasts: CD13, variable CD15, CD33, CD34, CD38, dimCD56, CD117, HLA-DR, MPO, partial/dim TdT | 40% promonocytes/monocytes: CD11b, CD13, variable CD14, variable CD16, CD33, CD38, CD64 and HLA-DR"
C350,S529,4951,18-00204,2718.0,BA3250D,BA3250R,Male,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13q22)[20] ","CBFB/MYH11:  165/200 cells (82.5%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion and consistent with the inverted chromosome 16 observed in the metaphase karyotype. ",CARD11 (p.N191S; VAF 45%)|KRAS (p.G12V; VAF 4%),Negative,Negative,,58.0,2.0,4951_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,22.0,Dead-Disease,82.0,63.0,,,,,,,,,,,,,,,,,26.58,29.0,,,,,7.4,,,,,98.7,"Myeloid blasts: CD13, CD33, CD34,  CD117, HLA-DR+ | Promonocytic/ monocytic population (56%): variable CD13, variable CD14, partial CD16, CD33, CD64, HLA-DR+"
C351,S530,4952,18-00205,2779.0,BA3205D,,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M2,M2,Adverse,MECOM_re, Inv(3)(q21q26.2) ,,GATA2 (p.Y322C; VAF 32%)|SF3B1 (p.H662Q; VAF 39%),Negative,Negative,,49.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,4.0,Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide",Decitabine,Standard Chemotherapy,Maintenance,4.0,Alive,1057.0,Alive,30.0,10.0,,,,,,,,,,,,,,,,,6.53,81.0,,,,,6.8,,,,,108.3,
C352,S531,4953,18-00206,2793.0,BA3177D,BA3177R,Male,66.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,Favorable,CBFB-MYH11,,,,Negative,Negative,,66.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,1.0,Dead-Disease,,82.0,,,0.0,0.9,,17.4,,7.8,,1.7,0.0,,,,,,310.71,57.0,2.8,,,2.11,5.6,,76.0,125.0,3316.0,94.6,"partial CD1a, CD13, variable CD14, CD33, CD34, CD38, dim CD117, HLA-DR and cMPO"
C353,S533,4961,18-00218,2804.0,BA3182D,BA3182R,Male,30.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M2,M2,Favorable,CBFB-MYH11,"46,XY,del(7)(q32q36),inv(16)(p13.1q22)[20]",CBFB/MYH11: 90% of cells had a 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16). ,,Negative,Negative,,30.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Intrathecal,4.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"FLAG-IDA, Gemtuzumab Ozogamicin|7+3 (Cytarabine, Idarubicin)|HiDAC|Methotrexate",HiDAC,Standard Chemotherapy,Consolidation,38.0,Alive,1076.0,Alive,80.0,75.0,,,,,,,,,,,,,,,,,41.42,14.0,,,,,5.7,,,,,100.6,"Myeloid blast immunophenotype: CD13, CD33, CD34, CD117, HLA-DR, MPO positive | Aberrant monocytoid population with variable CD14, CD15, and CD64 expression"
C356,S534,4965,18-00223,2621.0,BA3369D,BA3369R,Male,73.0,1.0,Melanoma,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[cp20]","CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion, consistent with the metaphase karyotype and the diagnosis of AML. ",EP300 (p.S1033L; VAF 50%)|FLT3-TKD (p.D835V; VAF 26%)|KRAS (p.G12V; VAF 19%)|WT1 (p.T225M; VAF 50%),Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,10.0,Dead-Unknown,,80.0,,,,,,,,,,,,,,,,,21.23,96.0,,,,,9.0,,,,,102.6,"Myeloid blasts: CD13, CD33, CD34, dimCD38, CD117, dim HLA-DR, and MPO. | Promonocytes/monocytes: dimCD4, CD11b, bright CD13, variable CD14, bright CD33, CD64, variable HLA-DR positive"
C354,S535,4967,18-00226,2737.0,BA3078D,BA3078R,Male,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,NotDetected,"46,XY[20]",Normal,,Negative,Negative,,68.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,24.0,Dead-Disease,74.0,,,,,,,,,,,,,,,,,,38.83,64.0,,,,,6.8,,,,,102.1,"dimCD2, partial CD7, dimCD13, CD34, CD38, CD117, HLA-DR"
C355,S536,4972,18-00230,2654.0,BA3386D,BA3386R,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",,DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%),Positive (MAF 97%; AR 32.333333333),Positive (p.W288fs*12; VAF 45%),,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,4.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),5.0,5.0,Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate",Gilteritinib or Placebo,Targeted Therapy - Kinase Inhibitor(s),Maintenance,734.0,Alive,1935.0,Alive,,,,,,,,,,,,,,,,,,,40.36,135.0,,,,,9.2,,,,,87.2,"dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive"
C357,S609,4977,18-00238,2786.0,BA3445D,BA3445R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Negative,Negative,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C359,S538,4989,18-00260,2739.0,BA3258D,BA3258R,Female,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XX[20]",Normal,DNMT3A (p.N797D; VAF 46%)|IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.Q61P; VAF 47%),Negative,Positive (p.W288fs*12; VAF 46%),,66.0,0.0,4989_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,5.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,1292.0,Dead-Other,90.0,,,,0.2,0.0,,8.1,,85.9,,4.0,0.1,,,,,,145.55,130.0,2.8,,,1.17,10.1,,30.0,25.0,363.0,86.8,"partial CD7 and CD9, CD11b, dim CD13, CD14, CD15, CD33, CD38, partial CD56, CD64, HLA-DR+"
C409,S539,4989,19-00334,2739.0,BA3446D,BA3446R,Female,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,NonInitial,Other,"46,XX,del(14)(q21q31)[20] ",Normal,BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%),Negative,Positive (p.W288fs*12; VAF 43%),,67.0,366.0,4989_2,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,5.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,1292.0,Dead-Other,26.0,,,,0.0,0.0,,7.9,,21.1,,22.8,0.1,,,,,,39.23,14.0,2.7,,,0.66,10.6,,35.0,39.0,775.0,90.1,"Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR  "
C360,S540,4991,18-00267,2763.0,BA3295D,BA3295R,Male,63.0,1.0,Prostate Cancer,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Germline DDX41 P/LP variant,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",CBFB/MYH11: 91% of cells had the 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16). ,NOTCH1 (p.V1739M; VAF 48%)|NRAS (p.Q61K; VAF 45%),Negative,Negative,,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-Ida-Mylotarg","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,953.0,Alive,57.0,70.0,,,0.8,2.5,,20.9,,46.7,,8.3,0.1,,,,,,50.68,27.0,3.2,,,1.66,7.1,,90.0,90.0,627.0,105.5,"Myeloid blast population, about 25%: CD13, CD33, CD34, CD117, HLA-DR and MPO.   | Atypical monocyte population, about 20%: dim CD4, partial CD9, bright CD11b, CD13, CD14, CD33, CD64, HLA-DR and MPO"
C361,S610,4992,18-00269,2723.0,BA3283D,BA3283R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,,,NonInitial,CBFB-MYH11,,,,Negative,Negative,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C362,S611,4993,18-00270,2744.0,BA3390D,BA3390R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,,Negative,Positive,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C455,C455,4995,20-00655,,,,Male,75.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,M4,M4,Adverse,Other,"45,XY,-18[10]/46,XY,del(20)(q11.2q13.1)[7]/46,XY[5]",Normal (hypereosinophilia probe panel),ETNK1 (p.R57L; VAF 50.3%)|IDH2 (p.R140Q; VAF 44.3%)|KRAS (p.G60D; VAF 14.5%)|MPL (p.Trp515Leu; VAF 92.2%)|NF1 (p.R1769*; VAF 1.6%)|PCLO (p.A720V; VAF 48.0%)|PRPF40B (p.P58L; VAF 47.3%)|RUNX1 (p.D198E; VAF 15.6%)|RUNX1 (p.R201Q; VAF 0.5%)|SRSF2 (p.P95R; VAF 45.6%)|TP53 (p.T253_I254insD; VAF 19.5%)|WHSC1 (p.S614N; VAF 50.9%),Negative,Negative,,75.0,847.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,62.0,"Venetoclax (ABT-199), Azacitidine|Enasidenib",Enasidenib,Standard Chemotherapy,Induction,62.0,Dead,183.0,Dead-Disease,38.0,27.0,,,0.0,0.0,,20.0,,16.5,,35.7,0.7,,,,,,11.72,364.0,3.8,,,1.15,9.4,,26.0,31.0,,97.7,"Myeloid blasts: CD13, CD33, CD34, CD38, CD117, MPO | Promonocytes: CD9, CD11c, dimCD13, CD14, CD15,  bright CD33, CD38, CD64,and MPO"
C363,S612,4998,18-00278,2639.0,BA3275D,BA3275R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Positive (MAF 28%; AR 0.388888889),Negative,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C364,S613,5000,18-00280,2726.0,BA3190D,BA3190R,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,Negative,Negative,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C575,S543,5007,18-00290,2693.0,BA3087D,BA3087R,Male,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,Other,"46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5] ","93% of cells were missing a signal for both 5q probes (EGR1, 5q31; and 5q33) but had two signals for 5p, consistent with 5q deletion. ",ASXL1 (p.D821fs*12; VAF 28%)|CREBBP (p.N970fs*21; VAF 8%)|JAK1 (p.T114A; VAF 49%)|KMT2D (p.R598H; VAF 49%)|WT1 (p.S165fs*35; VAF 45%),Negative,Negative,,31.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,1073.0,Alive,90.0,,,,0.0,0.9,,26.1,,1.7,,0.9,0.9,,,,0.9,,17.92,196.0,3.8,,,0.97,8.6,,13.0,10.0,165.0,98.0,"partial CD7, CD13, CD33, CD34, dim CD38, CD56, CD117, HLA-DR, partial MPO, and dim TDT."
C365,S544,5010,18-00298,2679.0,BA3454D,BA3454R,Female,82.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Intermediate,NotDetected,"46,XX[20] ",Normal,DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%),Positive (MAF 49%; AR 0.960784314),Positive (p.W288fs*12; VAF 48%),,82.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,14.0,Dead-Disease,50.0,50.0,,,0.0,0.0,,11.0,,5.0,,35.0,0.3,,,,,,87.73,71.0,3.2,,,0.8,9.4,,22.0,35.0,574.0,98.0,"CD13, CD33, CD117, and MPO"
C366,S545,5013,18-00305,2805.0,BA3302D,BA3302R,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,NotDetected,"46,XY[20] ",Normal,CBL (p.V363_Q365del; VAF 31%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 51%),Negative,Negative,,65.0,0.0,5013_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,80.0,80.0,,,1.7,0.0,,12.9,,1.7,,7.8,1.4,,,,,,32.75,29.0,3.5,,,1.4,8.5,,41.0,47.0,1042.0,95.4,"partial CD10, CD13, CD33, CD34, subset CD79a, CD117, HLA-DR, partial MPO, and TDT+"
C396,C396,5013,19-00254,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,ATG2B (p.L1989V; VAF 47%)|FLT3-ITD (Allelic Ratio: ~0.003 )|MED12 (p.N1049T; VAF 96%)|RTEL1 (p.S925Y; VAF 51%)|RUNX1 (p.D198N; VAF 51%)|SF3B1 (p.K666N; VAF 48%)|SH2B3 (p.S488Y; VAF 49%),Positive (AR ~0.003),Negative,,65.0,269.0,5013_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,45.0,,,,0.0,0.0,,27.0,,11.0,,12.0,6.6,,,,,,24.27,67.0,3.6,,,0.9,9.6,,22.0,38.0,590.0,109.2,"CD13, variable CD33, CD34, CD117, HLA-DR+"
C408,S546,5013,19-00332,2805.0,BA3242D,BA3242R,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 34%)|FLT3-ITD (Allelic Ratio: ~0.013)|MED12 (p.N1049T; VAF 97%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 47%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 49%),Negative,Negative,,66.0,316.0,5013_3,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,46.0,23.0,,,0.3,0.3,,43.8,,21.3,,21.7,3.9,,,,,,10.24,14.0,3.9,,,0.94,7.8,,12.0,22.0,530.0,105.3,"partial CD10, CD34, CD13, CD117, and HLA-DR"
C417,C417,5013,19-00429,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 37%)|FLT3-ITD (Allelic ratio: 0.07)|MED12 (p.N1049T; VAF 96%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 52%)|WT1 (p.R380fs*5; VAF 3%)|WT1 (p.R380fs*5; VAF 4%),Positive (AR 0.07),Negative,,66.0,379.0,5013_4,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,58.0,60.0,,,1.8,0.0,,13.3,,9.7,,14.1,3.7,,,,,,39.36,61.0,,,,0.86,9.6,,,,,105.2,"partial CD10, CD13, variable CD33, variable CD34, CD117, HLA-DR+"
C583,C583,5013,19-00438,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 37%)|FLT3-ITD (Allelic ratio: 0.07)|MED12 (p.N1049T; VAF 96%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 52%)|WT1 (p.R380fs*5; VAF 3%)|WT1 (p.R380fs*5; VAF 4%),Positive (AR 0.07),Negative,,66.0,386.0,5013_5,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,58.0,,,,2.6,0.9,,7.0,,10.4,,2.6,2.7,,,,,,51.96,45.0,4.1,,,0.97,8.1,,21.0,29.0,853.0,106.8,"partial CD10, CD13, variable CD33, variable CD34, CD117, HLA-DR+"
C587,C587,5013,19-00520,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,,,,,66.0,435.0,5013_6,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,,,,,0.0,0.0,,17.3,,3.6,,6.4,3.1,,,,,,18.66,51.0,3.8,,,1.03,8.3,,28.0,21.0,546.0,118.8,
C588,C588,5013,19-00523,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,,,,,66.0,442.0,5013_7,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,,,,,0.9,0.0,,11.4,,3.5,,5.3,2.9,,,,0.9,,26.32,42.0,3.6,,,0.92,7.9,,26.0,19.0,534.0,119.2,
C420,C420,5013,19-00541,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,NotDetected,"46,XY[20]",Normal,,,,,66.0,456.0,5013_8,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),5.0,3.0,Induction|Experimental|Re-induction,Refractory,Targeted Therapy - Other,24.0,"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Targeted Therapy - Kinase Inhibitor(s),Experimental,69.0,Dead,541.0,Dead-Disease,,,,,0.0,0.0,,6.3,,7.2,,5.4,3.2,,,,,,31.95,32.0,3.4,,,1.03,8.1,,22.0,15.0,488.0,113.1,
C367,S547,5021,18-00320,2629.0,BA3117D,BA3117R,Male,35.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,Other,"47,XY,del(9)(q13q22),+10[3]/46,XY[17] ",,CEBPA (p.A111fs*56; 35% (likely underestimate VAF))|CEBPA (p.D322delinsETQQKVLELTSDND; VAF 37% (likely underestimate VAF))|GATA2 (p.P304H; VAF 32%)|RUNX1 (p.R166Q; VAF 6%),Negative,Negative,bi,35.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Haploidentical - Parent|Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,5.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Fludarabine, Cyclophosphamide, TBI ","Fludarabine, Cyclophosphamide, TBI ",Bone Marrow Transplant,Haploidentical - Parent,-1.0,Alive,1064.0,Alive,85.0,53.0,,,0.0,0.0,,40.4,,0.0,,10.5,2.9,,,,,,4.18,18.0,4.4,,,0.9,7.6,,29.0,15.0,199.0,98.7,"CD7, CD33, CD34, CD38, CD117, HLA-DR, and MPO positive"
C369,S614,5024,18-00327,2692.0,BA3083D,BA3083R,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,,Positive (MAF 85%; AR 5.666666667),Positive,,57.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C412,C412,5026,19-00376,,,,Male,65.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"47~50,XY,+8[cp10]/46,XY,del(20)(q11.2)[5]/46,XY[5]",Normal,ASXL1 (p.R693*; VAF 44%)|ATG2B (p.Q1071E; VAF 50%)|BCOR (p.K1460fs*21; VAF 2%)|BCOR (p.M1575fs*11; VAF 2%)|BCOR (p.Q308fs*67; VAF 2%)|CEBPA (p.N321S; VAF 76%)|CSF3R (p.T618I; VAF 2%)|DNMT3A (p.S129L; VAF 51%)|PHF6 (p.A288D; VAF 3%)|PTPN11 (p.R138Q; VAF 35%)|RBBP6 (p.S1707del; VAF 48%)|RUNX1 (p.R204*; VAF 46%)|SRSF2 (p.P95H; VAF 48%)|STAG2 (p.M904fs*2; VAF 76%)|STAG2 (p.R953*; VAF 24%)|TET2 (p.Y1245fs*21; VAF 33%),Negative,Negative,,66.0,321.0,,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,6.0,4.0,Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,4.0,"Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|Decitabine, Venetoclax|Ruxolitinib, Venetoclax","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,1108.0,Dead-Disease,35.0,,,,1.0,2.0,,28.0,,1.0,,32.0,10.0,,,,,,4.98,27.0,3.7,,,,8.6,,30.0,31.0,354.0,97.2,"variable CD11b, CD13, CD33, CD34, CD38, CD117, and HLA-DR     "
C368,C368,5029,18-00336,,,,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,NotDetected,"46,XX[20]",Normal,"CREBBP (p.Q278P; VAF 51%)|FLT3-ITD (51-bp AR:0.695; VAF 41%)|GATA2 (p.V70F; VAF 48%)|KMT2A (Partial tandem duplications (exon 11/exon3 break, peak 497))|TET2 (p.I1873T; VAF 47%)|TNFRSF14 (p.R106H; VAF 52%)",Positive (51-bp VAF 41%; AR 0.695),Negative,,70.0,0.0,5029_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,2.0,Salvage|Induction,Complete Response,Targeted Therapy - Kinase Inhibitor(s),70.0,"Gilteritinib (ASP2215)|Gilteritinib, Decitabine, Venetoclax|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine","Gilteritinib, Decitabine, Venetoclax",Standard Chemotherapy,Salvage,524.0,Dead,1260.0,Dead-Disease,48.0,50.0,,,0.0,1.8,,17.6,,25.4,,21.9,3.2,,,,,,72.97,163.0,3.2,,,0.53,7.8,,23.0,50.0,1007.0,116.0,"CD13, CD33, CD34, CD38, CD117, HLA-DR and MPO positive"
C371,C371,5029,18-00358,,,,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,NotDetected,"46,XX[20]",Normal,"CREBBP (p.Q278P; VAF 51%)|FLT3-ITD (51-bp AR:0.695; VAF 41%)|GATA2 (p.V70F; VAF 48%)|KMT2A (Partial tandem duplications (exon 11/exon3 break, peak 497))|TET2 (p.I1873T; VAF 47%)|TNFRSF14 (p.R106H; VAF 52%)",Positive (VAF 41%; AR 0.695),Negative,,70.0,19.0,5029_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,2.0,Salvage|Induction,Complete Response,Targeted Therapy - Kinase Inhibitor(s),70.0,"Gilteritinib (ASP2215)|Gilteritinib, Decitabine, Venetoclax|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine","Gilteritinib, Decitabine, Venetoclax",Standard Chemotherapy,Salvage,524.0,Dead,1260.0,Dead-Disease,,,,,0.0,1.8,,36.5,,36.5,,22.6,0.2,,,,,,24.74,279.0,,,,,9.6,,,,,106.8,
C486,C486,5029,21-00453,,,,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,NonInitial,NotDetected,"46,XX[18]",Normal,"CREBBP (p.Q278P; VAF 50.1%)|DOCK8 (p.S1179N; VAF 48.2%)|FAT1 (p.Y4232C; VAF 49.8%)|FLT3 (p.F691L; VAF 28.8%)|FLT3-ITD (72-bp AR 0.12, VAF 7.7%; 108-bp AR 0.44, VAF 28.3%)|GATA2 (p.V70F; VAF 49.1%)|KMT2A (PTD exons 11/3 breakpoint)|NRAS (p.G12D; VAF 8.9%)|SPEN (p.P3456L; VAF 53.6%)|TET2 (p.I1873T; VAF 41.0%)|TNFRSF14 (p.R106H; VAF 49.6%)|USH2A (p.E4264K; VAF 48.9%)|USH2A (p.R2343Q; VAF 31.3%)",Positive (allelic ratio 0.56; VAF 36%),Negative,,73.0,967.0,5029_3,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4.0,2.0,Salvage|Induction,Complete Response,Targeted Therapy - Kinase Inhibitor(s),70.0,"Gilteritinib (ASP2215)|Gilteritinib, Decitabine, Venetoclax|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine","Gilteritinib, Decitabine, Venetoclax",Standard Chemotherapy,Salvage,524.0,Dead,1260.0,Dead-Disease,,,,,0.0,0.0,,16.4,,0.9,,6.0,0.3,,,,,,46.45,27.0,3.6,,,0.7,8.3,,43.0,54.0,,88.2,
C576,S548,5032,18-00341,2672.0,BA3266D,BA3266R,Female,83.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Intermediate,NotDetected,"46,XX[20]",,BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%),Positive (MAF 37%; AR 0.587301587),Positive (p.W288fs*12; VAF 42%),,83.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,28.0,Dead-Disease,75.0,52.0,,,0.9,0.0,,9.4,,14.5,,27.3,0.2,,,,,,44.85,273.0,2.7,,,0.77,6.5,,19.0,24.0,333.0,95.8,"dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive"
C373,S549,5053,18-00390,2773.0,BA3268D,BA3268R,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,Other,"46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1] ","D7S486/ CEP 7:  93/100 cells (90%) had a 1 red/ 2 green signal pattern, consistent with the deleted 7q observed in the metaphase karyotype.  | RUNX1T1/RUNX1:  10/200 cells (5%) had a 2 red/ 3 green signal pattern, suggesting low level presence of an extra copy of RUNX1 (21q22).  There was no evidence for RUNX1T1/RUNX1 fusion.  | EGR-1/ D5S23, D5S721: While this probe set showed a normal numeric signal pattern in interphase cells, metaphase FISH showed an EGR-1 (5q) signal on the add(11p) and a 5q33 signal on the add(21q).  (The G-banded chromosomes were not of adequate band length/morphology to establish specific breakpoints.  Therefore, it is possible that some or all of the apparently missing 5q material is actually accounted for on other chromosomes.  This probe set will not be useful for monitoring the abnormal 5q.)",DNMT3A (Splice site; VAF 46%)|IDH1 (p.R132S; VAF 44%)|STAG2 (p.F437fs*11; VAf 48%),Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,2.0,Induction|Maintenance,Complete Response,Standard Chemotherapy,324.0,"Azacitidine, Ivosidenib|Ivosidenib",Ivosidenib,Targeted Therapy - Other,Maintenance,-1.0,Alive,1028.0,Alive,92.0,90.0,,,0.0,0.0,,17.7,,1.0,,0.0,9.6,,,,,,11.49,48.0,2.7,,,0.85,8.3,,23.0,39.0,615.0,97.3,"CD7, dim CD13, CD33, CD34, CD38, CD117, partial HLA-DR, and partial MPO"
C374,S550,5061,18-00408,2619.0,BA3229D,BA3229R,Male,56.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,Adverse,Other,"49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]","Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21. ",ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%),Negative,Negative,,56.0,0.0,5061_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,5.0,"HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib","Decitabine, Ruxolitinib",Standard Chemotherapy,Salvage,-1.0,Dead,164.0,Dead-Disease,,35.0,,,2.5,2.5,,3.4,,12.6,,41.2,0.9,,,,,,85.46,112.0,3.3,,,1.31,8.7,,17.0,27.0,363.0,105.8,"partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive"
C377,S551,5061,19-00027,2619.0,BA3138D,BA3138R,Male,56.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6] ","Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21. ",,Negative,Negative,,56.0,48.0,5061_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,5.0,"HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib","Decitabine, Ruxolitinib",Standard Chemotherapy,Salvage,-1.0,Dead,164.0,Dead-Disease,,,,,1.7,0.3,,14.3,,16.0,,67.7,,,,,,,16.7,31.0,3.6,,,1.1,8.6,,19.0,21.0,201.0,106.9,
C379,S552,5061,19-00035,2619.0,BA3388D,BA3388R,Male,56.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,Other,"49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6] ","Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21. ",,Negative,Negative,,56.0,55.0,5061_3,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,4.0,Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,5.0,"HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib","Decitabine, Ruxolitinib",Standard Chemotherapy,Salvage,-1.0,Dead,164.0,Dead-Disease,,,,,2.6,0.0,,2.6,,10.4,,40.9,2.5,,,,,,23.94,43.0,3.5,,,1.3,9.0,,19.0,23.0,254.0,110.3,
C578,S553,5065,18-00414,2696.0,BA3353D,BA3353R,Female,71.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,Other,"46,XX,del(5)(q13q33)[14]/46,XX[6]","5q:  96% of cells were missing a signal for EGR1 (5q31) and 5q33, consistent with deletion, as seen on metaphase analysis. ",DNMT3A (p.R749H; VAF 42%)|ETV6 (p.R378Q; VAF 52%)|JAK2 (p.V617F; VAF 3%)|KMT2D (Partial tandem duplications (exon 9/exon3))|STAT3 (p.D661Y; VAF 38%),Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,103.0,"Venetoclax (ABT-199), Azacitidine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)","Venetoclax (ABT-199), Azacitidine",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,972.0,Dead-Other,98.0,44.8,,,1.0,3.8,,39.4,,1.0,,7.7,0.4,,,,,,4.92,100.0,3.4,,,0.7,9.5,,44.0,22.0,,107.5,"CD7, CD13, CD33, dim CD38, CD117, HLA-DR and variable MPO +"
C375,S554,5078,19-00019,2703.0,BA3312D,BA3312R,Male,43.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Favorable,Other,"46,XY,t(2;12)(p13;q13)[20]",Normal,CEBPA (p.G36fs*122; VAF 45%)|CEBPA (p.Q311_Q312linsRKAKQRNVETQ; VAF 45%)|DNMT3A (p.R19P; VAF 48%)|EZH2 (p.K30fs*17 (loss of function); VAF 65%)|GATA2 (p.R362Q; VAF 47%)|NRAS (p.G13D; VAF 43%),Negative,Negative,bi,43.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,132.0,Dead,472.0,Dead-Disease,70.0,68.0,,,0.0,1.7,,14.8,,5.2,,9.6,0.1,,,,,,79.15,21.0,2.9,,,0.84,5.5,,25.0,24.0,1024.0,102.5,"CD13, CD33, variable CD34, CD117, and HLA-DR positive (CD7, dim CD15, and MPO expression was noted on the prior flow cytometric analysis and was not tested in the current assay)"
C376,S555,5080,19-00025,2778.0,BA3119D,BA3119R,Female,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,NotDetected,"46,XX[20] ",Normal,ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%),Negative,Positive (p.W288fs*12; VAF 48%),,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|MiDAC",MiDAC,Standard Chemotherapy,Consolidation,101.0,Alive,1167.0,Alive,90.0,65.0,,,0.8,0.0,,30.2,,3.1,,6.2,5.3,,,,2.3,,4.68,104.0,3.4,,,0.5,10.8,,21.0,13.0,,95.7,"CD33, CD38, CD117, MPO positive"
C435,C435,5081,20-00276,,,,Male,77.0,1.0,Mantle Cell Lymphoma,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",M2,M2,NonInitial,Other,"45,X,-Y,del(12)(p12p13)[1]/45,sl,i(17)(q10)[19]",No evidence for deleted 11q.,ASXL1 (p.G646fs*12; VAF 36.3%)|EZH2 (p.P623R; VAF 55.0%)|EZH2 (p.Q735*; VAF 32.4%)|EZH2 (p.V626M; VAF 1.9%)|GATA2 (p.R396P; VAF 1.1%)|GATA2 (p.R396W; VAF 1.8%)|NF1 (p.Y1635dup; VAF 21.9%)|SETBP1 (p.D868N; VAF 44.4%)|SYNE1 (p.A6252T; VAF 51.8%)|SYNE1 (p.D4637N; VAF 44.3%)|USH2A (p.H1041Q; VAF 49.9%),Negative,Negative,,78.0,532.0,5081_1,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Salvage|Unknown|Experimental|Autologous,,,,"Decitabine, anti-PD1, anti-TIM3|Hyper-CVAD-R (Hyper-CVAD plus Rituximab)|Unknown|PLX2853 (BET inhibitor)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,56.0,Dead,777.0,Dead-Disease,5.0,3.0,,,0.0,5.6,,14.4,,1.6,,76.8,0.1,,,,,,24.29,73.0,2.8,,,,11.0,,16.0,11.0,,106.2,"dimCD13, dimCD33, CD34, dimCD117, HLA-DR"
C462,C462,5081,21-00004,,,,Male,77.0,1.0,Mantle Cell Lymphoma,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",M2,M2,NonInitial,Other,"45,X,-Y,del(12)(p12p13),i(17)(q10)[20]",No evidence for deleted 11q.,ASXL1 (p.G646fs*12; VAF 35.9%)|EZH2 (p.P623R; VAF 52.2%)|EZH2 (p.Q735*; VAF 48.9%)|EZH2 (p.S112fs*28; VAF 10.0%)|EZH2 (p.V626M; VAF 0.6%)|NF1 (p.A246P; VAF 4.4%)|NF1 (p.D1644H; VAF 10.8%)|NF1 (p.D946fs*1; VAF 2.9%)|NF1 (p.S2157*; VAF 18.1%)|NF1 (p.Y1635dup; VAF 2.8%)|NF1 (p.Y235*; VAF 4.0%)|SETBP1 (p.D868N; VAF 44.2%)|SYNE1 (p.A6252T; VAF 51.1%)|SYNE1 (p.D4637N; VAF 43.5%)|USH2A (p.H1041Q; VAF 51.2%),Negative,Negative,,78.0,712.0,5081_2,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Salvage|Unknown|Experimental|Autologous,,,,"Decitabine, anti-PD1, anti-TIM3|Hyper-CVAD-R (Hyper-CVAD plus Rituximab)|Unknown|PLX2853 (BET inhibitor)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,56.0,Dead,777.0,Dead-Disease,35.0,30.0,,,2.6,2.6,,11.1,,4.3,,28.2,0.9,,,,,,40.83,442.0,3.7,,,0.9,9.0,,9.0,4.0,,104.0,"dim CD5, CD13, dim CD33, CD34, partial CD56, CD117, and HLA-DR"
C473,C473,5081,21-00195,,,,Male,77.0,1.0,Mantle Cell Lymphoma,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",M2,M2,NonInitial,Other,"45,X,-Y,del(7)(p13p15),del(12)(p12p13),i(17)(q10)[17]/45,sl,del(9)(q13q22)[3]",No evidence for deleted 11q.,ASXL1 (p.G646fs*12; VAF 38.1%)|EZH2 (p.P623R; VAF 48.6%)|EZH2 (p.Q735*; VAF 42.6%)|EZH2 (p.S112fs*28; VAF 1.1%)|EZH2 (p.V626M; VAF 0.8%)|FLT3-ITD (allelic ratio 0.01)|NF1 (p.A246P; VAF 4.1%)|NF1 (p.D1644H; VAF 7.0%)|NF1 (p.D946fs*1; VAF 2.9%)|NF1 (p.S2157*; VAF 3.4%)|NF1 (p.Y1635dup; VAF 0.5%)|NF1 (p.Y235*; VAF 1.7%)|NRAS (p.G13R; VAF 27.1%)|SETBP1 (p.D868N; VAF 49.1%)|SYNE1 (p.A6252T; VAF 46.7%)|SYNE1 (p.D4637N; VAF 43.2%)|USH2A (p.H1041Q; VAF 49.3%),Positive (allelic ratio 0.01; VAF 1%),Negative,,79.0,775.0,5081_3,Residual,Residual,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5.0,4.0,Salvage|Unknown|Experimental|Autologous,,,,"Decitabine, anti-PD1, anti-TIM3|Hyper-CVAD-R (Hyper-CVAD plus Rituximab)|Unknown|PLX2853 (BET inhibitor)|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,56.0,Dead,777.0,Dead-Disease,65.0,45.0,,,0.9,8.8,,17.5,,4.4,,15.8,0.7,,,,,,28.83,156.0,3.6,,,1.06,7.2,,12.0,7.0,326.0,95.3,"partial CD5, dim CD7, partial CD9, partial/dim CD11b, dim CD13, CD33, CD34, dim CD38, partial CD56, CD117, and HLA-DR positive"
C378,S556,5082,19-00029,2731.0,BA3219D,BA3219R,Male,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Favorable,NotDetected,"46,XY[15]",Normal,CCND1 (p.R245W; VAF 48%)|DNMT3A (p.P633R; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.G13D; VAF 6%)|PTPN11 (p.T73I; VAF 33%)|TET2 (p.N926fs*28; VAF 16%),Negative,Positive (p.W288fs*12; VAF 46%),,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,1.0,Cytarabine,Cytarabine,Standard Chemotherapy,Induction,1.0,Dead,4.0,Dead-Disease,90.0,,,,0.4,0.4,,13.9,,80.0,,1.8,0.1,,,,,,104.23,35.0,2.1,,,6.6,6.0,,130.0,186.0,1072.0,89.4,"dim CD9, CD11b, variable CD13, partial CD14, dim CD15, dim CD16, CD33, CD38, dim CD56, CD64, CD123, and HLA-DR"
C580,S557,5096,19-00062,2623.0,BA3351D,BA3351R,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XX,t(15;17)(q22;q21)[20] ",positive for PML/RARA fusion,FLT3-ITD (allelic ratio 0.03; VAF 3.09%)|NRAS (p.A146T; VAF 19%),Positive (VAF 3.09%; AR 0.03092784),Negative,,72.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,-1.0,"ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Induction,-1.0,Alive,927.0,Alive,95.0,,,,0.0,0.9,,52.3,,0.0,,3.8,0.4,,,,,,5.6,93.0,3.4,,,0.67,7.2,,45.0,44.0,506.0,94.0,"CD7, CD11b, CD13, CD15, CD16, CD33, CD38, CD56, CD64, CD117, CD123, and MPO positive"
C579,S558,5104,19-00051,2788.0,BA3357D,BA3357R,Male,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,Other,"47,XY,+21[2]/46,XY[18]","RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21. ",CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%),Positive (MAF 14%; AR 0.162790698),Negative,mono,75.0,0.0,5104_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor",PIM kinase inhibitor,Targeted Therapy - Other,Salvage,21.0,Dead,583.0,Dead-Disease,48.0,,,,0.0,2.6,,15.0,,4.4,,25.7,1.3,,,,0.9,,10.15,16.0,3.4,,,1.15,8.7,,22.0,13.0,190.0,86.5,"dimCD7, dimCD11b, dimCD13, CD33, varibleCD34, CD38, CD117, partial HLA-DR, and MPO positive "
C380,C380,5104,19-00074,,,,Male,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,Other,"47,XY,+21[2]/46,XY[18]","RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21. ",CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%),Positive (VAF 15%; AR 0.18),Negative,,75.0,8.0,5104_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor",PIM kinase inhibitor,Targeted Therapy - Other,Salvage,21.0,Dead,583.0,Dead-Disease,,,,,0.0,1.7,,6.1,,1.8,,13.2,1.0,,,,,,35.16,11.0,3.9,,,1.14,9.4,,28.0,21.0,,89.9,
C581,C581,5104,19-00075,,,,Male,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Intermediate,Other,"47,XY,+21[2]/46,XY[18]","RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21. ",CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%),Positive (VAF 15%; AR 0.18),Negative,,75.0,8.0,5104_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor",PIM kinase inhibitor,Targeted Therapy - Other,Salvage,21.0,Dead,583.0,Dead-Disease,,,,,0.0,1.7,,6.1,,1.8,,13.2,1.0,,,,,,35.16,11.0,3.9,,,1.14,9.4,,28.0,21.0,,89.9,
C589,C589,5104,20-00295,,,,Male,75.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,NonInitial,NotDetected,"46,XY[20]",Normal,,,,,77.0,514.0,5104_3,Residual,Residual,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1.0,"Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor",PIM kinase inhibitor,Targeted Therapy - Other,Salvage,21.0,Dead,583.0,Dead-Disease,80.0,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13, dim CD33, CD34, CD56, CD117, and partial HLA-DR"
C381,S559,5109,19-00084,2620.0,BA3208D,BA3208R,Female,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Adverse,NotDetected,"46,XX[18]",Normal,"DNMT3A (p.R882H; VAF 47%)|FLT3-ITD (allelic ratio 0.03; VAF 3%)|KMT2A (PTD, exon 9/3 break)|TET2 (p.H578fs*2; VAF 36%)|TET2 (p.Y1345fs*14; VAF 27%)|WT1 (p.D367_V374delinsWS; VAF 3%)|WT1 (p.R370fs*6; VAF 5%)|WT1 (p.R380fs*5; VAF 2%)|WT1 (p.R380fs*5; VAF 47%)|WT1 (p.T377fs*73; VAF 23%)|ZRSR2 (p.R452C; VAF 48%)",Negative,Negative,,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,43.0,"Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)","Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)",Standard Chemotherapy,Induction,43.0,Dead,84.0,Dead-Disease,85.0,78.0,,,0.0,0.9,,19.3,,0.0,,0.0,1.2,,,,,,27.26,57.0,3.5,,,0.81,9.5,,30.0,34.0,623.0,110.6,"variable CD11b, CD13, CD33, CD34, variable CD38, dim variable cCD79a, CD117, HLA-DR, cMPO, and cTdT positive"
C382,S560,5111,19-00092,2716.0,BA3310D,BA3310R,Male,82.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,NotDetected,"46,XY[20]",Normal,CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%),Negative,Positive (p.W288fs*12; VAF 46%),,82.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,17.0,Dead-Disease,91.0,70.0,,,0.0,0.0,,1.7,,0.0,,16.7,0.2,,,,,,44.35,23.0,1.9,,,0.7,7.8,,11.0,38.0,421.0,88.6,"dim CD13, CD33, CD117 and MPO"
C383,C383,5113,19-00098,,,,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C384,S561,5119,19-00107,2665.0,BA3200D,BA3200R,Female,76.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Favorable,NotDetected,"46,XX[8]",Normal,NPM1 (p.W288fs*12; VAF 50%)|PHF6 (p.R274*; VAF 45%)|PRDM1 (p.P467L; VAF 48%)|TET2 (p.H1382R; VAF 50%)|TET2 (p.K1720*; VAF 48%),Negative,Positive (p.W288fs*12; VAF 50%),,76.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,2.0,Salvage|Induction,Complete Response i,Targeted Therapy - Other,357.0,"SY-1425 (Tamibarotene) plus Azacitidine|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,37.0,Dead,425.0,Dead-Disease,,,,,0.0,0.0,,9.8,,0.0,,0.0,0.1,,,,,,97.67,10.0,3.3,,,0.56,7.3,,24.0,21.0,411.0,97.3,"CD33, CD38, CD56, CD117, and cMPO positive"
C385,S562,5138,19-00137,2782.0,BA3325D,BA3325R,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",,,Negative,Negative,,57.0,0.0,5138_1,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),6.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine",Gilteritinib (ASP2215),Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,568.0,Dead-Disease,,,,,0.0,1.0,,22.0,,2.0,,17.0,27.3,,,,,,26.1,11.0,2.6,,,0.5,6.0,,20.0,52.0,1243.0,94.8,
C386,C386,5138,19-00151,,,,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Normal,FLT3 (p.V579A; VAF 1%)|FLT3-ITD (allelic ratio: 0.03; VAF 2.8%)|KMT2A (Partial tandem duplication (PTD) (exon 9/exon 3))|NRAS (p.G13D; VAF 50%)|PHF6 (p.N23fs*3; VAF 90%)|RUNX1 (p.F163D; VAF 49%)|WT1 (p.A382fs*72; VAF 2%)|WT1 (p.R370fs*17; VAF 3%)|WT1 (p.S381fs*68; VAF 52%)|WT1 (p.V371fs*14; VAF 1%),Positive (VAF 2.8%; AR 0.03),Negative,,57.0,10.0,5138_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),6.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine",Gilteritinib (ASP2215),Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,568.0,Dead-Disease,47.0,,,,0.0,0.0,,5.0,,3.0,,8.0,16.5,,,,,,19.2,10.0,2.7,,,0.6,6.4,,23.0,36.0,796.0,96.0,"CD13, CD33, CD34, CD117, and HLA-DR"
C388,C388,5138,19-00159,,,,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Normal,FLT3 (p.V579A; VAF 1%)|FLT3-ITD (allelic ratio: 0.03; VAF 2.8%)|KMT2A (Partial tandem duplication (PTD) (exon 9/exon 3))|NRAS (p.G13D; VAF 50%)|PHF6 (p.N23fs*3; VAF 90%)|RUNX1 (p.F163D; VAF 49%)|WT1 (p.A382fs*72; VAF 2%)|WT1 (p.R370fs*17; VAF 3%)|WT1 (p.S381fs*68; VAF 52%)|WT1 (p.V371fs*14; VAF 1%),Positive (VAF 2.8%; AR 0.03),Negative,,57.0,14.0,5138_3,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),6.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine",Gilteritinib (ASP2215),Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,568.0,Dead-Disease,47.0,70.0,,,0.0,1.0,,1.0,,4.0,,22.0,17.3,,,,,,22.74,14.0,2.9,,,0.37,7.1,,26.0,42.0,816.0,94.6,"CD13, CD33, CD34, CD117, and HLA-DR"
C391,C391,5138,19-00178,,,,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Normal,FLT3 (p.V579A; VAF 1%)|FLT3-ITD (allelic ratio: 0.03; VAF 2.8%)|KMT2A (Partial tandem duplication (PTD) (exon 9/exon 3))|NRAS (p.G13D; VAF 50%)|PHF6 (p.N23fs*3; VAF 90%)|RUNX1 (p.F163D; VAF 49%)|WT1 (p.A382fs*72; VAF 2%)|WT1 (p.R370fs*17; VAF 3%)|WT1 (p.S381fs*68; VAF 52%)|WT1 (p.V371fs*14; VAF 1%),Positive (VAF 2.8%; AR 0.03),Negative,,57.0,28.0,5138_4,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),6.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine",Gilteritinib (ASP2215),Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,568.0,Dead-Disease,,,,,0.0,0.0,,19.0,,2.0,,15.0,11.1,,,,,,38.97,18.0,3.0,,,0.5,5.8,,29.0,60.0,1412.0,98.5,
C392,C392,5138,19-00191,,,,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,,,NonInitial,NotDetected,"46,XY[20]",Normal,,Positive (VAF 2.8%; AR 0.03),Negative,,57.0,35.0,5138_5,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),6.0,4.0,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine",Gilteritinib (ASP2215),Targeted Therapy - Kinase Inhibitor(s),Experimental,-1.0,Dead,568.0,Dead-Disease,,,,,0.0,0.0,,6.4,,5.4,,9.1,10.4,,,,,,44.54,17.0,3.3,,,0.41,6.6,,39.0,90.0,1731.0,98.2,
C387,S563,5148,19-00154,2776.0,BA3146D,BA3146R,Male,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Intermediate,NotDetected,"46,XY[20]",Normal,DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%),Positive (MAF 15%; AR 0.176470588),Positive (p.W288fs*12; VAF 69%),,42.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Dead,140.0,Dead-Treatment,70.0,,,,0.0,1.0,,22.0,,30.0,,5.0,0.0,,,,4.0,,22.79,18.0,,,,0.95,8.0,,,,1811.0,98.7,"CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO."
C389,S564,5149,19-00156,2697.0,BA3211D,BA3211R,Male,69.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,Adverse,Other,"46,XY,del(20)(q11.2)[cp20]","CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3. ",FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%),Positive (MAF 15%; AR 0.176470588),Negative,,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,3.0,Salvage|Induction|Maintenance,Refractory,Standard Chemotherapy,6.0,"Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin",Gilteritinib (ASP2215),Targeted Therapy - Other,Salvage,-1.0,Dead,76.0,Dead-Disease,91.0,78.0,,,0.0,0.0,,35.0,,31.0,,7.0,0.0,,,,,,5.79,15.0,2.0,,,0.87,7.4,,12.0,8.0,198.0,87.8,"CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117"
C390,S565,5158,19-00179,2610.0,BA3130D,BA3130R,Male,61.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"48,XY,+7,+mar[4]/46,XY[16] ","Chromosome 7: 44% of cells had three signals for both chromosome 7 probes, consistent with trisomy 7",BRAF (p.V600E; VAF 36%)|TET2 (p.A1355V; VAF 48%)|TET2 (p.Q803*; VAF 44%)|ZRSR2 (Splice site; VAF 92%),Negative,Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Dead,110.0,Dead-Treatment,20.0,20.0,,,0.0,0.0,,20.5,,55.4,,15.2,0.1,,,,,,69.09,23.0,2.1,,,2.11,7.6,,160.0,228.0,,99.1,"CD4, dim CD7, CD11b, CD13, variable CD14, CD16, dim CD33, dim CD 38, dim CD56, CD64."
C393,S566,5169,19-00200,2781.0,BA3376D,BA3376R,Female,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,"46,XX[20]",Normal,CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%),Positive (AR 1.040816327),Positive (p.W290fs*10; VAF 49%),,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4.0,4.0,Allogeneic - Sibling|Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,6.0,"Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide",Gilteritinib or Placebo,Targeted Therapy - Other,Maintenance,-1.0,Alive,1697.0,Alive,91.0,,,,0.9,0.0,,4.3,,1.7,,1.7,0.2,,,,,,145.0,26.0,2.8,,,0.69,6.5,,49.0,90.0,1122.0,98.0,"CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive"
C394,C394,5180,19-00218,,,,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",M0/M1,M0/M1,Adverse,NotDetected,"46,XY[20]",,"ASXL2 (p.Q1053fs*8; VAF 50%)|ATG2B (p.K951T; VAF 48%)|FLT3 (p.E444V; VAF 20%)|FLT3-ITD (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD); VAR 0.232; VAF 18.82%)|FLT3-ITD (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS); VAF 1%)|KMT2C (p.D780G; VAF 18%)|PTCH1 (p.G1163S; VAF 47%)|RUNX1 (p.H242fs*14; VAF 71%)|SF3B1 (p.K666N; VAF 48%)","Positive (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD): VAF 18.82%; AR 0.232 | p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS): VAF 1%)",Negative,,66.0,0.0,5180_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,41.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Gilteritinib, Decitabine","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,-1.0,Unknown,68.0,,85.0,76.0,,,4.4,0.9,,14.0,,1.8,,14.0,4.3,,,,,,112.37,33.0,2.6,,,1.01,6.2,,21.0,43.0,1142.0,105.0,"partial CD7, partial CD10, CD13, partial CD19, CD25, dim CD33, CD34, CD38, partial cCD79a, CD117, HLA-DR and TdT+"
C582,C582,5180,19-00272,,,,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",M0/M1,M0/M1,NonInitial,NotDetected,"46,XY[16] ",,"ASXL2 (p.Q1053fs*8; VAF 48%)|ATG2B (p.K951T; VAF 49%)|FLT3 (p.E444V; VAF 22%)|FLT3-ITD (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD); VAF 0.589; VAF 37%)|FLT3-ITD (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS); VAF 0.4%)|KMT2C (p.D780G; VAF 20%)|PTCH1 (p.G1163S; VAF 47%)|RUNX1 (p.H242fs*14; VAF 58%)|SF3B1 (p.K666N; VAF 52%)","Positive (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD): VAF 37%; AR 0.589 | Positive (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS): VAF 0.4%)",Negative,,66.0,36.0,5180_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,41.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Gilteritinib, Decitabine","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,-1.0,Unknown,68.0,,92.0,,,,0.0,1.0,,14.0,,0.0,,6.0,6.3,,,,,,24.85,23.0,,,,,8.2,,,,,92.5,"dimCD7, partialCD10, CD13, CD33, CD34, CD38,CD117, HLA-DR, TdT"
C398,C398,5180,19-00273,,,,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",M0/M1,M0/M1,NonInitial,NotDetected,"46,XY[16] ",,"ASXL2 (p.Q1053fs*8; VAF 48%)|ATG2B (p.K951T; VAF 49%)|FLT3 (p.E444V; VAF 22%)|FLT3-ITD (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD); VAF 0.589; VAF 37%)|FLT3-ITD (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS); VAF 0.4%)|KMT2C (p.D780G; VAF 20%)|PTCH1 (p.G1163S; VAF 47%)|RUNX1 (p.H242fs*14; VAF 58%)|SF3B1 (p.K666N; VAF 52%)","Positive (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD): VAF 37%; AR 0.589 | Positive (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS): VAF 0.4%)",Negative,,66.0,36.0,5180_2,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,41.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Gilteritinib, Decitabine","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,-1.0,Unknown,68.0,,92.0,,,,0.0,1.0,,14.0,,0.0,,6.0,6.3,,,,,,24.85,23.0,,,,,8.2,,,,,92.5,"dimCD7, partialCD10, CD13, CD33, CD34, CD38,CD117, HLA-DR, TdT"
C400,C400,5180,19-00281,,,,Male,66.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",M0/M1,M0/M1,NonInitial,NotDetected,"46,XY[16] ",,"ASXL2 (p.Q1053fs*8; VAF 48%)|ATG2B (p.K951T; VAF 49%)|FLT3 (p.E444V; VAF 22%)|FLT3-ITD (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD); VAF 0.589; VAF 37%)|FLT3-ITD (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS); VAF 0.4%)|KMT2C (p.D780G; VAF 20%)|PTCH1 (p.G1163S; VAF 47%)|RUNX1 (p.H242fs*14; VAF 58%)|SF3B1 (p.K666N; VAF 52%)","Positive (p.F594delinsLEGDLGSFYVDF (33 nucleotides ITD): VAF 37%; AR 0.589 | Positive (p.K602delinsRYEYDLK (18 nucleotides ITD, low-level detected only by NGS): VAF 0.4%)",Negative,,66.0,40.0,5180_3,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,41.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Gilteritinib, Decitabine","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,-1.0,Unknown,68.0,,92.0,,,,0.0,0.0,,16.0,,2.0,,14.0,4.7,,,,,,29.54,19.0,3.0,,,1.05,7.6,,42.0,47.0,927.0,92.7,"dimCD7, partialCD10, CD13, CD33, CD34, CD38,CD117, HLA-DR, TdT"
C395,S568,5185,19-00232,2706.0,BA3125D,,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XY[20]",,BIRC6 (p.S3135C; VAF 52%)|BRCA2 (p.P59A; VAF 48%)|CDKN2C (p.D64N; VAF 51%)|DNAH5 (p.G2668R; VAF 48%)|DNMT3A (p.R882H; VAF 48%)|EFTUD1 (p.S504Y; VAF 49%)|FLT3-ITD (p.E598delinsDYVDFREYE (24-nucleotide ITD); VAR 0.082; VAF 5.2%)|FLT3-ITD (p.P606delinsPFREYEYDLKWEFP (39-nucleotides ITD); VAR 0.51; VAF 32%)|NPM1 (p.W288fs*12; VAF 49%)|NRAS (p.G13D; VAF 17%)|PCLO (p.P1053S; VAF 47%)|TET2 (p.T1980fs*44; VAF 45%),Positive (MAF 14%; AR 0.162790698),Positive (p.W288fs*12; VAF 49%),,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,20.0,"7+3 (Cytarabine, Idarubicin) plus Midostaurin","7+3 (Cytarabine, Idarubicin) plus Midostaurin",Standard Chemotherapy,Induction,20.0,Unknown,31.0,,,75.0,,,0.0,0.0,,11.9,,35.6,,1.7,0.1,,,,,,263.9,83.0,2.5,,,2.26,6.3,,54.0,158.0,3905.0,75.7,"Myloid blast population, about 25%: variable CD13, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and dim MPO | Monoblast population, about 50%: Dim CD9, bright CD11b, variable CD13, CD16, CD33, CD38, CD56, CD64, HLA-DR"
C397,S569,5194,19-00261,2759.0,BA3137D,BA3137R,Male,39.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20] ",,CUX1 (p.V88I; VAF 50%)|NRAS (p.G13D; VAF 6%)|NRAS (p.Q61H ((different allele from p.Q61K); VAF 3%)|NRAS (p.Q61K (different allele from p.Q61H); VAF 18%)|PTPN11 (p.G60R; VAF 3%)|USH2A (p.R2557T; VAF 48%),Negative,Negative,,39.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,7.0,6.0,Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Ruxolitinib|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|HIDAC + Gemtuzumab Ozogamicin|Busulfan, Cyclophosphamide",Ruxolitinib,Standard Chemotherapy,Maintenance,-1.0,Dead,751.0,Dead-Other,36.0,28.0,,,3.4,5.2,,19.8,,38.8,,6.9,0.0,,,,,,20.76,13.0,,,,1.17,7.6,,,,415.0,90.2,"CD13, CD33, CD34, CD38, CD117, HLA-DR, MPO  (the monocytic cells show an aberrant immunophenotype: CD11b, CD13, variable CD14, variable CD15, CD33, CD64, HLA-DR positive)"
C399,S570,5205,19-00290,2595.0,BA3300D,BA3300R,Male,0.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,"Mixed-phenotype acute leukaemia, T/myeloid",,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",,,Unknown,Other,"46,XY,t(3;12)(q29;p13),ins(12;?)(p13;?)[20]",ETV6 is disrupted by the insertion of unidentified material within the locus.  Any fusion partners with the ETV6 rearrangements were not identified in this study. ,FAT4 (p.S2691L; VAF 50%),Negative,Negative,,0.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,5.0,3.0,Induction|Intensification|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,28.0,"Cytarabine|Cytarabine, Mitoxantrone, Gemtuzumab ozogamicin|Cytarabine, Daunorubicin, and Etoposide|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,314.0,Dead-Disease,90.0,92.0,,,0.0,0.9,,13.0,,3.5,,2.6,0.1,,,,,,95.48,90.0,,,,0.21,6.0,,,,,75.1,"cCD3, CD7, CD11b, dim CD13, CD33, CD34, CD56, C117, MPO"
C402,C402,5210,19-00306,,,,Male,84.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Adverse,NotDetected,"46,XY[20]",Normal,FLT3 (p.N676S; VAF 3%)|FLT3 (p.V491L; VAF 17%)|FLT3-ITD (p.E596delinsDYVDFRE; allelic ratio 0.15; VAF 8%)|FLT3-ITD (p.E598delinsDSDNEYFYVDFREYE; allelic ratio 0.06; VAF 4%)|FLT3-ITD (p.Y589delinsTGSSDNEY; allelic ratio 0.02; VAF 2%)|HNRNPK (p.R22fs*13; VAF 5%)|NPM1 (p.W288fs*12; VAF 43%)|RIT1 (p.M107V; VAF 4%)|STAG2 (p.Q1108*; VAF 85%)|TET2 (p.M1522R; VAF 49%)|WT1 (p.R462Q; VAF 4%),Positive (p.E596delinsDYVDFRE: VAF 8%; AR 0.15| p.E598delinsDSDNEYFYVDFREYE: VAF 4%; AR 0.06 | p.Y589delinsTGSSDNEY: VAF 2%; AR 0.02),Positive (p.W288fs*12; VAF 43%),,84.0,0.0,5210_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2.0,2.0,Salvage|Induction,Complete Response,Targeted Therapy - Kinase Inhibitor(s),252.0,Gilteritinib (ASP2215)|Azacitidine,Azacitidine,Standard Chemotherapy,Salvage,82.0,Dead,512.0,Dead-Disease,80.0,50.0,,,0.0,0.0,,49.6,,0.0,,3.5,0.0,,,,,,1.73,12.0,3.1,,,1.27,8.5,,18.0,10.0,163.0,100.8,"CD13, CD33, partial CD34, CD117, variable HLA-DR"
C452,C452,5210,20-00604,,,,Male,84.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,NonInitial,Other,"46,XY,der(15)t(1;15)(q12;p11.1)[12]/46,XY,der(13)t(1;13)(q12;p11.1)[7]/46,XY,der(16)t(13;16)(p11.1;q11.2)t(1;13)(q12;p11.1)[2]/46,X,der(Y)t(Y;1)(q12;q12)[2]",Normal,NPM1 (p.W288fs*12; VAF 30.9%)|NRAS (p.G12D; VAF 27.8%)|PTPN11 (p.G503A; VAF 8.9%)|RIT1 (p.M107V; VAF 40.9%)|STAG2 (p.Q1108*; VAF 53.9%)|TET2 (p.M1522R; VAF 45.8%),Negative,Positive (p.W288fs*12; VAF 30.9%),,85.0,492.0,5210_2,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2.0,2.0,Salvage|Induction,Complete Response,Targeted Therapy - Kinase Inhibitor(s),252.0,Gilteritinib (ASP2215)|Azacitidine,Azacitidine,Standard Chemotherapy,Salvage,82.0,Dead,512.0,Dead-Disease,70.0,25.0,,,0.9,5.6,,52.8,,12.0,,11.1,1.7,,,,,,6.58,58.0,3.7,,,1.7,12.2,,29.0,24.0,1017.0,94.3,"CD4, CD11b, variable CD11c, CD15, CD33, CD38, CD64, and dim MPO"
C401,C401,5212,19-00312,,,,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,,Normal,CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; VAF 48%)|PLCG2 (p.Y206F; VAF 50%),Positive ( p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication): VAF 46%; AR 0.85),Positive (p.W288fs*12; VAF 48%),,63.0,0.0,5212_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,171.0,Dead-Treatment,96.0,85.0,,,0.8,0.8,,9.2,,2.3,,4.6,0.3,,,,,,62.54,30.0,,,,0.64,8.8,,,,476.0,94.1,"dim CD13, CD33, CD117 and MPO-positive"
C404,S571,5212,19-00313,2749.0,BA3375D,BA3375R,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M1,M1,Intermediate,NotDetected,,Normal,CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; VAF 48%)|PLCG2 (p.Y206F; VAF 50%),Positive (MAF 43%; AR 0.754385965),Positive (p.W288fs*12; VAF 48%),,63.0,1.0,5212_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7.0,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,171.0,Dead-Treatment,96.0,85.0,,,0.8,0.8,,9.2,,2.3,,4.6,0.3,,,,,,62.54,30.0,,,,0.64,8.8,,,,476.0,94.1,"dim CD13, CD33, CD117 and MPO-positive"
C403,S616,5213,19-00315,2774.0,BA3249D,BA3249R,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,KMT2A_re,,,,Negative,Negative,,28.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C405,C405,5216,19-00319,,,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,29.0,0.0,,Unknown,Unknown,,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C406,S572,5218,19-00327,2594.0,BA3385D,BA3385R,Female,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%),Positive (MAF 33%; AR 0.492537313),Positive (p.W288fs*12; VAF 44%),,50.0,0.0,5218_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,264.0,Dead-Disease,88.0,,,,0.0,0.0,,23.5,,48.7,,9.5,0.1,,,,,,31.8,29.0,2.9,,,0.65,6.8,,20.0,14.0,409.0,97.2,"Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR"
C407,C407,5218,19-00328,,,,Female,50.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XX[20]",Normal,DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%),Positive (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); AR 0.79; VAF 44%),Positive (p.W288fs*12; VAF 44%),,50.0,0.0,5218_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,264.0,Dead-Disease,88.0,,,,0.0,0.0,,23.5,,48.7,,9.5,0.1,,,,,,31.8,29.0,2.9,,,0.65,6.8,,20.0,14.0,409.0,97.2,"Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR"
C411,S573,5235,19-00369,2607.0,BA3416D,BA3416R,Male,54.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Favorable,Other,"46,XY[20]",RUNX1:  17/200 (8.5%) interphase cells had three RUNX1 (21q22) signals. There was no evidence for RUNX1T1/RUNX1 fusion.,CBL (p.Q490E; VAF 52%)|CEBPA (p.K304_T318dup; VAF at least 70%)|CHD2 (p.R1354K; VAF 49%)|DOCK8 (p.E766K; VAF 46%)|FAT1 (p.E38K; VAF 49%)|GATA2 (p.R307L; VAF 41%)|RUNX1 (p.I366_G367dup; VAF 46%),Negative,Negative,mono,54.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,3.0,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)","FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Standard Chemotherapy,Induction,3.0,Dead,24.0,Dead-Disease,92.0,85.0,,,0.0,0.0,,33.3,,2.6,,0.0,0.0,,,,,,4.67,8.0,,,,1.75,7.8,,,,528.0,89.5,"Partial immunophenotype: CD33, cCD79a, CD117, HLA-DR, and cMPO"
C451,C451,5240,20-00598,,,,Female,63.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XX,del(20)(q11.2q13.1)[20]","Performed with X and Y chromosome probes, as listed below.  97% of cells were XX, recipient, patient cells.  3% of cells were XY male donor.",ATM (p.C532Y; VAF 1.9%)|FAT1 (p.D3797G; VAF 1.1%)|FAT1 (p.R2755T; VAF 46.3%)|GATA2 (p.T387_G392del; VAF 47.5%)|JAK2 (p.V617F; VAF 96.8%)|KMT2A (p.D3946N; VAF 47.1%)|PTCH1 (p.P1383L; VAF 0.9%)|PTPN11 (p.A72T; VAF 45.5%)|RYR1 (p.V1783_E1793del; VAF 44.4%)|U2AF1 (p.Q157R; VAF 50.9%)|USH2A (p.K5185M; VAF 1.6%),Negative,Negative,,64.0,436.0,,Relapse,Relapse,Relapse|Post-Chemotherapy|Post-Transplant,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,22.0,"Fludarabine, Melphalan|Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)|Venetoclax (ABT-199), Azacitidine|Decitabine, Venetoclax","Decitabine, Venetoclax",Standard Chemotherapy,Salvage,63.0,Dead,571.0,Dead-Disease,17.0,12.5,,,0.0,0.0,,5.2,,11.3,,67.0,0.1,,,,,,64.49,34.0,2.9,,,0.99,6.7,,18.0,16.0,677.0,87.0,"CD9, dim CD11b, CD33, CD34, CD38, variable CD56, dim CD117 "
C413,C413,5253,19-00406,,,,Female,58.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,Unknown,,,,,,,,58.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C415,S575,5255,19-00418,2712.0,BA3088D,,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M2,M2,Favorable,Other,"46,XY,del(20)(q11.2q13.3)[19]/46,XY[1]","81% of cells were missing a signal for 20q12 but had two signals for 20q telomere, consistent with interstitial deletion.",ASXL1 (p.C872*; VAF 1%)|CEBPA (p.F31fs*131; VAF 8%)|CEBPA (p.N321D; VAF 10%)|CEBPA (p.P23fs*137; VAF 39%)|CEBPA (p.T310_Q311insLDPAQ; VAF 33%)|IRF4 (p.H441L; VAF 50%)|RUNX1 (p.L98fs*24; VAF 49%)|SRSF2 (p.P95H; VAF 49%)|STAG2 (Splice site; VAF 90%),Negative,Negative,bi,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,5.0,4.0,Consolidation|Induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5.0,"Ruxolitinib|Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo|Busulfan, Cyclophosphamide",Ruxolitinib,Standard Chemotherapy,Maintenance,25.0,Alive,725.0,Alive,35.0,25.0,,,0.0,0.0,,39.3,,0.9,,32.7,14.9,,,,,,5.18,39.0,2.4,,,0.75,7.1,,54.0,26.0,267.0,80.6,"CD7, CD11b, CD13, CD33, CD34, CD38, CD117, HLA-DR, partial TdT and MPO+"
C414,S617,5256,19-00393,2795.0,BA3309D,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,,Positive (MAF 49%; AR 0.960784314),Positive,,,0.0,,Unknown,Unknown,,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C416,S618,5260,19-00428,2791.0,BA3129D,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,,,,,Positive (MAF 17%; AR 0.204819277),Positive,,,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,122.41,,,,,,,,,,,,
C418,S576,5261,19-00431,2800.0,BA3284D,,Male,56.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XY[20]",,BLM (p.D1010fs*24; VAF 51%)|FLT3 (p.N676T; VAF 7%)|FLT3 (p.N841I; VAF 5%)|FLT3-D835 (p.D835H; VAF 7%)|FLT3-D835 (p.D835Y; VAF 6%)|NBN (p.L421S; VAF 48%)|NPM1 (p.W288fs*12; VAF 47%)|PTPN11 (p.E76Q; VAF 5%)|STAG2 (p.I1063fs*10; VAF 64%),Negative,Positive (p.W288fs*12; VAF 47%),,56.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,0.0,,68.0,55.0,,,0.0,0.0,,69.0,,0.9,,3.5,0.5,,,,,,8.39,23.0,3.6,,,1.09,8.1,,22.0,23.0,496.0,94.0,"CD7, CD13, bright CD33, partial CD34, CD38, CD117, dim HLA-DR+, dim MPO"
C419,S577,5262,19-00433,2722.0,BA3111D,,Female,4.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with minimal differentiation,Myeloid proliferations associated with Down syndrome,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,M0,M0,Intermediate,,,,EFTUD1 (p.P545A; VAF 47%)|FAM47A (p.P545L; VAF 48%)|GATA1 (p.V32fs*7; VAF 39%)|JAK2 (p.V617F; VAF 40%)|MSH6 (p.D217G; VAF 48%)|SUZ12 (Splice site; VAF 38%),Negative,Negative,,4.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,4.0,2.0,Salvage|Induction,Complete Response,Standard Chemotherapy,10.0,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|COG-AAML0431 (IT/IV Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Thioguanine)","FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Standard Chemotherapy,Salvage,4.0,Dead,239.0,Dead-Disease,,80.0,,,0.0,0.9,,14.6,,1.8,,32.7,0.2,,,,,,20.03,71.0,,,,0.4,6.3,,,,,89.1,"CD7, CD11b, CD33, CD38, partial CD117 positive"
C585,S579,5275,19-00465,2750.0,BA3100D,,Male,57.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XY[20]",Normal,ARID1B (p.G1483S; VAF 51%)|ATM (p.M3011V; VAF 49%)|DNMT1 (p.V1072I; VAF 48%)|DNMT3A (p.R882H; VAF 44%)|KMT2C (p.R3403C; VAF 50%)|MYD88 (p.A6fs*39; VAF 49%)|NBN (p.V210F; VAF 49%)|NPM1 (p.W288fs*12; VAF 62%)|NRAS (p.G12D; VAF 20%)|TET2 (p.R1359C; VAF 43%),Negative,Positive (p.W288fs*12; VAF 62%),,57.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4.0,"Fludarabine, Melphalan|HiDAC|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Dead,597.0,Dead-Treatment,40.0,29.0,,,0.9,0.0,,22.6,,5.2,,58.2,0.3,,,,,,16.71,142.0,3.7,,,1.14,9.1,,27.0,26.0,412.0,105.2,"CD13, CD33, CD117, and HLA-DR"
C586,C586,5291,19-00495,,,,Female,23.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11p15; NUP98 rearrangement,Acute monocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Adverse,NUP98_re,"46,XX[20]",NUP98:  77/100 cells (77%) had the abnormal signal pattern reflecting NUP98 rearrangement,,Negative,,,23.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,2.0,Dead-Disease,,75.0,,,0.9,0.9,,12.4,,0.0,,14.2,0.6,,,,,,75.78,62.0,2.5,,,0.55,11.0,,16.0,39.0,1628.0,91.1,"dim CD4, CD11b, partial CD13, variable CD14, dim CD15, CD33,  CD38, CD56, CD64, CD103, HLA-DR, MPO positive"
C421,C421,5317,20-00016,,,,Female,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Favorable,NotDetected,"46,XX[20]",Normal (AML probe panel plus TP53 and chromosome 20.),DNMT3A (p.R882C; VAF 45%)|FOXO1 (p.A511S; VAF 51%)|JAK3 (p.R180Q; VAF 48%)|KLF2 (p.R142H; VAF 51%)|MECOM (p.I847F; VAF 50%)|NPM1 (p.W290fs*10; VAF 42%)|PDGFRA (p.N103H; VAF 39%)|TET2 (p.P1725fs*4; VAf 33%),Negative,Positive (p.W290fs*10; VAF 42%),,42.0,0.0,5317_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,110.0,Alive,1548.0,Alive,32.0,16.0,,,6.8,0.0,,24.6,,4.2,,47.5,7.3,,,,,,14.34,115.0,,,,,10.5,,,,,95.3,"dimCD13, bright CD33, partial CD34, CD38, CD117, and dim MPO"
C436,C436,5317,20-00311,,,,Female,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,NonInitial,NotDetected,"46,XX[20]",Normal (AML probe panel plus TP53 and chromosome 20.),DNMT3A (p.R882C; VAF 37.9%)|FOXO1 (p.A511S; VAF 49.5%)|JAK3 (p.R180Q; VAF 50.3%)|KLF2 (p.R142H; VAF 51.0%)|MECOM (p.I847F; VAF 50.3%)|PDGFRA (p.N103H; VAF 1.0%),Negative,Negative,,42.0,197.0,5317_2,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,110.0,Alive,1548.0,Alive,2.0,0.0,,,3.4,1.7,,19.8,,17.2,,57.8,0.0,,,,,,2.7,212.0,3.6,,,0.5,10.4,,43.0,18.0,,92.4,
C423,C423,5326,20-00041,,,,Female,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XX[20]",,CEBPA (p.Q312delinsLL; VAF 44.0%)|CEBPA (p.Q83fs*77; VAF 39.2%)|JAK3 (p.K563_C565del; VAF 3.0%)|ZRSR2 (p.S447_R448del; VAF 47.2%),Negative,Negative,,49.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC",HiDAC,Standard Chemotherapy,Consolidation,-1.0,Alive,196.0,Alive,90.0,85.0,,,0.0,1.6,,7.4,,2.5,,2.5,4.2,,,,,,33.18,21.0,3.5,,,0.58,9.2,,24.0,31.0,,91.8,"Partial CD7, dim CD13, partial CD15, CD33, dim CD34, CD38, partial CD56, CD117, variable HLA-DR, MPO positive"
C424,C424,5332,20-00062,,,,Female,58.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,,,NonInitial,NotDetected,"46,XX[20]",Normal,CCND3 (p.I94_H95del; VAF 20%)|DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (Allelic ratio: 0.87; VAF 46.49%)|NPM1 (p.W288fs*12; VAF 24%)|PLCG2 (p.T26M; VAF 51%)|RIT1 (p.M107I; VAF 46%)|SETD2 (p.Q1734H; VAF 48%),Positive (VAF 46.49%; AR 0.87),Positive (p.W288fs*12; VAF 24%),,59.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,6.0,"HiDAC + Midostaurin|Cytarabine|Gilteritinib (ASP2215)|Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Midostaurin",Gilteritinib (ASP2215),Targeted Therapy - Other,Salvage,10.0,Dead,502.0,Dead-Disease,,,,,0.0,0.0,,7.0,,1.0,,6.0,0.0,,,,,,31.12,41.0,2.0,,,0.69,8.8,,13.0,12.0,311.0,98.9,"CD13, CD33, CD117, variable CD34, CD11b, CD25, variable CD38, CD123, variable CD103, dim HLA-DR, and partial cMPO"
C426,C426,5344,20-00079,,,,Male,41.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,"Mixed-phenotype acute leukaemia, T/myeloid",,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",,,Unknown,NotDetected,,Normal,GATA3 (p.A173fs*24; VAF 44.5%)|GATA3 (p.Y290C; VAF 45.3%)|JAK1 (p.F734S; VAF 42.0%)|NOTCH1 (p.V2443fs*35; VAF 47.3%)|NRAS (p.G12D; VAF 15.0%)|USH2A (p.P3688S; VAF 49.5%),Negative,Negative,,41.0,0.0,5344_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Induction,Complete Response,Standard Chemotherapy,156.0,"Nelarabine|HAM (Cytarabine, Mitoxantrone)|HyperCVAD","HAM (Cytarabine, Mitoxantrone)",Standard Chemotherapy,Salvage,-1.0,Dead,410.0,Dead-Disease,93.0,,,,0.0,0.0,,10.8,,11.7,,14.4,0.0,,,,,,61.72,29.0,,,,,11.1,,,,,93.3,"T lymphoblasts: CD2, cCD3, CD7, dimCD10, CD25, partial CD34, CD38, dimCD56, variable CD117 | Myeloid blasts:  dimCD4, dimCD10, CD11b, CD13, CD14, CD15, CD16, CD33, variable CD117, CD38, dimCD56, CD64, cMPO, and dimTDT"
C468,C468,5344,21-00027,,,,Male,41.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,"Mixed-phenotype acute leukaemia, T/myeloid",,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",,,NonInitial,Other,"46,XY,del(9)(p12)[18]/46,idem,t(5;8)(q31;q21)[2]",Normal,,,,,41.0,323.0,5344_2,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Induction,Complete Response,Standard Chemotherapy,156.0,"Nelarabine|HAM (Cytarabine, Mitoxantrone)|HyperCVAD","HAM (Cytarabine, Mitoxantrone)",Standard Chemotherapy,Salvage,-1.0,Dead,410.0,Dead-Disease,,94.0,,,0.0,0.0,,12.7,,0.7,,4.5,0.0,,,,,,173.26,19.0,2.9,,,0.6,5.1,,86.0,82.0,1536.0,104.3,"T-lymphoblast population (90%) with immunophenotype: CD2, cCD3, CD7, CD25, partial CD34, CD38, and dim CD56 positive | Myeloid blast population (4%) with immunophenotype: dim CD10, CD11b, dim CD11c, CD13, CD14, CD15, CD16, CD33, CD38, dim CD56, dim CD64, cTDT, and cMPO positive"
C425,C425,5345,20-00083,,,,Female,45.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"46,XX,t(1;1)(p22;q21),del(7)(q22),del(16)(q22)[20]","D7S486 (7q31):  97% of cells were missing a signal, consistent with 7q deletion | CBFB (16q22):  92.5% of cells were missing a signal, consistent with 16q deletion",BCOR (Splice site; VAF 48% (low depth))|FAT4 (p.R1169W; VAF 50%)|FAT4 (p.V1834G; VAF 49%)|NRAS (p.G12V; VAF 9%)|NRAS (p.G13D; VAF 23%)|NRAS (p.G13V; VAF 10%)|SPEN (p.A2653T; VAF 51%),Negative,Negative,,45.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,6.0,Dead,14.0,Dead-Treatment,72.0,86.0,,,0.0,0.9,,15.0,,0.9,,3.5,0.0,,,,,,80.09,184.0,2.6,,,0.5,10.8,,18.0,19.0,,98.7,"CD7, CD9, variable CD11b, CD13, variable CD15, CD33, CD34, CD38, dim CD56, CD117, HLA-DR"
C427,C427,5348,20-00143,,,,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,NotDetected,"46,XX[20]",Normal,"DNMT3A (p.R882C; VAF 45%)|FLT3 (p.H564Y; VAF 10%)|FLT3 (p.N676S; VAF 7%)|FLT3-ITD (2 variants, 24- and 81-bp ITDs; (Combined) 23%, 0.30 (AR))|IDH1 (p.R132H; VAF 3%)|NPAT (p.T688M; VAF 50%)|NPM1 (p.W288fs*12; VAF 43%)","Positive (2 variants, 24- and 81-bp ITDs; (Combined) AR 0.30; VAF 23%)",Positive (p.W288fs*12; VAF 43%),,72.0,0.0,5348_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4.0,5.0,Consolidation|Salvage|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,17.0,"MIDAC, Midostaurin|Gilteritinib (ASP2215)|Rituximab|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin",Rituximab,Targeted Therapy - Other,Maintenance,4.0,Alive,332.0,Alive,51.0,,,,0.0,0.0,0.0,31.0,,21.6,,43.1,0.0,,,,4.3,,17.29,133.0,3.2,,0.2,1.24,8.6,,16.0,16.0,,95.2,"myeloid blasts: dim CD7, CD13, CD33, partial CD34, CD38, CD117,  HLA-DR and dim MPO+ | monocytic cell population: dim CD9, CD13, CD14, CD33, CD64 and HLA-DR+."
C443,C443,5348,20-00424,,,,Female,72.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,NotDetected,"46,XX[20]",Normal,"DNMT3A (p.R882C; VAF 45%)|FLT3-ITD (54 bp(AR 0.15), 69 bp(AR 0.028), 72 bp(AR 0.07), 84 bp(AR 1.76))|NPAT (p.T688M; VAF 43%)|NPM1 (p.W288fs*12; VAF 32%)","Positive (54 bp(AR 0.15), 69 bp(AR 0.028), 72 bp(AR 0.07), 84 bp(AR 1.76))",Positive (p.W288fs*12; VAF 32%),,72.0,213.0,5348_2,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4.0,5.0,Consolidation|Salvage|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,17.0,"MIDAC, Midostaurin|Gilteritinib (ASP2215)|Rituximab|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin",Rituximab,Targeted Therapy - Other,Maintenance,4.0,Alive,332.0,Alive,,,,,0.0,0.0,0.0,10.3,,1.9,,0.9,0.1,,,,,,82.06,74.0,2.8,,0.2,0.91,9.6,,18.0,34.0,719.0,99.0,"CD13, CD33, variable CD34, CD117, and HLA-DR positive"
C428,C428,5364,20-00171,,,,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,NotDetected,"46,XX[19]",Normal,ATM (p.T2853M; VAF 55.1%)|CBLC (p.P49S; VAF 47.3%)|CHEK2 (p.N105Y; VAF 45.1%)|DNMT3A (p.F732del; VAF 34.3%)|DNMT3A (p.S764fs*12; VAF 39.9%)|DOCK8 (p.S606N; VAF 51.0%)|IDH1 (p.R132G; VAF 44.4%)|IKZF1 (p.R69H; VAF 51.3%)|PCLO (p.D2090V; VAF 48.0%)|PMS2 (p.L56V; VAF 43.2%)|PRDM1 (p.N259S; VAF 49.9%)|RTEL1 (p.P996H; VAF 48.8%)|XPO1 (p.N735Y; VAF 44.9%),Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,-1.0,Dead,387.0,Dead-Disease,65.0,46.0,,,0.0,0.0,,34.8,,11.6,,11.6,0.5,,,,,,12.34,149.0,2.5,,,1.05,8.9,,15.0,25.0,409.0,93.9,"Myeloid blast immunophenotype (35%): CD13, dim CD14, CD33, CD34, CD38, CD117, variable HLA-DR and MPO positive | Monocytic cell immunophenotype: CD11b, CD13, partial CD14, CD15, variable CD16, CD33, CD38, partial CD56, partial HLA-DR, MPO positive"
C434,C434,5450,20-00273,,,,Male,71.0,1.0,ANCA vasculitis,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Adverse,RARA_re,"45,XY,t(1;1)(p34.1;q44),del(5)(q13q35),der(7)t(7;17)(q22;q11.2),-17,add(17)(q21),del(20)(q11.2q13.1),+1~2mar[cp18]/46,idem,+8[cp4] ","EGR-1/ 5q33/  5p15:  84/100 cells (84%) had a 1 red/ 1 green/ 2 aqua signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype. | D7S486/ CEP 7:  94/100 cells (94%) had a 1 red/ 2 green signal pattern, indicating a deleted 7q, consistent with the metaphase karyotype. | RUNX1T1:  33/200 cells (16.5%) had 3 RUNX1T1 (8q21.3) signals, consistent with the trisomy 8 sideline observed in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1fusion | RARA:  47/200 cells (23.5%) had a single RARA (17q21) signal, consistent with the loss of 17q from the add(17)(q21) observed in the metaphase karyotype.  There was no evidence for PML/RARA fusion. | MECOM:  49/200 cells (24.5%) had an amplified MECOM (3q26,2) signal pattern.  By metaphase FISH, the amplified regions appear to be on a least five different chromosome regions and may include one or more markers.",FAT4 (p.A4009V; VAF 41.9%)|IDH2 (p.R140Q; VAF 47.7%)|PLCG1 (p.R830Q; VAF 54.3%)|SETD2 (p.E965del; VAF 40.4%)|SRSF2 (p.P95L; VAF 45.4%)|TERT (p.T1111M; VAF 51.0%)|TP53 (p.R213*; VAF 66.4%),Negative,Negative,,71.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,18.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,18.0,Dead,41.0,Dead-Disease,41.0,24.0,,,0.0,3.6,,79.1,,1.8,,6.4,1.8,,,,,,4.47,26.0,3.0,,,1.05,8.6,,55.0,25.0,1258.0,91.2,"partial CD7, CD13, CD33, CD34, CD38, CD117, HLA-DR, and dimMPO"
C433,C433,5452,20-00275,,,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,84.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C429,C429,5453,20-00259,,,,Male,57.0,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46, XY[20]",,DNMT3A (Splice site; VAF 43.1%)|GATA3 (p.R275Q; VAF 18.1%)|NF1 (p.E163*; VAF 7.7%)|NRAS (p.Q61R; VAF 28.0%)|RUNX1 (p.T196R; VAF 47.6%)|SF3B1 (p.K666N; VAF 43.8%)|SPEN (p.A2615V; VAF 46.7%),Negative,Negative,,57.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,52.0,,,30.0,,,0.8,0.0,,5.0,,24.8,,43.8,0.4,,,,,,48.99,163.0,3.2,,,0.57,11.3,,36.0,67.0,295.0,116.8,"Myeloid blast immunophenotype: CD13, CD25, CD33, CD34, CD38, CD117, and HLA-DR | Monocyte immunophenotype: dim CD4, partial CD9, CD11b, CD13, CD14, CD33, CD38, CD64, HLA-DR, dim MPO"
C430,C430,5454,20-00260,,,,Female,77.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute myelomonocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Intermediate,NotDetected,"46,XX[13]",,BCORL1 (p.T1516fs*11; VAF 15.5%)|CBL (p.C384Y; VAF 80.4%)|CBL (p.P417S; VAF 4.4%)|ERBB4 (p.R393W; VAF 2.8%)|JAK2 (p.V617F; VAF 2%)|KMT2D (p.D4530N; VAF 50.3%)|SPI1 (p.I215_G218del; VAF 8.3%)|SPI1 (p.R171H; VAF 6.6%)|TET2 (p.G1408*; VAF 42.4%)|TET2 (p.Q1524*; VAF 44.9%)|USH2A (p.L105F; VAF 48.6%),Negative,Negative,,77.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,7.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,7.0,Dead,51.0,Dead-Disease,,40.0,,,0.0,0.9,,10.5,,26.3,,27.2,1.4,,,,,,82.03,32.0,3.0,,,1.07,11.0,,126.0,163.0,2757.0,93.9,"dim CD4, variable dim CD9, CD11b, CD13, CD14, partial CD15, partial CD16, CD33, partial CD38, CD56, CD64, HLA-DR, and MPO "
C431,C431,5455,20-00266,,,,Male,18.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(6;9)(p23;q34); DEK::NUP214 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,M2,M2,Adverse,DEK-NUP214,"46,XY,t(6;9)(p22;q34)[20] ",,FAT4 (p.A2487E; VAF 48%)|FLT3-ITD (allelic ratio 1.80; VAF 64% (2 separate ITDs detected; 24 nucleotides and 72 nucleotides in length))|MGA (p.E1345*; VAF 43%),Positive (2 separate ITDs detected: 24 nucleotides and 72 nucleotides in length; AR 1.80; VAF 64% ),Negative,,18.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Daunorubicin) plus Midostaurin","Fludarabine, Melphalan",Standard Chemotherapy,Re-induction,6.0,Alive,991.0,Alive,65.0,58.0,,,1.8,0.0,,7.1,,2.7,,33.6,0.3,,,,,,52.37,56.0,3.8,,,0.86,7.5,,20.0,24.0,594.0,97.0,"CD13, CD33, variable CD34, CD38, CD117, and HLA-DR"
C432,C432,5456,20-00270,,,,Male,30.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",CBFB/MYH11:  96% of cells had an atypical 1r1g1f single fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16),ARID1A (p.P234A; VAF 55%)|NOTCH1 (p.V2229M; VAF 50%)|TERT (p.R669Q; VAF 66%),Negative,Negative,,30.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|HIDAC + Gemtuzumab Ozogamicin",HIDAC + Gemtuzumab Ozogamicin,Standard Chemotherapy,Consolidation,46.0,Alive,181.0,Alive,70.0,76.0,,,0.0,0.0,,20.2,,47.4,,3.5,0.0,,,,,,45.78,30.0,3.7,,,1.01,11.3,,45.0,25.0,,88.5,"Myeloid blasts (36%): CD13, CD33, CD34, CD117, HLA-DR positive | Monocytes/promonocytes (40%): dim CD4, CD13, CD14, variable CD16, CD33, CD64, HLA-DR positive"
C496,C496,5459,21-00683,,,,Female,62.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",M1,M1,Adverse,NotDetected,"46,XX[20]",Normal,ASXL1 (p.E635fs*15; VAF 46.9%)|BIRC6 (p.H2750Y; VAF 49.6%)|FAM5C (p.E480Q; VAF 5%)|FLT3-ITD (allelic ratio 0.55)|IDH1 (p.R132G; VAF 37.5%)|PHF6 (p.Y313*; VAF 45.6%)|SF3B1 (p.K866R; VAF 36.1%)|STAG2 (Splice site; VAF 8.1%),Positive (allelic ratio 0.55; VAF 38.5%),Negative,,62.0,448.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,4.0,Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,20.0,"Vyxeos (Daunorubicin, Cytarabine - liposomal), Midostaurin|HAM (Cytarabine, Mitoxantrone)|Venetoclax (ABT-199), Azacitidine|Venetoclax, Gilteritinib","HAM (Cytarabine, Mitoxantrone)",Standard Chemotherapy,Salvage,5.0,Dead,90.0,Dead-Treatment,58.0,,,,0.0,0.0,,22.0,,3.7,,3.7,4.7,,,,,,10.74,9.0,2.9,,,0.61,7.3,,14.0,20.0,421.0,90.0,"dim CD13, CD33, dim/partial CD34, CD117, and HLA-DR"
C437,C437,5474,20-00318,,,,Female,53.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,,"CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion. ",NRAS (p.G12A; VAF 92.0%)|SRSF2 (p.P95_R117del; VAF 18.6%),Negative,Negative,,53.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|5+2 (Ara-C, Daunorubicin)|Venetoclax, LDAC (low-dose Cytarabine)","Venetoclax, LDAC (low-dose Cytarabine)",Standard Chemotherapy,Consolidation,98.0,Alive,270.0,Alive,,57.0,,,0.0,0.0,,9.1,,54.5,,3.9,0.2,,,,,,69.54,26.0,3.1,,,2.37,7.3,,43.0,34.0,774.0,93.0,"Myeloid blasts immunophenotype: CD9, dim CD11b, CD13, variable CD15, CD33, CD34, CD38, CD56, CD117, variable HLA-DR, cMPO | Monocytic population immunophenotype: dim CD2, CD9, CD11b, CD11c, CD13, CD14, variable CD15, CD16, partial/dim CD23, CD33, CD38, CD56, CD64, HLA-DR, and cMPO"
C438,C438,5482,20-00330,,,,Male,76.0,1.0,Prostate Cancer,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Adverse,,Not done,,,,,,77.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,3.0,2.0,Salvage|Induction,Complete Response i,Standard Chemotherapy,244.0,"Gilteritinib (ASP2215)|Gilteritinib, Decitabine, Venetoclax|Venetoclax (ABT-199), Azacitidine","Gilteritinib, Decitabine, Venetoclax",Standard Chemotherapy,Salvage,-1.0,Dead,1024.0,Dead-Disease,,,,,0.0,0.9,,17.2,,39.7,,2.6,,,,,,,,,2.6,,,0.7,,,37.0,18.0,361.0,,
C439,C439,5486,20-00349,,,,Female,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,Other,"47,XX,+8[18]/46,XX[2]","RUNX1T1:  163/200 cells (81.5%) had three RUNX1T1 (8q21.3) signals, reflecting the trisomy 8 observed in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1 fusion. ",DNMT3A (p.R882H; VAF 43.7%)|IDH2 (p.R172K; VAF 48.1%)|KMT2D (p.I5232V; VAF 44.4%)|SETDB1 (p.E992D; VAF 47.9%)|SMC1A (p.N34K; VAF 46.1%)|STXBP2 (p.A102T; VAF 46.9%)|TP53 (p.R333H; VAF 50.1%),Negative,Negative,,56.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,267.0,Alive,85.0,30.0,,,0.0,0.0,,61.2,,11.2,,5.2,0.0,,,,,,1.56,34.0,2.1,,,0.64,7.1,,45.0,44.0,222.0,101.0,"dim/partial CD9, CD11c, CD13, partial CD15, CD33, variable CD34, CD38, dim/partial CD64, CD117, variable HLA-DR and cMPO positive"
C590,C590,5489,20-00363,,,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,Unknown,,,,,,,,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,78.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD13 (dim), CD33, partial CD34 (60%) , CD38, dim CD45, CD117, HLA-DR, MPO, partial CD7 (24%), CD11b, CD64, CD123"
C440,C440,5490,20-00365,,,,Female,73.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,Other,"44,XX,-3,del(5)(q13q35),der(7)add(7)(p12)add(7)(q32),-12,-15,del(17)(p12p13),del(20)(q11.2q13.3),+mar[6]/43,sl,-8,-9,+15[10]/44~46,sdl1,+4,+mar[cp2]/46,XX[2] ","GATA2 (3q21):  88/200 cells (44%) had a single signal, reflecting the monosomy 3 observed in the metaphase karyotype.  However, one MECOM (3q26.2) signal was present on the marker. There was no evidence for GATA2/MECOM fusion. | EGR-1/ 5q33/ 5p15:  58/100 cells (58%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q31, consistent with the deleted 5q in the metaphase karyotype.  One distal 5q33 signal was present on the derivative chromosome 7q.  | RUNX1T1 (8q21.3):  84/200 cells (42%) had a single signal, reflecting the monosomy 8 observed in the two sidelines.  There was no evidence for RUNX1T1/RUNX1 fusion. | ABL1/ASS (9q34):  75/200 cells (37.5%) had a single signal for both probes, reflecting the monosomy 9 observed in the two sidelines.  There was no evidence for BCR/ABL fusion. | NUP214 (9q34):  92/200 cells (46%) had a single signal, reflecting the monosomy 9 observed in the two sidelines.  There was no evidence for DEK/NUP214 fusion. | PML (15q24):  67/200 cells (33.5%) had three signals, reflecting the extra 15q24 material attached to the derivative chromosome 7q.  There was no evidence for PML/RARA fusion.",,Negative,Negative,,73.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,2.0,2.0,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,76.0,"Decitabine, TP-0903 (AXL kinase inhibitor)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)","Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,625.0,Alive,80.0,2.0,,,0.9,5.4,,27.9,,11.7,,47.7,2.4,,,,,,4.15,22.0,2.4,,,0.67,8.7,,89.0,89.0,412.0,95.3,"positive for dim CD4, CD11b, CD15, CD33, MPO (subset) and HLA-DR"
C591,C591,5494,20-00376,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,,2.0,5494_1,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C453,C453,5494,20-00624,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,,90.0,5494_2,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C441,C441,5497,20-00383,,,,Male,74.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NotDetected,"46,XY[20]",Normal,ASXL1 (p.R693*; VAF 2.8%)|BIRC6 (p.M2919T; VAF 46.9%)|DNMT3A (p.V546fs*105; VAF 48.7%)|KMT2A (Detected)|KMT2D (p.M1660V; VAF 47.0%)|NRAS (p.Q61K; VAF 7.4%)|RAD21 (p.A544V; VAF 48.3%)|TET2 (p.E885fs*36; VAF 85.3%)|U2AF1 (p.S34F; VAF 43.8%),Negative,Negative,,74.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,7.0,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC",Azacitidine,Standard Chemotherapy,Maintenance,71.0,Dead,294.0,Dead-Disease,,,,,0.0,0.9,,37.4,,40.9,,0.0,0.3,,,,,,19.55,53.0,2.0,,,2.2,10.3,,35.0,63.0,1746.0,95.9,"CD4, dim CD7, CD56, CD13, CD33, CD64, HLA-DR, dim CD14, CD15, CD11b, CD38, CD11c, CD9, and TdT positive"
C442,C442,5507,20-00412,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,,7.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C444,C444,5521,20-00436,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,Acute monocytic leukaemia,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,M5,M5,Unknown,NotDetected,"46, XX[20]",Normal,FLT3-D835,,,,,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,44.0,41.0,,,,,,,,,,,,,,,,,247.58,45.0,,,,,,,,,,,"subset CD7 (5-10%+), partial CD13 (40%+), partial CD33, CD34, CD38, dim CD45, CD117, CD123,  HLA-DR, MPO "
C446,C446,5524,20-00442,,,,Male,0.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,Adverse,KMT2A_re,"46,XY,t(11;10;2)(q23;p11.2;p11.2),t(8;13)(q24;q22)[9]/45,idem,der(8)t(8;13)(q24;q22),der(12)t(12;13)(p12;q22)t(8;13)(q24;q22),-13[10]/46,XY[1]","MLL (11q23): 93% of cells had a 1r2f signal pattern, consistent with rearrangement.  Visualization on available metaphase cells showed one normal fusion signal on the normal chromosome 11, one normal fusion signal on chromosome 10p, and a red (proximal) signal on the der(11) that had 2p material on  | ETV6 (12p13): 38.5% of cells were missing a signal, consistent with deletion due to t(12;13). | MYC (8q24):  Two abnormal, banded metaphase cells were hybridized with the MYC probe.  In one cell, the distal MYC signal was on the der(13); in the other cell, the distal MYC signal was on the der(12).  These results are most consistent with stepwise process where the der(13) of the initial t(8;13) | BCR (22q11.2): 5.5% of cells had an extra signal - chromosomal context unknown. | RUNX1T1 (8q21.3): 11% of cells had an extra signal - chromosomal context unknown",ASXL1 (p.R549H; VAF 51.1%)|BRCA2 (p.T3033fs*11; VAF 43.6%)|CBL (p.Q367_Y371del; VAF 38.6%)|DNAH5 (p.I3135T; VAF 54.7%)|RYR1 (p.Q4108H; VAF 49.1%),Negative,Negative,,0.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Induction|Re-induction,Refractory,Standard Chemotherapy,49.0,"COG-AAML1831 (Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Vyxeos (Daunorubicin, Cytarabine - liposomal)","Vyxeos (Daunorubicin, Cytarabine - liposomal)",Standard Chemotherapy,Re-induction,12.0,Dead,162.0,Dead-Disease,,79.0,,,0.0,1.0,,40.6,,7.9,,3.0,0.0,,,,,,19.32,106.0,,,,0.24,7.1,,,,505.0,87.8,"dim CD4, dim CD7,  CD9, variable CD11b, variable CD11c, dimCD13, dimCD14, variable CD15, CD33, CD34,  CD38, dimCD56, variable CD64, dimCD123, HLA-DR, and dim MPO positive"
C447,C447,5528,20-00450,,,,Female,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Intermediate,Other,"46,XX,del(9)(q13q22)[10]/46,XX[10]",Normal,DNMT3A (p.R882C; VAF 43.6%)|FLT3 (p.D835Y; VAF 10.3%)|FLT3-ITD (<1% VAF; 0.01 allelic ratio)|HNRNPK (p.M27fs*8; VAF 31.7%)|KMT2C (p.A311S; VAF 5.1%)|KMT2C (p.E640K; VAF 51.3%)|NPM1 (p.W288fs*12; VAF 61.5%)|PCLO (p.E1277D; VAF 47.5%)|PDGFRA (p.V167M; VAF 50.0%)|PTPN11 (p.D61H; VAF 30.3%)|USH2A (p.Q895fs*6; VAF 3.3%),Positive (AR 0.01; <1% VAF),Positive (p.W288fs*12; VAF 61.5%),,31.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,20.0,"HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1238.0,Alive,90.0,,,,0.4,0.9,,29.3,,42.2,,16.4,0.0,,,,,,46.56,90.0,3.5,,,1.1,7.9,,18.0,14.0,385.0,98.0,"dimCD4, variable CD9,  bright CD11b,  CD11cvariable CD13, variable CD14, bright, dimCD15, CD33, CD38, dimCD56, CD64, dimCD123, HLA-DR, dimMPO"
C445,C445,5531,20-00465,,,,Male,60.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M2,M2,Intermediate,Other,,"RUNX1 (21q22): 4.5% of cells had three signals, just above cutoff (2%); chromosomal context unknown.",DNMT3A (p.Q374P; VAF 44.0%)|DNMT3A (p.T834I; VAF 54.1%)|FLT3-ITD (allele ratio 0.36)|NOTCH1 (p.G2126R; VAF 49.1%)|NPM1 (p.W288fs*12; VAF 43.1%)|SPEN (p.R807P; VAF 52.5%),Positive (AR 0.36),Positive (p.W288fs*12; VAF 43.1%),,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,5.0,4.0,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,20.0,"MIDAC, Midostaurin|Azacitidine, Midostaurin|FLAG, Gilteritinib|Gilteritinib, Cytarabine, Venetoclax|Venetoclax, Gilteritinib|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin","Gilteritinib, Cytarabine, Venetoclax",Standard Chemotherapy,Salvage,16.0,Dead,541.0,Dead-Disease,17.0,23.0,,,1.7,0.0,,16.7,,5.0,,63.3,0.1,,,,,,17.75,13.0,2.8,,,0.79,6.8,,59.0,30.0,379.0,103.0,"dimCD7, dimCD13, CD33, variable CD34, CD38, CD117,  HLADR, MPO positive"
C448,C448,5539,20-00494,,,,Male,64.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,Adverse,NotDetected,"46,XY[3]",Normal,ASXL1 (p.S689*; VAF 45%)|BCOR (Splice variant; VAF 70%)|BCORL1 (p.R1196*; VAF 12%)|DNMT3A (p.K299fs*17; VAF 54%)|IDH2 (p.R140Q; VAF 47%)|NT5C2 (p.E555D; VAF 48%)|RUNX1 (p.K152*; VAF 93%)|RUNX1 (p.V101fs*31; VAF 2%),Negative,Negative,,64.0,0.0,5539_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax, Azacitidine, Enasidenib|MiDAC|Enasidenib|Busulfan, Fludarabine, Thiotepa",Enasidenib,Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1411.0,Alive,90.0,50.0,,,0.0,0.0,0.8,33.6,,3.4,,10.1,1.2,,,,52.1,,22.77,82.0,3.2,,0.3,0.64,9.6,,15.0,10.0,178.0,99.0,"variable CD9, variable CD11b, variable CD13, variable CD25, variable CD33, CD34, CD38, variable cCD79a, variable CD117, variable HLA-DR, variable PAX5, and TdT | Small CD5 clonal B cell population (less than 1% of total cells, ~10% of lymphocytes), immunophenotype: CD5, CD19, CD20, CD22, CD23, cCD79a, and lambda (the criteria for mixed phenotype are not met because there is no CD19 and only two other B cell antigens, PAX5 and cCD79a, were expressed, neither completely or strongly)"
C449,C449,5539,20-00497,,,,Male,64.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,M0,M0,NonInitial,NotDetected,"46,XY[3]",Normal,ASXL1 (p.S689*; VAF 45%)|BCOR (Splice variant; VAF 70%)|BCORL1 (p.R1196*; VAF 12%)|DNMT3A (p.K299fs*17; VAF 54%)|IDH2 (p.R140Q; VAF 47%)|NT5C2 (p.E555D; VAF 48%)|RUNX1 (p.K152*; VAF 93%)|RUNX1 (p.V101fs*31; VAF 2%),Negative,Negative,,64.0,2.0,5539_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax, Azacitidine, Enasidenib|MiDAC|Enasidenib|Busulfan, Fludarabine, Thiotepa",Enasidenib,Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1411.0,Alive,90.0,,,,0.6,0.2,,68.0,,12.1,,17.0,0.6,,,,,,5.31,50.0,2.7,,,0.64,6.9,,13.0,10.0,140.0,100.5,"variable CD9, variable CD11b, variable CD13, variable CD25, variable CD33, CD34, CD38, variable cCD79a, variable CD117, variable HLA-DR, variable PAX5, and TdT | Small CD5 clonal B cell population (less than 1% of total cells, ~10% of lymphocytes), immunophenotype: CD5, CD19, CD20, CD22, CD23, cCD79a, and lambda (the criteria for mixed phenotype are not met because there is no CD19 and only two other B cell antigens, PAX5 and cCD79a, were expressed, neither completely or strongly)"
C450,C450,5625,20-00577,,,,Male,61.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11p15; NUP98 rearrangement,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,Intermediate,NUP98_re,"46,XY[20].ish t(5;11)(q35;p15.4)(3'NUP98+;5'NUP98+)","NUP98 (11p15.4): 85% of cells had a split signal pattern, consistent with rearrangement",CDH11 (p.T339N; VAF 44.7%)|CEBPA (p.P23fs*81; VAF 54.1%)|FLT3-ITD (allelic ratio 0.47)|KRAS (p.G12D; VAF 4.3%)|MECOM (p.F251L; VAF 51.2%)|PTPN11 (p.A72P; VAF 2.7%)|WT1 (p.A382fs*69; VAF 49.9%),Positive (AR 0.47),Negative,,61.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,3.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,39.0,"Decitabine, Gemtuzumab Ozogamicin|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine","Decitabine, Gemtuzumab Ozogamicin",Standard Chemotherapy,Salvage,4.0,Dead,193.0,Dead-Disease,,53.0,,,2.4,0.0,,4.8,,35.2,,6.4,1.7,,,,,,91.67,85.0,2.8,,,1.17,6.3,,36.0,62.0,1703.0,91.3,"CD13, CD33,CD34, CD38, CD117, dim HLA-DR and MPO positive"
C489,C489,5641,21-00523,,,,Male,68.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,NonInitial,NotDetected,"46,XY[19]",Normal,BRCA1 (p.R466W; VAF 47.4%)|CCR4 (p.L21Q; VAF 45.9%)|CEBPA (p.N281fs*40; VAF 6.3%)|FAT1 (p.D2423Y; VAF 46.6%)|IDH1 (p.R132H; VAF 39.8%)|MGA (p.K2075fs*1; VAF 17.3%)|MGA (p.K428fs*1; VAF 13.5%)|MYC (Splice site; VAF 24.8%)|NAF1 (p.G388D; VAF 52.8%)|NPM1 (p.W288fs*12; VAF 35.6%)|SAMD9L (p.Q569*; VAF 46.6%)|SRSF2 (p.P95H; VAF 40.6%),Negative,Positive (p.W288fs*12; VAF 35.6%),,69.0,236.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,2.0,3.0,Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,28.0,"Venetoclax (ABT-199), Azacitidine|Ivosidenib","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,9.0,Dead,292.0,Dead-Disease,,50.0,,,0.0,0.0,,59.0,,22.9,,17.1,0.0,,,,,,4.3,18.0,1.7,,,2.81,6.7,,11.0,11.0,523.0,91.8,"CD4, CD9, CD11b, CD11c, CD13, CD14, CD15, partial CD16, CD33, CD38, partial CD56, CD64, HLA-DR, and cMPO positive"
C454,C454,5652,20-00631,,,,Male,70.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13.1q22)[20]",CBFB/MYH11: 96% of cells had a dual fusion pattern consistent with inv(16).,JAK2 (p.V366M; VAF 51.5%)|NRAS (p.Q61K; VAF 43.7%),Negative,Negative,,70.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,8.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,8.0,Dead,34.0,Dead-Other,40.0,21.0,,,0.0,4.5,,11.6,,58.0,,11.6,0.2,,,,,,31.46,43.0,2.5,,,4.68,7.4,,25.0,36.0,887.0,113.1,"Blast immunophenotype: dim CD9, CD13, CD33, CD34, CD38, CD117, variable HLA-DR, MPO | Monocytic blast equivalent immunophenotype: CD9, CD11b, CD11c, CD13, CD14, dim CD16, CD33, CD38, CD64, MPO"
C456,C456,5658,20-00641,,,,Male,65.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2 (with prominent eosinophilia),M2,Adverse,Other,"47,XY,+19[4]/46,XY[16]","Chromosome 7: 15/200 cells (7.5%) were missing a signal for both probes, consistent with very low-level monosomy 7.  ",ASXL1 (p.E635fs*15; VAF 39.9%)|BCORL1 (p.T677fs*65; VAF 45.7%)|KRAS (p.G12V; VAF 31.2%)|NRAS (p.G12D; VAF 1.4%)|PTPN11 (p.D61V; VAF 11.3%)|RUNX1 (p.L161fs*53; VAF 9.7%)|SETBP1 (p.G870S; VAF 36.2%)|STAG2 (p.T966fs*13; VAF 14.6%)|SYNE1 (p.E1052Q; VAF 3.7%)|U2AF2 (p.I191_K195del; VAF 26.6%),Negative,Negative,,65.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,2.0,2.0,Induction|Maintenance,Unknown,Standard Chemotherapy,94.0,"Venetoclax (ABT-199), Azacitidine|Decitabine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,94.0,Dead,99.0,Dead-Disease,21.0,20.0,,,5.8,48.2,,8.8,,8.8,,11.7,0.2,,,,,,64.97,21.0,2.8,,,1.92,7.6,,58.0,64.0,1086.0,94.8,"dim CD5, CD9, CD13, variable CD33, CD34, CD38, dim CD45, dim CD56, CD117, HLA-DR positive"
C469,C469,5659,20-00686,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,84.0,11.0,5659_1,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C470,C470,5659,20-00687,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,84.0,15.0,5659_2,Unknown,Unknown,,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C595,C595,5659,21-00843,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,85.0,375.0,5659_3,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C457,C457,5665,20-00671,,,,Male,28.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,M1,M1,Intermediate,NotDetected,"46,XY[3] (only 3 metaphase cells found, but subsequent samples also had normal karyotype)",Normal,ARID1B (p.P218A; VAF 60.1%)|CEBPA (p.R300_D301delinsQY; VAF 96.1%)|DNAH5 (p.L1460F; VAF 48.4%)|FAT4 (p.N2762H; VAF 52.0%)|FLT3-ITD (VAF 48.2%; allelic ratio 0.93)|GATA2 (p.P41A; VAF 51.7%)|PRKCB (p.V393L; VAF 52.4%),Positive (VAF 48.2%; AR 0.93),Negative,,28.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,27.0,"7+3 (Cytarabine, Daunorubicin) plus Crenolanib|HIDAC + Crenolanib",HIDAC + Crenolanib,Standard Chemotherapy,Consolidation,-1.0,Alive,67.0,Alive,85.0,80.0,,,0.0,0.0,,5.8,,10.7,,10.7,0.2,,,,,,174.7,40.0,3.2,,,0.94,6.6,,58.0,36.0,565.0,86.5,"CD13, dim CD33, variable CD34, CD117, and variable HLA-DR positive"
C458,C458,5688,21-00023,,,,Male,28.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,M2,M2,Favorable,RUNX1-RUNX1T1,"45,X,-Y,t(8;21)(q22;q22)[20]",FISH for t(8;21) [RUNX1T1/RUNX1] showed 91% of cells with the 1r1g2f fusion pattern consistent with t(8;21).,ASXL2 (p.L521fs*1; VAF 15.3%)|CBL (p.G838V; VAF 49.1%)|DNMT1 (p.P811S; VAF 50.8%)|FLT3 (p.A680V; VAF 11.9%)|FLT3-ITD (allelic ratio 0.02)|JAK2 (p.E543_D544del; VAF 2.7%)|KRAS (p.G12A; VAF 6.1%)|NRAS (p.G13D; VAF 8.9%)|SMC1A (p.P23T; VAF 45.2%)|SPEN (p.G2022S; VAF 50.9%),Positive (AR 0.02),Negative,,28.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,2.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,5.0,"FLAG-IDA, Gemtuzumab Ozogamicin|HIDAC + Gemtuzumab Ozogamicin",HIDAC + Gemtuzumab Ozogamicin,Standard Chemotherapy,Consolidation,46.0,Alive,1296.0,Alive,45.0,35.0,,,0.9,1.8,,41.2,,3.5,,21.1,0.0,,,,,,8.57,18.0,3.4,,,0.65,8.0,,21.0,15.0,516.0,92.4,"CD13, CD15, dim CD19, CD33, CD34, CD38, partial CD56, partial/dim CD79a, CD117, HLA-DR, dim TDT, and cMPO positive"
C459,C459,5689,21-00034,,,,Male,53.0,1.0,Thyroid Cancer,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11q23; KMT2A rearrangement,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,KMT2A_re,"46,XY,t(11;17)(q23;q25)[20]","MLL:  78/100 cells (78%) had the abnormal 1 red/ 1 green/ 1 yellow signal pattern, reflecting MLL rearrangement and consistent with the 11;17 translocation observed in the metaphase karyotype.",ARID1A (p.A167dup; VAF 35%)|DNMT3A (p.I705T; VAF 45%)|FLT3-ITD (weak positive)|PTPN11 (p.E76K; VAF 36%),Positive (weak positive),Negative,,53.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Dead,3.0,Dead-Disease,90.0,,,,0.0,0.0,,21.1,,75.4,,0.9,0.7,,,,,,33.57,52.0,2.6,,,1.33,7.9,,23.0,15.0,266.0,102.0,"dim CD4, CD11b, CD11c, CD15, CD33, CD38, dim CD64, dim CD117, HLA-DR, bright cMPO | dim CD4, CD9, CD11b, CD11c, variable CD13, variable CD14, variable CD15, dim CD16, CD33, CD38, CD64, variable HLA-DR, dim cMPO"
C460,C460,5690,21-00036,,,,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,78.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C461,C461,5691,21-00038,,,,Male,40.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 11p15; NUP98 rearrangement,AML with mutated CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,M4,M4,Adverse,NUP98_re,"46,XY,t(5;16)(q32;p13)[14]/49,sl,+3,+8,+10[6] ","GATA2/MECOM: 43/200 cells (21.5) had three signals for both probes, consistent with the trisomy 3 observed in the metaphase karyotype.  There was no evidence for GATA2/MECOM fusion. | RUNX1T1/RUNX1:  32/200 cells (16%) had three RUNX1T1 (8q21.3) signals, consistent with the trisomy 8 observed in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion | NUP98:  94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting NUP98 (11p15.4) rearrangement. In one metaphase cell, the green signal appeared to be present on a chromosome 19.  The translocation was not observable in the metaphase karyotype.",CEBPA (p.Y285C; VAF 10.4%)|ETV6 (p.R378Q; VAF 48.0%)|FLT3-ITD (VAF 43%; allelic ratio 0.72)|IDH2 (p.R140Q; VAF 48.9%)|NF1 (p.P2310L; VAF 52.3%)|PCLO (p.I2784V; VAF 50.6%)|WT1 (p.S381fs*67; VAF 4.3%),Positive (VAF 43%; AR 0.72),Negative,,40.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,20.0,"7+3 (Cytarabine, Idarubicin) plus Midostaurin|FLAG-Ida, Enasidenib|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,147.0,Alive,95.0,90.0,,,0.0,0.0,,15.9,,10.6,,10.6,0.1,,,,,,75.12,70.0,2.7,,,0.91,7.4,,104.0,73.0,1226.0,108.5,"CD4(dim), CD9, CD11b, CD11c, CD13(partial), CD14(dim), CD15, CD25, CD33 (bright), CD34 (partial), CD38, CD64 (dim), CD117, HLA-DR and MPO"
C464,C464,5697,21-00057,,,,Female,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,Other,"46,XY,add(16)(q24)[14]",Normal,DNMT3A (p.R729G; VAF 48.6%)|IDH1 (p.R132H; VAF 46.8%)|NPM1 (p.W288fs*12; VAF 46.5%)|PTPN11 (p.D61N; VAF 4.4%)|PTPN11 (p.T73I; VAF 41.2%)|SMC1A (p.V639L; VAF 50.7%),Negative,Positive (p.W288fs*12; VAF 46.5%),,67.0,0.0,5697_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5.0,5.0,Consolidation|Salvage|Induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|MiDAC",Gilteritinib (ASP2215),Targeted Therapy - Other,Maintenance,-1.0,Alive,1126.0,Alive,80.0,40.0,,,0.9,0.0,,18.4,,66.7,,1.8,0.2,,,,0.9,,298.26,37.0,2.3,,,0.69,8.5,,20.0,51.0,1226.0,100.0,"dim CD4, CD9, CD11b, CD11c, partial CD13, partial CD14, variable CD15, variable CD16, CD33, variable CD38,  CD64, CD123, dim HLA-DR"
C465,C465,5697,21-00058,,,,Female,67.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M4,M4,Favorable,Other,"46,XY,add(16)(q24)[14]",Normal,DNMT3A (p.R729G; VAF 48.6%)|IDH1 (p.R132H; VAF 46.8%)|NPM1 (p.W288fs*12; VAF 46.5%)|PTPN11 (p.D61N; VAF 4.4%)|PTPN11 (p.T73I; VAF 41.2%)|SMC1A (p.V639L; VAF 50.7%),Negative,Positive (p.W288fs*12; VAF 46.5%),,67.0,0.0,5697_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,3.0,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5.0,5.0,Consolidation|Salvage|Induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|MiDAC",Gilteritinib (ASP2215),Targeted Therapy - Other,Maintenance,-1.0,Alive,1126.0,Alive,80.0,40.0,,,0.9,0.0,,18.4,,66.7,,1.8,0.2,,,,0.9,,298.26,37.0,2.3,,,0.69,8.5,,20.0,51.0,1226.0,100.0,"dim CD4, CD9, CD11b, CD11c, partial CD13, partial CD14, variable CD15, variable CD16, CD33, variable CD38,  CD64, CD123, dim HLA-DR"
C463,C463,5699,21-00061,,,,Male,16.0,1.0,B-ALL,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,Acute undifferentiated leukaemia,,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,Acute undifferentiated leukaemia,,M0,Adverse,Other,"45,XY,inv(1)(p34q21),t(2;6)(p13;q23),der(5)t(5;15)(q13;q24),dic(6;7)(p10;q10),der(12)t(5;12)(q22;q15),der(15)t(5;15)(q13;q23)t(5;12)(q22;q15)[13]/47,idem,+14,+20[7]","6q21/6q23: 91% of cells were missing both signals for 6q probes (6q21 and MYB at 6q23) but had two signals for the centromere, consistent with deletion due to dic(6;7) formation. | Chromosome 20: 35.5% of cells had an extra signal for both probes, consistent with trisomy 20. | IGH (14q32): 30.5% of cells had an extra intact signal, consistent with trisomy 14.",BCOR (p.R748W; VAF 99.8%)|BLM (p.L401F; VAF 48.5%)|CD27 (Splice site; VAF 48.5%)|FAT4 (p.E4255K; VAF 49.0%)|ID3 (p.S49T; VAF 49.3%)|KIT (p.D816V; VAF 14.8%)|NF1 (p.S2467*; VAF 75.1%)|SYNE1 (p.L1306M; VAF 78.8%)|WHSC1 (p.E1099K; VAF 36.9%),Negative,Negative,,16.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant,Peripheral Blood,3.0,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,14.0,"CPX-351 (Liposomal Cytarabine + Daunorubicin), Venetoclax|Avapritinib|Midostaurin",Midostaurin,Targeted Therapy - Kinase Inhibitor(s),Salvage,11.0,Dead,78.0,Dead-Disease,24.0,,,,25.7,5.3,,7.1,,9.7,,34.5,0.4,,,,,,16.07,87.0,3.4,,,0.55,9.6,,22.0,9.0,198.0,76.5,"positive for CD2(partial), cCD22(dim), cCD79a, CD34(variable),CD33(partial), CD38, CD56, CD58, CD117, HLA-DR"
C466,C466,5704,21-00067,,,,Female,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M4,M4,Adverse,MECOM_re,,"Chromosome 7: 94% of cells were missing a signal for both probes, consistent with monosomy 7. | GATA2/MECOM: 92% of cells had a 1r1g2f fusion signal pattern consistent with GATA2/MECOM fusion.",BIRC3 (p.I361V; VAF 48.9%)|PCLO (p.M1137V; VAF 9.7%)|PDGFRA (p.S935R; VAF 50.6%)|PTPN11 (p.E76K; VAF 46.0%)|RUNX1 (p.F163fs*69; VAF 5.4%)|SF3B1 (p.K700E; VAF 46.7%),Negative,Negative,,51.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Targeted Therapy - Other,5.0,3.0,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"3+7 (Cytarabine, Daunorubicin)|RTX-240|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine, Venetoclax","Decitabine, Venetoclax",Standard Chemotherapy,Salvage,-1.0,Dead,288.0,Dead-Disease,,,,,0.9,0.9,,7.0,,7.8,,16.5,0.0,,,,,,37.23,145.0,2.9,,,0.88,7.1,,20.0,16.0,622.0,90.7,"dim CD5, dim CD7, dim CD9, dim CD11b, dim CD11c, CD13, dim CD33, CD34, variable CD38, CD117, and variable HLA-DR positive"
C467,C467,5707,21-00074,,,,Male,61.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,Adverse,Other,"47,XY,+8[8]",,ASXL1 (p.G1376fs*12; VAF 1.1%)|CTCF (p.Y343N; VAF 47.8%)|IDH1 (p.R132C; VAF 47.6%)|MPL (p.W515L; VAF 46.0%)|RELN (p.I1029T; VAF 52.1%)|SRSF2 (p.P95L; VAF 50.4%)|TET2 (p.H1380Y; VAF 51.0%)|TET2 (p.Q1852*; VAF 49.6%),Negative,Negative,,61.0,0.0,5707_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,27.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,63.0,Dead,596.0,Dead-Disease,,95.0,,,0.0,0.0,,4.8,,0.8,,0.8,0.9,,,,,,107.87,20.0,2.9,,,0.79,5.1,,20.0,17.0,560.0,91.6,"CD9, CD13, dim CD33, CD34, CD38, CD117, HLA-DR, and cMPO"
C491,C491,5707,21-00571,,,,Male,61.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,Other,"46,XY,t(1;15)(p36.3;q11.2)[18]/46,XY[2]",Chromosome 8 probe set: Normal,ASXL1 (p.G646fs*12; VAF 35.3%)|CTCF (p.Y343N; VAF 47.9%)|MPL (p.W515L; VAF 51.4%)|RELN (p.I1029T; VAF 50.7%)|RUNX1 (p.V360fs*240; VAF 47.9%)|SRSF2 (p.P95L; VAF 48.3%)|TET2 (p.H1380Y; VAF 50.7%)|TET2 (p.Q1852*; VAF 50.3%),Negative,Negative,,61.0,187.0,5707_2,Residual,Residual,Post-Chemotherapy|Residual Disease,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,27.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,63.0,Dead,596.0,Dead-Disease,1.0,18.0,,,0.0,0.0,,0.0,,33.1,,40.7,0.3,,,,,,23.76,30.0,3.5,,,0.61,15.1,,24.0,23.0,,83.9,"#1 (5%): CD13, Dim CD33 , CD34, CD117, HLA-DR | #2: (10%): CD13, dim CD33, dim CD34 positive "
C497,C497,5707,21-00712,,,,Male,61.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M1,M1,NonInitial,Other,"46,XY,t(1;15)(p36.3;q11.2)[20]","FISH with a chromosome 8 probe set, to detect a previous clone with trisomy 8, was normal.",ASXL1 (p.G646fs*12; VAF 37.9%)|CTCF (p.Y343N; VAF 47.8%)|MPL (p.W515L; VAF 49.2%)|RELN (p.Ile1029Thr; VAF 48.5%)|RUNX1 (p.V360fs*240; VAF 50.6%)|SRSF2 (p.P95L; VAF 47.0%)|TET2 (p.H1380Y; VAF 46.9%)|TET2 (p.Q1852*; VAF 47.6%),,,,62.0,256.0,5707_3,Residual,Residual,Residual Disease|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,3.0,2.0,Salvage|Induction,Refractory,Standard Chemotherapy,27.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Ruxolitinib, Venetoclax","Ruxolitinib, Venetoclax",Standard Chemotherapy,Salvage,63.0,Dead,596.0,Dead-Disease,,11.0,,,0.0,0.0,,4.4,,30.1,,41.6,3.9,,,,,,12.02,36.0,2.7,,,0.77,6.7,,14.0,19.0,,84.6,"Immunophenotype 1 (2%): CD13, CD33 (dim), CD34, CD117 and HLA-DR | Immunophenotype 2 (9%): CD13, CD33 (dim), CD117 (bright)"
C471,C471,5722,21-00143,,,,Female,22.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,APL with t(15;17)(q22;q12); PML::RARA fusion,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,M3,M3,Intermediate,PML-RARA,"46,XX,t(15;17)(q24;q21)[19]/46,XX[1] ","PML/RARA t(15;17) dual fusion probe set: Of 100 interphase cells scored, 88 (88%) had the abnormal 1 red/ 1 green/ 2 yellow fusion signal pattern reflecting PML/RARA fusion and consistent with the 15;17 translocation ",AKT1 (p.R367H; VAF 49.1%)|CALR (p.D187H; VAF 39.4%)|CASP10 (p.L24I; VAF 52.4%)|ELANE (p.G164R; VAF 48.9%)|PTCH1 (p.V622L; VAF 50.3%),Negative,Negative,,22.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,26.0,"ATRA, Arsenic Trioxide","ATRA, Arsenic Trioxide",Standard Chemotherapy,Consolidation,25.0,Alive,91.0,Alive,86.0,13.0,,,0.0,0.0,,73.0,,1.8,,19.8,0.0,,,,,,0.82,7.0,3.8,,,0.58,7.3,,49.0,25.0,219.0,82.4,"CD9, dim CD13, dim CD15, dim CD16, CD33, dim CD34, CD117, dim CD123, and strong MPO"
C472,C472,5733,21-00176,,,,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,NotDetected,"46,XY[20]",Normal,ASXL1 (p.E635fs*15; VAF 32.2%)|DAXX (p.E381_E382del; VAF 49.2%)|RUNX1 (p.M52K; VAF 49.8%)|SRSF2 (p.P95H; VAF 47.1%)|STAG2 (p.D482fs*3; VAF 74.7%),Negative,Negative,,59.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Complete Response,Standard Chemotherapy,20.0,"7+3 (Cytarabine, Daunorubicin) plus Pemigatinib","7+3 (Cytarabine, Daunorubicin) plus Pemigatinib",Standard Chemotherapy,Induction,20.0,Alive,188.0,Alive,20.0,11.0,,,0.9,0.0,,71.1,,2.6,,20.2,0.9,,,,,,2.22,39.0,3.5,,,0.91,8.1,,78.0,73.0,230.0,95.8,"CD13, CD33, CD34, CD38, CD117, HLA-DR "
C474,C474,5766,21-00232,,,,Female,25.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XX[20]",Normal,CEBPA (p.A66fs*42; VAF 46.2%)|CEBPA (p.E309dup; VAF 48.3%)|EP300 (Splice site; VAF 16.9%)|EP300 (p.C1204R; VAF 4.6%)|EP300 (p.M718fs*82; VAF 17.5%)|GATA2 (p.L321H; VAF 15.7%)|GATA2 (p.R308P; VAF 13.8%)|MYC (p.P74L; VAF 9.6%)|WT1 (p.P124fs*65; VAF 7.4%),Negative,Negative,,25.0,0.0,5766_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,46.0,Alive,1231.0,Alive,73.0,84.0,,,0.0,0.0,,20.9,,1.8,,4.5,1.9,,,,,,21.5,42.0,3.0,,,0.78,6.7,,24.0,24.0,407.0,80.3,"dim CD7, dim/partial CD15, CD33, partial CD34, CD38, partial CD56, CD117, HLA-DR and MPO positive"
C475,C475,5766,21-00237,,,,Female,25.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated CEBPA,AML without maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,M1,M1,Favorable,NotDetected,"46,XX[20]",Normal,CEBPA (p.A66fs*42; VAF 46.2%)|CEBPA (p.E309dup; VAF 48.3%)|EP300 (Splice site; VAF 16.9%)|EP300 (p.C1204R; VAF 4.6%)|EP300 (p.M718fs*82; VAF 17.5%)|GATA2 (p.L321H; VAF 15.7%)|GATA2 (p.R308P; VAF 13.8%)|MYC (p.P74L; VAF 9.6%)|WT1 (p.P124fs*65; VAF 7.4%),Negative,Negative,,25.0,0.0,5766_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)","FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Standard Chemotherapy,Salvage,46.0,Alive,1231.0,Alive,73.0,84.0,,,0.0,0.0,,20.9,,1.8,,4.5,1.9,,,,,,21.5,42.0,3.0,,,0.78,6.7,,24.0,24.0,407.0,80.3,"dim CD7, dim/partial CD15, CD33, partial CD34, CD38, partial CD56, CD117, HLA-DR and MPO positive"
C476,C476,5767,21-00235,,,,Male,77.0,0.0,,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,Other,"47,XY,+8[20]",Normal,AKT1 (p.R174H; VAF 46.7%)|CEBPA (p.L52Q; VAF 2.2%)|CHEK2 (p.I200T; VAF 46.2%)|FAT4 (p.N3706S; VAF 50.5%)|GNAS (p.R844C; VAF 44.1%)|IDH1 (p.R132G; VAF 4.5%)|NF1 (p.F1584Y; VAF 45.3%)|NF1 (p.G1519V; VAF 43.7%)|RBBP6 (p.A595T; VAF 50.1%)|RUNX1 (p.F396fs*205; VAF 27.1%)|RUNX1 (p.M466fs*129; VAF 4.9%)|RUNX1 (p.T196R; VAF 11.7%)|SRSF2 (p.P95_R102del; VAF 43.4%)|STAG2 (p.T349fs*9; VAF 34.2%),Negative,Negative,,77.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Hypomethylating/Low Dose Cytarabine|Induction|Maintenance,Unknown,Targeted Therapy - Kinase Inhibitor(s),-1.0,"Azacitidine|Venetoclax (ABT-199), Azacitidine|Ivosidenib",Ivosidenib,Targeted Therapy - Kinase Inhibitor(s),Induction,-1.0,Dead,31.0,Dead-Disease,21.0,,,,0.0,0.0,,14.8,,0.0,,83.5,0.0,,,,,,3.33,7.0,3.3,,,0.7,10.1,,47.0,26.0,121.0,83.9,"dim CD13, variable CD33, CD34, CD38, CD117, HLA-DR"
C488,C488,5769,21-00524,,,,,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,,108.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C477,C477,5783,21-00278,,,,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"47,XY,+4[11]",Normal,ATM (p.Q2108R; VAF 51.9%)|IL7R (p.R140Q; VAF 50.9%)|NAF1 (p.P27T; VAF 31.7%)|NRAS (p.Q61P; VAF 43.2%)|PHF6 (p.R129*; VAF 95.3%)|RUNX1 (p.K110Q; VAF 47.1%)|TNFAIP3 (p.F30L; VAF 48.1%),Negative,Negative,,49.0,0.0,5783_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,166.0,Alive,54.0,31.0,,,0.0,0.0,,29.7,,0.9,,19.8,1.2,,,,,,28.26,76.0,3.9,,,1.02,6.9,,74.0,42.0,570.0,99.5,"partial CD9, CD13, CD34, CD38, CD117, HLA-DR, MPO"
C478,C478,5783,21-00279,,,,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"47,XY,+4[11]",Normal,ATM (p.Q2108R; VAF 51.9%)|IL7R (p.R140Q; VAF 50.9%)|NAF1 (p.P27T; VAF 31.7%)|NRAS (p.Q61P; VAF 43.2%)|PHF6 (p.R129*; VAF 95.3%)|RUNX1 (p.K110Q; VAF 47.1%)|TNFAIP3 (p.F30L; VAF 48.1%),Negative,Negative,,49.0,0.0,5783_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,166.0,Alive,54.0,31.0,,,0.0,0.0,,29.7,,0.9,,19.8,1.2,,,,,,28.26,76.0,3.9,,,1.02,6.9,,74.0,42.0,570.0,99.5,"partial CD9, CD13, CD34, CD38, CD117, HLA-DR, MPO"
C483,C483,5783,21-00421,,,,Male,49.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with maturation,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,NonInitial,NotDetected,"46,XY[20]",Normal,ATM (p.Q2108R; VAF 50.6%)|IL7R (p.R140Q; VAF 48.7%)|NAF1 (p.P27T; VAF 48.4%)|TNFAIP3 (p.F30L; VAF 51.2%),Negative,Negative,,49.0,43.0,5783_2,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,4.0,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,166.0,Alive,2.0,3.0,,,0.0,0.0,,6.0,,12.9,,66.4,0.8,,,,,,25.13,560.0,3.2,,,1.44,11.0,,76.0,32.0,481.0,85.8,
C592,C592,5786,21-00297,,,,Male,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with mutated CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Intermediate,NotDetected,"46,XY[20]",Normal,ASXL1 (p.E198K; VAF 44.7%)|BIRC6 (p.M2919T; VAF 48.7%)|CEBPA (p.R343fs*79; VAF 26.0%)|CHD2 (p.P1782L; VAF 50.5%)|FBXW7 (p.R83K; VAF 51.0%)|FLT3-ITD (allelic ratio 0.88; VAF 46.81)|NPM1 (p.W288fs*12; VAF 45.3%),Positive (allelic ratio 0.88; VAF 46.81%),Positive (p.W288fs*12; VAF 45.3%),,51.0,0.0,5786_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,21.0,"Busulfan, Fludarabine|Crenolanib|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|HIDAC + Crenolanib",Crenolanib,Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1206.0,Alive,67.0,70.0,,,0.0,0.0,,19.3,,58.8,,5.9,0.1,,,,,,148.28,149.0,2.7,,,1.03,11.6,,42.0,75.0,1532.0,105.8,"Myeloid blast immunophenotype: CD9, dim CD11b, CD11c, CD13, CD14 (subset), partial CD15, CD33, CD38, partial CD117, CD123, and variable HLA-DR positive | Atypical monocyte immunophenotype: CD9, bright CD11b, CD11c, partial CD13, variable CD14, CD15, variable CD16, CD33, CD38, CD64, CD123, and HLA-DR positive"
C479,C479,5786,21-00305,,,,Male,51.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,AML with mutated CEBPA,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,M5,M5,Intermediate,NotDetected,"46,XY[20]",Normal,ASXL1 (p.E198K; VAF 44.7%)|BIRC6 (p.M2919T; VAF 48.7%)|CEBPA (p.R343fs*79; VAF 26.0%)|CHD2 (p.P1782L; VAF 50.5%)|FBXW7 (p.R83K; VAF 51.0%)|FLT3-ITD (allelic ratio 0.88; VAF 46.81)|NPM1 (p.W288fs*12; VAF 45.3%),Positive (allelic ratio 0.88; VAF 46.81%),Positive (p.W288fs*12; VAF 45.3%),,51.0,1.0,5786_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,21.0,"Busulfan, Fludarabine|Crenolanib|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|HIDAC + Crenolanib",Crenolanib,Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,1206.0,Alive,67.0,70.0,,,0.0,0.0,,19.3,,58.8,,5.9,0.1,,,,,,148.28,149.0,2.7,,,1.03,11.6,,42.0,75.0,1532.0,105.8,"Myeloid blast immunophenotype: CD9, dim CD11b, CD11c, CD13, CD14 (subset), partial CD15, CD33, CD38, partial CD117, CD123, and variable HLA-DR positive | Atypical monocyte immunophenotype: CD9, bright CD11b, CD11c, partial CD13, variable CD14, CD15, variable CD16, CD33, CD38, CD64, CD123, and HLA-DR positive"
C480,C480,5798,21-00350,,,,Male,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,Favorable,CBFB-MYH11,"46,XY,inv(16)(p13;q22)[20]",CBFB/MYH11 fusion (1r1g2f) in 97% of cells,DOCK8 (p.R1406Q; VAF 49.1%)|GATA2 (p.M236V; VAF 50.3%)|KIT (p.D816Y; VAF 33.2%)|NRAS (p.G12D; VAF 11.7%),Negative,Negative,,31.0,0.0,5798_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Leukapheresis,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Busulfan, Fludarabine, Thiotepa","Busulfan, Fludarabine, Thiotepa",Standard Chemotherapy,Salvage,4.0,Alive,1189.0,Alive,,,,,1.7,0.0,,10.4,,30.4,,4.3,0.2,,,,,,55.86,22.0,2.3,,,0.81,8.6,,232.0,46.0,573.0,92.4,"Myeloid blasts immunophenotype (~56% of the WBC): CD9, CD13, partial CD15, CD33, CD34, dim CD38, CD117, HLA-DR, cMPO | Monocytic population immunophenotype (~29% of the WBC): CD9, CD11b, CD11c, CD13, CD14, partial CD15, dim CD16,CD33, CD38, dim CD64, HLA-DR, and cMPO"
C485,C485,5798,21-00426,,,,Male,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,Acute myelomonocytic leukaemia,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M4,M4,NonInitial,NotDetected,"46,XY[20]",Normal,,Negative,Negative,,31.0,30.0,5798_2,Remission,Remission,Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,3.0,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Busulfan, Fludarabine, Thiotepa","Busulfan, Fludarabine, Thiotepa",Standard Chemotherapy,Salvage,4.0,Alive,1189.0,Alive,2.5,1.0,,,0.3,1.8,,13.0,,20.0,,54.7,0.0,,,,,,12.47,465.0,3.7,,,0.63,11.7,,42.0,15.0,171.0,90.5,
C481,C481,5815,21-00397,,,,Female,55.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE LEUKAEMIAS OF MIXED OR AMBIGUOUS LINEAGE,Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1,,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1,,,Adverse,BCR-ABL1,"45,XX,der(7)t(7;18)(q11.2;q11.2),t(9;22)(q34;q11.2),-18[20]","BCR/ABL:  94% of cells had the 1r1g2f pattern consistent with BCR/ABL fusion and t(9;22). | D7S486 (7q31):  83% of cells were missing a signal, consistent with deletion due to t(7;18).",FAT1 (p.I3243V; VAF 49.4%)|FAT4 (p.G2403S; VAF 52.0%)|PCLO (p.T2916P; VAF 24.7%)|RUNX1 (p.D123fs*11; VAF 31.7%)|RUNX1 (p.S141*; VAF 33.9%),Negative,Negative,,55.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,4.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,13.0,"HyperCVAD Course B (Cytarabine, Methotrexate) plus Dasatinib|Cyclophosphamide, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine) plus Dasatinib","Cyclophosphamide, TBI",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Dead,613.0,Dead-Treatment,,43.0,,,0.9,0.0,,22.6,,14.8,,18.3,0.0,,,,,,17.49,217.0,3.2,,,0.62,11.0,,74.0,40.0,,90.7,"B lymphoblasts (23%)-  partial CD9, CD13, CD19, partial CD22, CD25, CD38, CD34, CD79a, dim/partial CD123, HLA-DR, TdT positive   | Myeloid blasts (20%)- Immunophenotype: partial CD9, CD13, partial CD33, CD34, CD38, dim/partial CD123, HLA-DR, TdT, and MPO positive"
C482,C482,5817,21-00404,,,,Male,77.0,1.0,Follicular lymphoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with mutated NPM1,Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M2,M2,Favorable,NotDetected,"46,XY[20]",,CRLF2 (p.T171S; VAF 50.0%)|DNMT3A (p.W305*; VAF 94.3%)|FLT3 (p.D835E; VAF 6.7%)|IDH1 (p.R132H; VAF 10.4%)|NPM1 (p.W288fs*12; VAF 26.4%)|NRAS (p.G12D; VAF 3.8%),Negative,Positive (p.W288fs*12; VAF 26.4%),,77.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,13.0,"Gilteritinib, Decitabine, Venetoclax","Gilteritinib, Decitabine, Venetoclax",Standard Chemotherapy,Induction,13.0,Dead,93.0,Dead-Disease,29.0,59.0,,,0.0,0.0,,10.5,,0.9,,31.6,0.4,,,,,,21.54,77.0,2.7,,,1.12,8.5,,63.0,51.0,288.0,101.6,"dim CD13, CD33, partial CD34, CD38, CD117, HLA-DR, and MPO positive"
C484,C484,5830,21-00432,,,,Female,63.0,1.0,Granulomatosis with polyangiitis ,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M0,M0,Adverse,MECOM_re,"45,XX,inv(3)(q21q26),del(5)(q31q34),-7[20]","AML panel confirmed the chromosome results, with all cells showing inv(3) [GATA2/MECOM fusion, 1r1g2f], 5q deletion [loss of EGR1 and 5q33] and monosomy 7.",MGA (p.M2851V; VAF 53.9%)|NF1 (p.S2771N; VAF 45.5%)|NRAS (p.Q61K; VAF 52.9%)|PCLO (p.V2910I; VAF 98.8%)|PPM1D (p.S503*; VAF 49.7%)|RBBP6 (p.K1473E; VAF 47.5%)|TET2 (p.S305fs*3; VAF 29.9%)|ZRSR2 (p.S447_R448del; VAF 53.3%),Negative,Negative,,63.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,35.0,"Venetoclax (ABT-199), Azacitidine","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Induction,35.0,Dead,38.0,Dead-Disease,97.0,,,,0.0,0.0,,1.6,,0.0,,1.6,0.0,,,,,,70.05,317.0,3.1,,,0.84,7.2,,19.0,18.0,664.0,92.4,"variable CD11b, CD13, CD25, CD33, CD34, CD38, CD56, CD117, HLA-DR"
C487,C487,5874,21-00506,,,,Male,64.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,NotDetected,"46,XY[20]",,ASXL1 (p.G646fs*12; VAF 36.6%)|FLT3-ITD (VAF 19%; AR 0.296)|RUNX1 (p.W279*; VAF 45.5%)|SRSF2 (p.P95H; VAF 48.0%),Positive (VAF 19%; AR 0.296),Negative,,64.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Peripheral Blood,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,2.0,"7+3 (Cytarabine, Idarubicin)","7+3 (Cytarabine, Idarubicin)",Standard Chemotherapy,Induction,2.0,Dead,6.0,Dead-Disease,25.0,4.0,,,0.0,0.9,,8.8,,6.2,,71.7,1.15,,,,,,31.325000000000003,100.5,1.8,,,1.06,6.65,,26.0,167.0,2975.0,96.0,"CD9, CD13, CD33 (partial), CD34, CD38 (partial), CD117, HLA-DR, and MPO positive "
C490,C490,5987,21-00547,,,,Female,48.0,1.0,Squamous cell carcinoma,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",Myeloid neoplasm post cytotoxic therapy,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,M5,M5,Adverse,NUP98_re,"46,XX,inv(11)(p15q22)[20]",76% of cells show a split signal pattern for NUP98 (11p15.4),BCORL1 (p.A971G; VAF 48.1%)|DNAJC21 (p.S335fs; VAF 50.9%)|KDM6A (p.R1111P; VAF 10.9%)|KRAS (p.G12A; VAF 30.2%)|SRSF2 (p.R186L; VAF 44.9%)|U2AF1 (p.Q157P; VAF 4.8%)|WT1 (p.D464Y; VAF 31.3%)|WT1 (p.L378fs*71; VAF 10.5%),Negative,Negative,,48.0,1.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,3.0,3.0,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6.0,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC","Fludarabine, Melphalan",Bone Marrow Transplant,Allogeneic - Matched Unrelated Donor,-1.0,Alive,192.0,Alive,85.0,60.0,,,0.8,1.7,,21.2,,45.8,,18.6,0.5,,,,,,16.46,64.0,2.8,,,0.69,8.1,,54.0,26.0,324.0,104.3,"positive for partial CD9, CD11b, CD11c, CD13, CD14, CD15, CD33, CD38, CD64, dim CD123, HLA-DR, and cMPO; negative for CD34, CD117"
C492,C492,6002,21-00574,,,,Female,31.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 fusion,AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,M2,M2,Favorable,CBFB-MYH11,"46,XX,inv(16)(p13q22)[16]/47,idem,+15[4] ","CBFB/MYH11: 67% of cells had an atypical single fusion pattern, 1r1g1f, still consistent with inv(16) | PML (15q24): 13/200 cells (6.5%) had an extra signal, most likely reflecting the trisomy 15 seen on metaphase analysis",KRAS (p.G12D; VAF 15.0%)|KRAS (p.G12V; VAF 16.9%)|PLCG2 (p.R1001C; VAF 51.2%),Negative,Negative,,31.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,3.0,2.0,Consolidation|Induction,Complete Response,Standard Chemotherapy,4.0,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG-Ida-Mylotarg|IDAC",IDAC,Standard Chemotherapy,Consolidation,42.0,Alive,350.0,Alive,22.0,18.0,,,2.6,0.9,,37.4,,29.6,,11.3,0.3,,,,,,6.53,46.0,3.3,,,1.05,10.8,,14.0,9.0,,107.1,"Myeloid blast immunophenotype (19% by flow): dim CD9, CD13, variable CD15, CD33, CD34, dim CD38, CD117, HLA-DR, and dim cMPO | Atypical monocyte immunophenotype (14% by flow): dim CD4, dim CD9, CD11b, CD11c, variable CD13, CD14, variable dim CD16, CD33, CD38, CD64, dim cMPO"
C493,C493,6006,21-00589,,,,Male,59.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M2,M2,Adverse,NotDetected,"46,XY[20]",Normal,ASXL1 (p.Y591fs*1; VAF 20.7%)|EZH2 (p.I651fs*24; VAF 45.3%)|RUNX1 (p.L144P; VAF 44.0%)|SRSF2 (p.P95H; VAF 46.3%)|STAG2 (p.R110*; VAF 92.6%)|TET2 (Splice site; VAF 27.7%)|USH2A (p.G2801R; VAF 53.9%),Negative,Negative,,60.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Other,4.0,4.0,Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6.0,"Decitabine, Gemtuzumab Ozogamicin|3+7 (Cytarabine, Daunorubicin)|Venetoclax (ABT-199), Azacitidine|LSD1 inhibitor",LSD1 inhibitor,Targeted Therapy - Other,Salvage,63.0,Dead,426.0,Dead-Disease,22.5,21.0,,,2.6,4.4,,49.1,,0.9,,24.6,5.1,,,,,,3.51,152.0,4.1,,,0.84,8.0,,17.0,28.0,300.0,96.8,"partial CD13, dim CD33, CD34, CD117, and HLA-DR"
C593,C593,6014,21-00606,,,,Male,56.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",,,NonInitial,Other,"46,XY,del(7)(q22)[16]/47,sl,+del(7)(q22)[2]/46,XY,t(12;22)(p13;q11.2)[3]","D7S486/ CEP 7:  146/200 cells (73%) had a 1 red/ 2 green signal pattern, reflecting deleted 7q; 5 cells (2.5%) had a 1 red/ 3 green signal pattern, reflecting two copies of the deleted 7q.   | ETV6:  27/200 cells (13.5%) had the abnormal 1 red/ 1 green/ 1 yellow signal pattern, reflecting ETV6 (12p13) rearrangement and consistent with the 12;22 translocation observed in the metaphase karyotype",DNMT3A (p.R882H; VAF 44.3%)|FAT4 (p.Q1228E; VAF 50.7%)|GATA2 (p.L321del; VAF 46.8%)|IDH1 (p.R132C; VAF 48.4%)|IKZF1 (p.I344fs*146; VAF 29.5%)|RUNX1 (p.G365D; VAF 47.0%)|SPI1 (p.P79Q; VAF 6.6%),Negative,Negative,,57.0,0.0,,Relapse,Relapse,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,2.0,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3.0,3.0,Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,6.0,"7+3 (Cytarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Ivosidenib","Venetoclax (ABT-199), Azacitidine",Standard Chemotherapy,Salvage,-1.0,Dead,603.0,Dead-Other,17.5,17.0,,,0.0,0.9,,34.8,,19.1,,18.3,13.1,,,,,,11.19,136.0,,,,,12.5,,,,,113.8,"CD13, CD33, CD34, CD117, HLA-DR positive"
C494,C494,6015,21-00610,,,,Male,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,62.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C495,C495,6020,21-00619,,,,Female,80.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with maturation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,M2,M2,Adverse,Other,"46,XX,del(5)(q12q33)[12]/46,sl,add(2)(p23)[5]/47-48,sdl1,-13,+2-3mar [cp4] ",90% of cells missing both 5q probes,ASXL1 (p.G643fs*15; VAF 41.1%)|ATRX (Splice site; VAF 41.7%)|CBLC (p.P434S; VAF 45.4%)|CDKN2C (p.I98V; VAF 93.2%)|RYR2 (p.R2100Q; VAF 49.2%)|SF3B1 (p.K700E; VAF 48.1%)|TP53 (p.S127Y; VAF 85.3%),Negative,Negative,,80.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Unknown,Standard Chemotherapy,-1.0,"Decitabine, TP-0903 (AXL kinase inhibitor)","Decitabine, TP-0903 (AXL kinase inhibitor)",Standard Chemotherapy,Induction,-1.0,Alive,38.0,Alive,15.0,13.0,,,2.6,2.6,,16.4,,0.9,,49.1,0.0,,,,,,12.16,253.0,3.5,,,0.6,7.7,,35.0,18.0,347.0,108.6,"CD5 (dim), CD9 (dim), CD13, CD33, CD34, CD38 (dim), CD117, HLA-DR"
C498,C498,6057,21-00734,,,,Female,69.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",AML with minimal differentiation,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M0,M0,Adverse,Other,"46,XX,add(4)(q12),-5,der(6)t(6;17)(p21,p12),der(7)del(7)(p11.1)del(7)(q11.1),+11,add(17)(p12),der(17)t(7;17)(q31;p13)t(6;17)(p22;q25)[2]/47,sl,i(8)(q10),der(5;15)(p10;q10),+22[cp5]/46,sdl1,-i(8)(q10),der(8;22)(q10;q10)x1~2,+mar[cp5]/45~47,sdl2,-der(5;15),der(15)t(8;15)(q13;p13)[cp8]","Chromosome 5 probes:  81% of cells were missing a signal for the 5q probes but had two signals for 5p; another 19% of cells were missing a signal for the 5q probes but had 3-4 signals for 5p. | BCR (22q11.2): 81% of cells had 3-4 signals, consistent with gain of 22. | NUP98 (11p15.4), MLL (11q23): ~90% of cells had three signals, consistent with trisomy 11. | CEP8: 35% of cells had 3-4 signals, consistent with gain of chromosome 8.",ASXL2 (p.E502G; VAF 50.3%)|CSF3R (p.P527L; VAF 52.3%)|PLCG1 (p.A224V; VAF 53.8%)|SYNE1 (p.Q5190E; VAF 51.1%),Negative,Negative,,69.0,0.0,,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,1.0,Standard Chemotherapy,1.0,1.0,Induction,Refractory,Standard Chemotherapy,77.0,"Decitabine, TP-0903 (AXL kinase inhibitor)","Decitabine, TP-0903 (AXL kinase inhibitor)",Standard Chemotherapy,Induction,77.0,Alive,89.0,Alive,86.0,58.0,,,0.0,0.0,,28.7,,0.9,,2.6,0.5,,,,,,14.78,108.0,,,,,8.7,,,,,103.6,"dim/partial CD4, CD7, CD9, CD13, CD15, dim/partial CD22, CD33, CD34, CD38, CD56, CD117, HLA-DR positive "
C499,C499,6070,21-00779,,,,Female,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M2,M2,Adverse,MECOM_re,"46,XX,inv(3)(q21q26)[7]/46,sl,t(3;15)(q27;q15)[2]/45,sdl1,dic(7;17)(q11.1;p13.1),del(16)(q22)[5]/46,sdl2,-dic(7;17),+2mar[7]/45,sl,add(X)(p22.1),-6,-7,+mar[2]/46,XX[2]","GATA2/MECOM:  67/100 cells (67%) had a 1 red/ 1 green/ 2 yellow signal pattern reflecting GATA2/MECOM fusion and consistent with the inverted 3q observed in the metaphase karyotype.  Metaphase FISH confirmed the inversion | CBFB:  82/200 cells (41%) had a single CBFB (16q22) signal, consistent with the deleted 16q in the metaphase karyotype. | D7S486/ CEP 7:  61/100 cells (61%) had a 1 red/ 2 green signal pattern, consistent with deleted 7q and the isodicentric 7;17 observed in the metaphase karyotype | A small proportion of cells had single signals for EGFR1/5q33 (9%) and MLL (11q23 - 12.5%), as well as three signals for RUNX1 (21q22 - 10.5%).  The chromosomal context of these signal patterns were not apparent in the metaphase karyotype.  There was no evidence for rearrangements.",ASXL2 (p.Q592fs*207; VAF 2.2%)|CHEK2 (p.L381F; VAF 84.3%)|GATA2 (p.W10C; VAF 48.2%)|JAK2 (p.V617F; VAF 97.4%)|KMT2D (p.R3167W; VAF 50.4%)|SF3B1 (p.K666N; VAF 48.7%),Negative,Negative,,42.0,0.0,6070_1,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,6.0,5.0,Allogeneic - Sibling|Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,16.0,"Decitabine, Gemtuzumab Ozogamicin|Venetoclax (ABT-199), Azacitidine|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Venetoclax|7+3 (Cytarabine, Daunorubicin) plus Pemigatinib|Interferon|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,232.0,Alive,27.0,35.0,,,0.0,5.0,,13.0,,7.0,,28.0,34.9,,,,,,58.0,,,,,,10.9,,,,,68.8,"dim/partial CD7, partial CD11b, CD13, CD33, CD34, dim/partial CD38, partial CD56, CD117, HLA-DR, and partial cMPO positive"
C500,C500,6070,21-00794,,,,Female,42.0,0.0,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,ACUTE MYELOID LEUKAEMIA,AML with 3q26; MECOM rearrangement,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,M2,M2,Adverse,MECOM_re,"46,XX,inv(3)(q21q26)[7]/46,sl,t(3;15)(q27;q15)[2]/45,sdl1,dic(7;17)(q11.1;p13.1),del(16)(q22)[5]/46,sdl2,-dic(7;17),+2mar[7]/45,sl,add(X)(p22.1),-6,-7,+mar[2]/46,XX[2]","GATA2/MECOM:  67/100 cells (67%) had a 1 red/ 1 green/ 2 yellow signal pattern reflecting GATA2/MECOM fusion and consistent with the inverted 3q observed in the metaphase karyotype.  Metaphase FISH confirmed the inversion | CBFB:  82/200 cells (41%) had a single CBFB (16q22) signal, consistent with the deleted 16q in the metaphase karyotype. | D7S486/ CEP 7:  61/100 cells (61%) had a 1 red/ 2 green signal pattern, consistent with deleted 7q and the isodicentric 7;17 observed in the metaphase karyotype | A small proportion of cells had single signals for EGFR1/5q33 (9%) and MLL (11q23 - 12.5%), as well as three signals for RUNX1 (21q22 - 10.5%).  The chromosomal context of these signal patterns were not apparent in the metaphase karyotype.  There was no evidence for rearrangements.",ASXL2 (p.Q592fs*207; VAF 2.2%)|CHEK2 (p.L381F; VAF 84.3%)|GATA2 (p.W10C; VAF 48.2%)|JAK2 (p.V617F; VAF 97.4%)|KMT2D (p.R3167W; VAF 50.4%)|SF3B1 (p.K666N; VAF 48.7%),Negative,Negative,,42.0,9.0,6070_2,Initial Diagnosis,Diagnosis,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,2.0,Standard Chemotherapy|Bone Marrow Transplant,6.0,5.0,Allogeneic - Sibling|Salvage|Induction|Maintenance|Re-induction,Refractory,Standard Chemotherapy,16.0,"Decitabine, Gemtuzumab Ozogamicin|Venetoclax (ABT-199), Azacitidine|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Venetoclax|7+3 (Cytarabine, Daunorubicin) plus Pemigatinib|Interferon|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",Bone Marrow Transplant,Allogeneic - Sibling,-1.0,Alive,232.0,Alive,,,,,2.0,3.1,,11.2,,4.1,,32.7,,,,,,,100.52,465.0,3.2,,,0.56,10.6,,27.0,41.0,1509.0,72.7,
C594,C594,6072,21-00780,,,,Female,,0.0,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,unknown,,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,13.0,0.0,,Unknown,Unknown,,Peripheral Blood,0.0,,0.0,0.0,,,,,,NONE,NONE,NONE,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C501,C501,6076,21-00804,,,,Male,41.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(9;22)(q34;q11); BCR::ABL1 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,NonInitial,BCR-ABL1,"47,XY,del(3)(q21q26.2),+r [2]/47,sl,t(9;22)(q34;q11.2)[18]",,ATM (p.W1221*; VAF 48.1%)|BCOR (Splice site; VAF 22.0%)|BCOR (p.C1044*; VAF 37.9%)|BCOR (p.E1076_C1080delinsG; VAF 2.3%)|BCOR (p.Q1371*; VAF 12.6%)|CHD2 (p.P1353L; VAF 0.9%)|ERBB4 (p.V1134L; VAF 49.4%)|FAT1 (p.G2485S; VAF 48.8%)|IKZF1 (p.N159S; VAF 46.3%)|JAK2 (p.T108A; VAF 0.9%)|KMT2D (p.R2105C; VAF 1.4%)|MPL (p.G404R; VAF 51.6%)|NF1 (p.C1817fs*52; VAF 94.9%)|PDGFRA (p.I473V; VAF 0.5%)|RELN (p.A1493G; VAF 0.5%)|RTEL1 (p.P759A; VAF 1.7%)|RYR1 (p.A140T; VAF 49.3%)|SBDS (Splice site; VAF 50.1%)|SF3B1 (p.K666N; VAF 52.3%)|SPEN (p.Y184C; VAF 50.8%)|SYNE1 (p.S5943P; VAF 48.0%)|WT1 (p.S381*; VAF 50.3%),Negative,Negative,,42.0,2.0,6076_1,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant|Post-DLI,Bone Marrow Aspirate,5.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),14.0,5.0,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|Dasatinib|HiDAC|HAM (Cytarabine, Mitoxantrone)|Gemtuzumab|Decitabine|Ponatinib|7+3 (Cytarabine, Idarubicin)|Unknown|Azacitidine|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Venetoclax|Ruxolitinib, Venetoclax",Ponatinib,Targeted Therapy - Kinase Inhibitor(s),Salvage,4.0,Dead,544.0,Dead-Disease,17.0,15.0,,,0.0,0.0,,5.5,,61.8,,9.1,4.7,,,,,,2.98,27.0,3.5,,,0.77,7.5,,31.0,12.0,326.0,85.8,"Myeloid blasts immunophenotype: dim CD5, partial CD7, dim CD11b, CD13, CD33, CD34, partial CD38, CD117, HLA-DR. (by flow ~7%)  | Monocytic blast equivalents immunophenotype: bright CD13, CD11b, CD11c, dim CD14, bright CD33, CD38, CD56, CD64, HLA-DR. (by flow ~11%)"
C502,C502,6076,21-00825,,,,Male,41.0,0.0,,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,AML with t(9;22)(q34;q11); BCR::ABL1 fusion,"AML, myelodysplasia-related",ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,M4,M4,NonInitial,BCR-ABL1,"47,XY,del(3)(q21q26.2),+r [2]/47,sl,t(9;22)(q34;q11.2)[18]",,ATM (p.W1221*; VAF 48.1%)|BCOR (Splice site; VAF 22.0%)|BCOR (p.C1044*; VAF 37.9%)|BCOR (p.E1076_C1080delinsG; VAF 2.3%)|BCOR (p.Q1371*; VAF 12.6%)|CHD2 (p.P1353L; VAF 0.9%)|ERBB4 (p.V1134L; VAF 49.4%)|FAT1 (p.G2485S; VAF 48.8%)|IKZF1 (p.N159S; VAF 46.3%)|JAK2 (p.T108A; VAF 0.9%)|KMT2D (p.R2105C; VAF 1.4%)|MPL (p.G404R; VAF 51.6%)|NF1 (p.C1817fs*52; VAF 94.9%)|PDGFRA (p.I473V; VAF 0.5%)|RELN (p.A1493G; VAF 0.5%)|RTEL1 (p.P759A; VAF 1.7%)|RYR1 (p.A140T; VAF 49.3%)|SBDS (Splice site; VAF 50.1%)|SF3B1 (p.K666N; VAF 52.3%)|SPEN (p.Y184C; VAF 50.8%)|SYNE1 (p.S5943P; VAF 48.0%)|WT1 (p.S381*; VAF 50.3%),Negative,Negative,,42.0,15.0,6076_2,Residual,Residual,Residual Disease|Post-Chemotherapy|Post-Transplant|Post-DLI,Peripheral Blood,5.0,DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),14.0,5.0,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,-1.0,"Fludarabine, Melphalan|Dasatinib|HiDAC|HAM (Cytarabine, Mitoxantrone)|Gemtuzumab|Decitabine|Ponatinib|7+3 (Cytarabine, Idarubicin)|Unknown|Azacitidine|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Venetoclax|Ruxolitinib, Venetoclax",Ponatinib,Targeted Therapy - Kinase Inhibitor(s),Salvage,4.0,Dead,544.0,Dead-Disease,,,,,2.6,0.0,,6.1,,36.0,,3.5,3.2,,,,,,34.03,71.0,3.9,,,1.09,7.7,,19.0,20.0,988.0,93.4,
C503,C503,6092,21-00839,,,,Male,37.0,0.0,,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,ACUTE MYELOID LEUKAEMIA,"AML, myelodysplasia-related",,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Unknown,,,NonInitial,,,,,,,,37.0,0.0,,Residual,Residual,Post-Transplant|Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,0.0,,0.0,0.0,,,,,"Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) plus Gilteritinib|Venetoclax (ABT-199), Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide","Busulfan, Cyclophosphamide",NONE,NONE,,Alive,850.0,Alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HC1,HC1,5058,18-00396,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Healthy,Healthy,,Bone Marrow Aspirate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HC2,HC2,5059,18-00397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Healthy,Healthy,,Bone Marrow Aspirate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HC3,HC3,5091,19-00048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Healthy,Healthy,,Bone Marrow Aspirate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
HC4,HC4,5435,19-00373,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Healthy,Healthy,,Bone Marrow Aspirate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
